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ABSTRACT 
Contemporary management of patients with heart failure (HF) includes treatment with 
cardiac resynchronisation therapy (CRT). The benefit of CRT results from several 
mechanisms, predominantly correction of dyssynchrony. The development of a novel 
method of measuring left ventricular global dyssynchrony using cardiovascular magnetic 
resonance (CMR), termed CMR-tissue synchronisation index (CMR-TSI) is described. 
A study of 225 patients with HF who underwent CMR-TSI found that HF appears 
synonymous with dyssynchrony. The importance of myocardial scar is illustrated in a 
study of 95 patients which revealed a significantly higher mortality in patients 
undergoing CRT who had postero-lateral (PL) scar on CMR. 
A study into the effects of a combination of CMR-TSI and scar imaging found that 
presence of either CMR-TSI >110ms or PL scar resulted in a worse outcome, whilst the 
presence of both was associated with the highest mortality. 
A final study in 148 patients allowed the development of a risk score to predict mortality 
from CRT on the basis of 16 candidate variables. PL scar, dyssynchrony and creatine 
discriminated between survivors and non-survivors and were used to derive the score. 
The score is discussed in the context of data derived from echocardiography and clinical 
studies. 
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CHAPTER 1. INTRODUCTION 
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INTRODUCTION 
Systolic heart failure was first described by the Egyptians, believed to be around 3000 
BC. (Saba et al., 2006) The Edwin Smith Papyrus described “his heart (his spirit or his 
mind) is too weary to speak. His heart beats feebly.”  
Worldwide systolic heart failure is an important cause of morbidity and mortality. 
Pharmacological treatment has been refined and implemented. However, despite 
excellent pharmacological treatment, many patients remain highly symptomatic and at 
risk of premature death. Over the last decade, cardiac resynchronisation therapy has 
emerged as a valuable treatment, substantially reducing morbidity and mortality in 
selected patients. (Cleland et al., 2005b) 
Cardiac resynchronisation therapy is thought to exert its effect by several mechanisms, of 
which the main mechanism is improving the co-ordination of left ventricular contraction 
in patients who have dyssynchrony. Dyssynchrony was first recognised in patients with 
cardiomyopathy and bundle branch block, who were noted to have delay in the 
contraction of the posterior wall relative to the septum on m-mode echocardiography in 
1994. (Xiao et al., 1994) The presence of bundle branch block identified electrical delay 
in conduction results in mechanical delay in contraction. 
Electrical delay is significant as it identifies a population of patients with heart failure 
who are at high risk of mortality. The presence of left bundle branch block is associated 
with a higher mortality in patients with heart failure. (Baldasseroni et al., 2002) 
Furthermore, prolongation of the QRS is associated with adverse left ventricular 
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haemodynamic performance. An inverse relationship between QRS duration and left 
ventricular end diastolic pressure has been found. (Burkhoff et al., 1986) Furthermore, 
prolonged QRS has been shown to have other adverse consequences, resulting in 
diastolic mitral regurgitation, and reduced cardiac output. 
1.1.1 Cardiac resynchronisation pacing 
The demonstration of the relationship between poor left ventricular systolic function with 
prolonged QRS duration resulting and adverse outcomes lead to attempts to pre-excite 
myocardial areas using pacing, which became known as “resynchronisation”. The aim of 
resynchronisation is to restore the normal conduction and hence the normal mechanical 
activation.  
Potentially, resynchronisation pacing could result in improved left ventricular function by 
improving left ventricular co-ordination, thus improving dyssynchrony. The first 
testament to this was in patient who underwent temporary biventricular pacing having 
failed to respond to other therapies. The patient was found to have such a dramatic 
improvement in haemodynamics that a permanent system was implanted. (Cazeau et al., 
1994) The patient’s breathing improved from NYHA class IV to II.  
Since that time, CRT has been shown in large multi-centre randomised studies to 
improve quality of life and survival in selected patients with moderate to severe systolic 
heart failure. (Bristow et al., 2004, Cleland et al., 2005b) Overall, CRT is estimated to 
result in a 26% reduction in mortality and 22% reduction in hospitalisation for heart 
failure. (Cleland et al., 2005b)  CRT has been shown to be cost effective in heart failure 
patients. (Caro et al., 2006) 
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The physiological benefits of cardiac resynchronisation in patients with heart failure can 
be dramatic. As a result of resynchronisation, cardiac output is increased. (Duncan et al., 
2003) Systolic blood pressure and maximum rates of left ventricular pressure rise 
improve. 
In patients with mitral regurgitation, CRT can improve the function of the papillary 
muscles, immediately reducing mitral regurgitation. (Kanzaki et al., 2004) Over time, the 
adverse geometric changes that occur in patients with heart failure are reversed achieving 
with reverse remodelling and improved ejection fraction. (Yu et al., 2005b) As a result of 
left ventricular remodelling, the loss of mitral valve coaptation can be reversed, resulting 
in reduction of mitral valve regurgitation. 
Whilst CRT is a highly successful treatment for selected patients with heart failure some 
patients do not report improvements in symptoms. It is unclear how to determine which 
patients with heart failure will have symptomatic improvement following CRT, as not all 
do. Imaging techniques which can identify patients who will benefit from CRT could be 
used to exclude patients who do not gain a symptomatic or survival benefit. (Sanderson, 
2009) Increasingly, clinicians and purchasers are looking towards advanced imaging to 
predict outcome from CRT. 
Cardiac resynchronisation therapy often results in a noticeable improvement in 
symptoms, such that an absence of symptomatic improvement can be regarded as a 
failure of therapy, or “non-response”. In addition, CRT results in left ventricular 
remodelling and some authors propose that a response to CRT in terms of improvement 
in left ventricular function implies a survival advantage, and the therapy is not effective if 
a significant improvement in left ventricular function is not seen. (Yu et al., 2005b) 
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However, clinical trials have failed to identify a sub-group who do not benefit from CRT. 
(Cleland et al., 2008b) 
Furthermore, there is discordance between the symptomatic response and survival benefit 
from CRT. (Foley et al., 2008) Indeed patients who demonstrate reverse remodelling may 
not demonstrate a survival benefit. (Yu et al., 2005b) 
The aim of this thesis is to determine whether pre-implant cardiac magnetic resonance 
can predict response to CRT. Cardiac magnetic resonance (CMR) has many advantages 
over echocardiography for determination of both the aetiology of heart failure, left 
ventricular volume assessment and prognosis in patients not treated with CRT. Using 
CMR to assess response to cardiac resynchronisation is novel. 
 
1.2 Clinical studies of CRT 
1.2.1 Baseline characteristics in clinical trials 
Large scale randomised clinical trials of CRT have used similar selection criteria. These 
include impaired ejection fraction, NYHA class II to IV and evidence of broad QRS 
duration (greater than 120 ms). Overall, all these studies have shown benefit in terms of 
symptomatic response (see Table 1-1). 
Suspicion that the selection of patients could be improved to increase the benefit of CRT 
by excluding those deemed not likely to benefit has lead to the application of novel 
imaging techniques. Sophisticated echocardiographic methods of dyssynchrony have 
been used to determine if these could improve selection of patients. 
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As yet no randomised studies have enrolled patients on the basis of echocardiographic 
criteria alone, although a study of echocardiographic predictors of response to CRT 
(PROSPECT study) has reported. (Chung et al., 2008) Additionally, a major randomised 
clinical trial of patients with narrow QRS (≤ 130 ms), a group excluded from current 
guidelines, has reported. In this study, patients were selected on the basis of the presence 
of sufficient mechanic dyssynchrony, measured using tissue Doppler (RETHINQ). 
(Beshai et al., 2007)  The details of the studies are discussed below (see Table 1-1). 
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Table 1-1 The baseline entry parameters of patients entered into trials of CRT. 
  
 
MUSTIC 
 
(Cazeau et 
al., 2001) 
PATH 
-CHF 
(Auricchio 
et al., 2002) 
MIRACLE 
 
(Abraham 
et al., 2002) 
MIRACLE-
ICD 
(Young 
et al., 
2003) 
CONTAK 
 
(Higgins et 
al., 2003) 
  COMPANION 
 
(Bristow et al., 
2004) 
  CARE-
HF 
 
(Cleland 
et al., 
2005b) 
No. 
 
Device 
67 
 
CRT-
P 
36 
 
CRT-
P 
453 
 
CRT-
P 
369 
 
CRT-
D 
490 
 
CRT-D 
1520 
 
Both 
813 
 
CRT-P 
Rhythm SR SR SR SR SR SR SR 
NYHA class III III, IV III, IV III, IV II, III, 
IV 
III, IV III, IV 
NYHA class 
distribution, 
% 
100 86/14 91/9 89/9 33/59/8 85/15 94/6 
IHD or DCM Both Both Both Both Both Both Both 
Distribution, 
% 
37/63 29/71 54/46 70/30 69/31 55/45 38/62 
 
QRS, ms 150 120 130 130 120 
 
120 
 
>120 
Mean ± SD, 
ms 
176 ± 
19 
175 ± 
32 
166 ± 
20* 
164 ± 
22* 
158 ± 
26* 
  
LVEF 0.35 N/A 0.35 0.35 0.35 0.35 0.26 
Mean ± SD 0.23 
± 7 
0.21 ± 
7 
0.22 ± 
6.3* 
0.24 ± 
0.06* 
0.21 ± 
7* 
0.22 0.25 
LVEDD, mm 60 N/A 55 55 N/A N/A NA 
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CRT-P = cardiac resynchronisation pacemaker. CRT-D = cardiac resynchronisation 
pacemaker with defibrillator. QRS is QRS duration. NYHA class = New York health 
association Class. 6 minute walk test is the distance walked in 6 minutes. LVEF = left 
ventricular ejection fraction. LVEDD = left ventricular end diastolic diameter. 
Mean ± SD, 
mm 
73 ± 
10 
73 ± 
11 
69 ± 
10* 
76 ± 
10* 
71 ± 
10* 
67 72 
6-Min walk, 
m 
N/A N/A 450 450 N/A N/A NA 
Mean ± SD, 
m 
320 ± 
97 
357 ± 
20 
298 ± 
93* 
243 ± 
123* 
318 ± 
120* 
262 NA 
*SD is estimated from data provided in citation.  
Median value is shown  
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1.3 Response to CRT 
The magnitude of any treatment effect will vary between patients depending on host 
factors including the severity of the underlying condition. Measuring effectiveness is 
difficult beyond binary measures such as mortality. However, the response to therapy is 
well recognised in other field of medicine, such as response of cancers to chemotherapy, 
(Dose Schwarz et al., 2005) and in the field of acute myocardial infarction after 
revascularisation in terms of ST segment change, cardiac biomarker release and left 
ventricular function. (Markis et al., 1981) 
The use of the term response in patients treated with CRT is controversial. The 
identification of non-responders is often made difficult by the absence of control patients 
in clinical studies. (Cleland et al., 2009) Clinical studies suggest that there is no evidence 
that patients who do not gain a symptomatic response or evidence of reverse remodelling 
are worse off after CRT, and clinical trials suggest that all patients meeting current 
criteria gain a mortality advantage. (Cleland et al., 2008b) However, in the field of CRT, 
“response to therapy” is regularly measured in clinical studies, which may simply be a 
reflection of the dramatic effectiveness of CRT to improve some patients’ symptoms. 
Heart failure treatments can improve symptoms without necessarily having an effect on 
mortality.  
Clinical response to diuretics is well characterised in terms of loss of oedema, but the 
long term change in condition after initiation of prognostic heart failure medication is not 
discussed in routine or research clinical practice. Hence, the term “response” used in the 
context of treatment with CRT is almost unique and is not discussed in relation to other 
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prognostic treatments of HF, such as angiotensinogen converting enzyme inhibitors 
(ACEI) or beta blockers. 
Clinical response is commonly assessed by measuring exercise tolerance in terms of six 
minute hall walk distance and symptom score using both the NYHA class and the 
Minnesota living with heart failure questionnaire. (Rector, 2005)  Clinical response is 
usually defined as an increase in 6 minute walk time by 25% or a reduction in NYHA 
class by one or more. (Chung et al., 2008) Additionally, a reduction in Minnesota living 
with heart failure score by 10 points has been used in some studies as an indicator of 
clinical response. (Gras et al., 1998) 
Reverse left ventricular remodelling is well described after CRT. Echocardiographic 
response has been used in some studies as an endpoint, and has been defined as reflecting 
a reduction of the left ventricular end systolic volume by 15%. (Chung et al., 2008)  
Dichotomising groups of patients as responders and non-responders is common in 
clinical studies. (Bleeker et al., 2006a) However, the so-called non-response is relative to 
other patients treated with CRT, rather than controls. Therefore, non-response does not 
exclude benefit from CRT.  
Failure to demonstrate either clinical or echocardiographic response to CRT is multi-
factorial. Reverse left ventricular remodelling after CRT appears to be greater in patients 
with dilated cardiomyopathy (DCM) compared with patients with previous myocardial 
infarction (Duncan et al., 2003) and a history of ischaemic heart disease is associated 
with a worse outcome after CRT.(Zhang et al., 2009)  
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Response may be affected by the viability of the myocardium. Studies into response to 
revascularisation (Kim et al., 2000) and beta blockers (Bello et al., 2003) have shown 
that sufficient viable myocardium is required to obtain a response from these treatments. 
Two small studies into patients undergoing CRT have suggested that the position of the 
scar as well as the volume of viable myocardium may be implicated. (Bleeker et al., 
2006c,  White et al., 2006)  
 
1.3.1 The surface electrocardiogram and CRT 
Initial studies into CRT required a broad QRS duration as a criterion for inclusion. 
Prolonged QRS duration (greater than 120 ms) is a marker of delayed ventricular 
depolarisation and is a surrogate for mechanical dyssynchrony. Patients with left 
ventricular dilation and impairment have worse outcome than those with normal 
function. (Grines et al., 1989, Xiao et al., 1996) A study of 5517 heart failure outpatients 
found that the presence of left bundle branch block (n = 1391) was associated with 
increased 1 year mortality (hazard ratio (HR), 1.70) and sudden death (HR 1.58). 
(Baldasseroni et al., 2002) 
Patients with left bundle branch block (LBBB) have delay in left ventricular activation, 
contraction and relaxation due to the reversal of the normal sequence of ventricular 
activation. (Grines et al., 1989) 18 subjects who were found to have incidental LBBB 
were examined. The subjects had normal size hearts on echocardiography, and no 
regional wall motion abnormalities. Ten controls were compared with those with LBBB. 
The onset of anterior and posterior wall contraction was timed from the onset of the QRS 
complex on M-mode ultrasound, and the septal position measured in relation to the 
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maximal left ventricular ejection period (see Table 1-2). The timing of the contraction of 
the left and right ventricles was assessed using radionuclide imaging. 
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Table 1-2 Comparison of the onset of left ventricular contraction in controls vs 
LBBB measured using signal average ECG (ms).1 
 
 Left bundle 
branch block (ms) 
Controls (ms) P 
Q to apex 72 ± 20 35 ± 12 0.0005 
Q to posterior 
wall contraction 
165 ± 25 122 ± 22 0.0001 
Delay between 
RV and LV 
contraction 
85 ± 31 6 ± 9 0.0001 
 
                                                
1 Reproduced from Grines, C.L., Bashore, T.M., Boudoulas, H., et al. (1989) Functional 
abnormalities in isolated left bundle branch block. The effect of interventricular 
asynchrony. Circulation, 79: (4): 845-853. 
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The period of isovolumic contraction was similar in controls (62 ms) and patients with 
left bundle branch block (68 ms), although the later group had a wider range which 
implies delay in activation of the ventricle. 15 of the 18 patients had intra-ventricular 
asynchrony, with septal contraction occurring prior to posterior, and one patient had 
paradoxical septal motion. Right ventricular contraction was delayed in patients with 
LBBB in comparison to the controls. Radionuclide imaging showed that whilst the apical 
and lateral walls contracted normally, the inter-ventricular septum contribution to 
ejection fraction was reduced (40% ± 16 compared with 67 ± 7%, p < 0.001).  
Patients with dilated hearts and LBBB pattern have delay in activation of the lateral wall 
of the left ventricle on m-mode echocardiography compared with controls. (Xiao et al., 
1994) This study was a landmark study which initiated the interest in both the assessing 
and treatment of dyssynchrony. 77 patients with dilated left ventricles, with diastolic left 
ventricular diameter greater than 6mm and fractional shortening less than 15% were 
included. The time to contraction was measured from the onset of the R wave. The QRS 
duration was longer in patients with dilated hearts (127 ms ± 25) vs. normal sized hearts 
(90 ms ± 10, p < 0.05). Patients with dilated hearts had delayed activation of the free wall 
whether there was intra-ventricular conduction delay (110 - 120 milliseconds, or > 120 
ms with septal q wave) or LBBB (see Figure 1-1, Table 1-3).  
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Figure 1-1 Signal averaged ECG from normal patient and patient with dilated 
cardiomyopathy and left bundle branch block pattern 
 
 
The arrows mark the early potential time. Y axis = micro volts, x axis = time.2  
 
 
                                                
2 Reproduced from Xiao, H.B., Roy, C. and Gibson, D.G. (1994) Nature of ventricular 
activation in patients with dilated cardiomyopathy: evidence for bilateral bundle branch 
block. Br Heart J, 72: (2): 167-174 with permission from BMJ Publishing Group Ltd. 
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Table 1-3 Table showing mean relative time intervals from Q wave to onset of wall 
motion measured using M mode echocardiography  
 Normal RBBB Intra-ventricular 
conduction 
defect 
Left bundle 
branch block 
 (n = 15) (n = 6) (n = 29) (n = 20) 
Q to septal 
thickening SD (ms) 
75 (15) 75 (15) 43 (14)* 43 (12)* 
Corrected Q to 
septal thickening SD 
(ms) 
82 (12)  75 (12) 78 (15) 
Septum to LV 
posterior wall SD 
(ms) 
30 (13) 35 (15) 85 (30)* 100 (25)* 
Septum to left free 
wall SD (ms) 
20 (12) 27 (25) 95 (30)* 100 (30)* 
Septum to right free 
wall SD (ms) 
20 (14) 75 
(10)* 
65 (25)* 65 (12)* 
Corrected Q to septal thickening = signal averaged ECG Q wave to septal thickening. P < 
0.01 vs. normal.3 
                                                
3 Reproduced from Xiao, H.B., Roy, C. and Gibson, D.G. (1994) Nature of ventricular 
activation in patients with dilated cardiomyopathy: evidence for bilateral bundle branch 
block. Br Heart J, 72: (2): 167-174 with permission from BMJ Publishing Group Ltd. 
17 
 
 
This study suggests that the onset of QRS complex does not mark the onset of ventricular 
activation. The signal averaged ECG is able to detect small voltage potentials which are 
too small for the 12 lead ECG. These lasted up to 25 ms in controls, and up to 60 ms in 
patients with dilated left ventricles. Furthermore, all patients with dilated hearts had 
delay in the longitudinal motion of the right atrio-ventricular junction on M mode, 
similar to patients with right bundle branch block.  
 
1.3.2 Role of 12 lead ECG in predicting response to CRT 
The twelve lead ECG has shortcomings which may limit the ability to determine 
response to CRT. The correlation between QRS duration and acute response to CRT is 
modest (r = 0.6). (Bleeker et al., 2004) In addition, QRS duration does not predict 
outcome from CRT. (Molhoek et al., 2004) A 12 lead ECG does not accurately determine 
the onset of ventricular contraction when compared with signal averaged ECGs. (Xiao et 
al., 1994) In addition, neither the mass of myocardium affected by the dyssynchrony or 
the site of latest activation can be determined. Comparison of ECG and tissue Doppler 
imaging (TDI) has found disagreement in 20 to 50% of patients regarding the presence of 
dyssynchrony. (Achilli et al., 2003)  
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1.3.3 Relationship between QRS duration and mechanical dyssynchrony 
The relationship between dyssynchrony and QRS does not appear consistent when 
examined with TDI. (Bleeker et al., 2004) The left ventricular volumes at baseline were 
related to the QRS duration. The greater the size of the left ventricle, the wider the QRS 
duration. The QRS duration did not correspond with difference in the time of peak 
velocity between the septal and the lateral wall delay on tissue Doppler. It was found that 
30 - 40% of patients with a broad QRS duration did not have dyssynchrony; whilst 27% 
of those with QRS duration of less than 120ms had dyssynchrony when using tissue 
Doppler based criteria. 
 
1.3.4 QRS and response to CRT 
QRS duration does not appear to predict response to CRT. (Molhoek et al., 2004) In a 
study of 61 patients, the reduction in QRS duration in responders between baseline and 6 
months was not significantly different from the non-responders (20 ± 29 ms vs. 3 ± 38 
ms, p = 0.08). Using receiver operator characteristic analysis, the optimum cut-off value 
for predicting response was a QRS reduction of 30ms (sensitivity 56%, specificity 56%). 
In summary, a reduction in QRS duration is not suggestive of a response to CRT due to 
its modest sensitivity and specificity.  
CRT may be effective in patients with narrow QRS. Achilli et al. compared the effect of 
CRT in patients with wide QRS duration, and 14 patients with normal (< 120ms) 
duration. (Achilli et al., 2003) There was no significant difference in mortality between 
the groups 21.4% vs. 18.4% (p = 1). There were no significant differences in the change 
of echocardiographic parameters of dyssynchrony in both groups at follow up.  This 
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study supports the concept that QRS duration alone does not predict response to CRT, 
and that heart failure patients with a normal QRS may respond to CRT. 
In summary, the ECG does not determine the onset of ventricular activation, and a wide 
QRS duration may not ensure benefit from CRT. The ECG may be too blunt a tool to 
determine which patients with heart failure should receive CRT. 
 
1.3.5 Response to CRT in patients with a narrow QRS 
In large randomised clinical trials CRT has been restricted to patients with a QRS of 
greater than 120 milliseconds. The effect of CRT in patients with narrow QRS has not 
been well established. A demonstration of benefit from CRT in narrow QRS heart failure 
patients would suggest either that this group has dyssynchrony or an alternative 
mechanism lies behind the benefit. This was examined in an acute study of nine patients 
with NYHA class III or IV heart failure and narrow QRS (79 to 120ms) undergoing left 
ventricular pacing of the free wall showing clinical benefit in terms of reduced NYHA 
class immediately post procedure. (Turner et al., 2004) Biventricular pacing in patients 
with a narrow QRS resulted in decreased mitral regurgitation, increased filling time, and 
a trend towards increased synchrony both radially and longitudinally. The authors 
conclude that patients with heart failure and narrow QRS duration experience 
electromechanical uncoupling. 
The only multi-centre randomised clinical study of CRT in patients with narrow QRS (≤ 
130ms) selected patients on the additional basis of the presence of sufficient mechanical 
dyssynchrony, measured using tissue Doppler. (Beshai et al., 2007) At six months, there 
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was no benefit of CRT in terms of six minute walk distance or maximum oxygen uptake, 
although there was a benefit in terms of NYHA class.  
1.4  Diastolic function and diastolic ventricular interaction 
Systolic heart failure is associated with left ventricular dilation, and this has been shown 
to be associated with diastolic ventricular interaction. Left ventricular filling is impaired 
in approximately 50% of patients with heart failure with raised pulmonary capillary 
wedge pressure (PCWP) due to diastolic ventricular interaction (DVI). (Bleasdale et al., 
2004) Right ventricular overload results in the inter-ventricular septum physically 
impeding the left ventricle, resulting in reduced left ventricular filling. The pericardium 
constrains both ventricles. (see Figure 1-2) 
Reduction in right ventricular filing by use of lower body negative pressure increases the 
left ventricular volume and stroke volume by reducing right ventricular and pericardial 
constraint. DVI occurs when the PCWP is greater than 15 mmHg, when external 
constraint increases LV diastolic pressure reducing LV filling. Whilst the PCWP is an 
indirect measure of left atrial pressure, and therefore LVEDP, it will also be raised by 
external constraint, such as from the pericardium.  
Patients with elevated PWCP (>15 mmHg) and heart failure (NYHA II – IV) have been 
demonstrated to show acute haemodynamic benefit from left ventricular pacing despite 
narrow QRS duration (Turner et al., 2004). A temporary wire paced the left ventricle 
resulting in a significant increase in cardiac output from 3.9 to 4.5 l/min, with a fall in 
PCWP from 24.7 mmHg to 21.0 mmHg. In the 10 patients with normal PCWP and good 
baseline cardiac output (CO) (5.4 ± 1.1 l/min) there was no change in PCWP, or CO. 
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Figure 1-2 Effect of lower body negative pressure on diastolic ventricular 
interaction4  
 
A – normal 
B – heart failure with pericardial constraint 
 
                                                
4 Reproduced from Atherton, J.J., Moore, T.D., Lele, S.S., et al. (1997) Diastolic 
ventricular interaction in chronic heart failure. The Lancet, 349: (9067): 1720-1724 with 
the permission of Elsevier 
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Overdrive left ventricular pacing has been shown to reduce diastolic ventricular 
interaction. 18 patients with congestive heart failure underwent temporary left ventricular 
pacing. (Morris-Thurgood et al., 2000) In 9 of these patients the QRS duration was less 
than 120ms. The patients were dichotomized into two groups on the basis of the PCWP, 
normal pressure (< 15mm Hg) and raised PCWP indicative of likely DVI. The PCWP 
significantly decreased during left ventricular pacing (25.3 vs. 19.5 mmHg) and cardiac 
output significantly increased (3.9 vs. 4.4 L/min) in patients with baseline high PCWP 
values and likely DVI. In patients with normal PCWP, where the diastolic ventricular 
interaction would be small, there was no significant effect of LV pacing in terms of 
PCWP (10.5 vs. 10.5 mmHg) or CO (5.5 vs. 5.3 L/min).  
 
1.4.1 Reduction of DVI with left ventricular pacing is independent of QRS 
The relationship between DVI and QRS was explored. There was no relationship 
between QRS duration and haemodynamic response to left ventricular pacing in terms of 
stroke volume or pulmonary capillary wedge pressure. The haemodynamic benefit of LV 
pacing was seen in the patients with raised PCWP and normal QRS duration. It is 
postulated that LV pacing reduces diastolic ventricular interaction, increases LV filling 
and improves cardiac output. One of the mechanisms by which CRT may benefit patients 
is may be the reduction of DVI, although reduction of DVI has only been demonstrated 
with LV pacing alone.  
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1.5 Echocardiographic assessment of dyssynchrony 
Dyssynchrony is associated with systolic heart failure, and its presence is believed to be a 
sine non qua for CRT, and its absence results in failure of response to CRT. (Bax et al., 
2003a) On this basis, in the absence of other factors affecting response, the greater the 
dyssynchrony, the greater then benefit. 
In an attempt to quantify dyssynchrony with the aim of improving selection of patients 
for CRT, a number of different echocardiographic measures have been devised. Since 
visual assessment of 2D echocardiography by the human eye cannot detect differences of 
less than 70 milliseconds, more reliable methods of assessment are required. (Kvitting et 
al., 1999) Single centre studies of echocardiographic measures of dyssynchrony have 
been shown to correspond to short term clinical response, and a few studies have 
followed up patients for outcome at up to 14 months. It should be noted that no study has 
excluded patients from CRT on the basis of absent dyssynchrony.  
 
1.5.1  M-Mode echocardiography 
Calculation of intra-ventricular conduction delay can be determined using M-mode to 
determine and compare septal to lateral wall delay. (Xiao et al., 1994) Pitzalis et al found 
the extent of posterior - lateral delay corresponded with response to CRT in 20 patients 
(see Figure 1-3). (Pitzalis et al., 2002) Pitzalis et al. found a delay of greater than one 
hundred and thirty milliseconds between the septum and posterior wall had a specificity 
of 63% and positive predictive value of 80% for reverse LV remodelling in a study of 20 
patients undergoing CRT. However, this measurement can be difficult to obtain, with one 
study obtaining the measurement in only 45% of patients. (Marcus et al., 2005) The main 
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problem with this measurement arises where one of the walls is akinetic; hence this 
measurement is more suited to patients with DCM than to those with ICM.  
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Figure 1-3 Measuring septal to posterior wall motion delay 
 
 
Short axis M-mode at the level of the papillary muscles.  
a marks the onset of septal contraction and b marks the onset of posterior contraction. The 
difference is termed the septal to posterior wall motion delay. 5 
                                                
5 Reproduced from Pitzalis, M.V., Iacoviello, M., Romito, R., et al. (2002) Cardiac 
resynchronization therapy tailored by echocardiographic evaluation of ventricular 
asynchrony. J Am Coll Cardiol, 40: (9): 1615-1622 with permission of Elsevier.  
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The critical amount of dyssynchrony required to predict a response is unknown. (M. V. 
Pitzalis et al., 2005) A SPWMD ≥ 130ms was associated with benefit from CRT (see 
Figure 1-4) Kaplan-Meier survival curves for patients with septal to posterior wall 
motion delay). The SPWMD correlated with heart failure progression on univariate 
analysis (HR 0.9) and on multivariate analysis was the only factor to be associated with 
heart failure progression (HR 0.91). Interestingly, QRS duration did not predict response. 
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Figure 1-4 Kaplan-Meier survival curves for patients with septal to posterior wall 
motion delay 
 
Dichotomised by septal to posterior wall motion delay of 130ms.6 
 
                                                
6 Reproduced from Pitzalis, M.V., Iacoviello, M., Romito, R., et al. (2005) Ventricular 
asynchrony predicts a better outcome in patients with chronic heart failure receiving 
cardiac resynchronization therapy. J Am Coll Cardiol, 45: (1): 65-69.with permission of 
Elsevier. 
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 The role of SPWMD and prediction of response from CRT remains unclear. Marcus et 
al. analysed data from two multi-centre studies and found that septal to posterior wall 
motion delay did not correlate with response. (Marcus et al., 2005) This may be due to 
the inter-observer precision of this measurement, which was found to be poor.  
 
1.5.2  Doppler blood pool echocardiography 
Blood pool spectral Doppler can be used to determine mechanical delay. The aortic pre-
ejection delay is the delay between the onset of the QRS to the start of the aortic ejection 
envelope on Doppler. It allows assessment of the left intra-ventricular delay (with a value 
of greater than >140 ms taken as abnormal), and prolongation of this reduces the left 
ventricular filling time.  
Pulse Doppler in the outflow tracts of the pulmonary and aortic valves allows 
differentiation between the ejection times of the right and left ventricle (inter-ventricular 
delay). A delay in the time to aortic valve (left ventricular pre-ejection delay) opening 
greater than 140ms was a criterion for entry in the CARE-HF trial. (J. G. Cleland et al., 
2001) Delay in contraction of the right ventricle is measured from the start of the 
ventricular QRS complex to the onset of pulmonary contraction (right ventricular pre-
ejection delay). Blood pool Doppler is one of the most reproducible measures of 
dyssynchrony. (Chung et al., 2008) 
Two out of the following three criteria had to be satisfied to enter CARE-HF if the QRS 
duration was between 120 and 149 ms: a delay of greater than 40 ms between the left and 
right pre-ejection times, a pre-aortic ejection delay of greater than 140 ms or intra-
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ventricular mechanical delay. (Cleland et al., 2001) The number of patients enrolled with 
QRS between 120 and 149ms was relatively small.  Sub-group analysis of the CARE-HF 
trial found the HR  of the composite end points were reduced in patients with a QRS 
<160ms treated with CRT rather than medical treatment (hazard ratio (HR) 0.74, 95% CI 
0.54 – 1.02), and where the intra-ventricular delay (all QRS duration) was less than 49.2 
ms (HR 0.77, 95% CI 0.58-1.02). 
1.5.3 Use of an echocardiographic global measure of dyssynchrony and CRT 
A global measure of dyssynchrony is the total isovolumic time (IVT), which is the period 
when the heart is resting, neither emptying nor filling. (Duncan et al., 2006) Peak oxygen 
consumption is accurately predicted by the total isovolumic time in patients with DCM. 
The ejection time per minute = ET per cycle * heart rate/1000. The total isovolumic time 
= 60 – (total ejection time + filling time). The difference between the onset of pulmonary 
and aortic ejection was calculated as left ventricular pre-ejection period – right 
ventricular pre-ejection period (D-PEP).  
The IVT can predict response from CRT. In a retrospective analysis reduction in IVT 
predicted short term response. Responders at six months (29/39) had a significant 
reduction in isovolumic relaxation time due to shorter isovolumic contraction time 
(IVCT) and longer filling time as D-PEP decreased by 38 ms. In non-responders IVCT 
increased and filling time shortened. The only variables to independently predict 
response to CRT were IVT and D-PEP on univariate analysis.  Patients with IVT and D-
PEP in the normal ranges did not benefit from CRT, and actually became more 
dyssynchronous on echocardiographic parameters.   
30 
 
 
1.5.4 Tissue Doppler imaging 
Tissue Doppler imaging (TDI) measures the velocity of the myocardium. TDI is 
restricted to measuring longitudinal myocardial velocities in systole and diastole. The 
apex of the heart is relatively fixed, so the velocity of movement of the mitral annulus 
will give a measure of longitudinal function. Some torsional movement will be included 
in the measurement of longitudinal function. Measurement of radial and circumferential 
movement is limited as Doppler relies on detecting motion in parallel to the ultrasound 
beam. Due to the effect of tethering, myocardial movement can result from attachment to 
actively contracting tissue rather than contracting itself. A limitation in interpreting the 
results is that scar tissue may have a velocity resulting entirely from passive movement. 
There are two different methods of TDI: Pulsed spectral TDI relies on specifying a sector 
of interest; whereas colour coded TDI can acquire information about a sector of interest.  
Early studies used TDI imaging to determine the SPWD with greater precision than m-
mode imaging, and now multiple indexes have been derived. Differences between the 
peak myocardial motion of the basal regions of greater than 65ms or standard deviation 
of greater than 33 milliseconds are taken as indicative of dyssynchrony. Over 19 different 
methods of determining dyssynchrony had been published, yet only 4 had clinical 
outcome data with the longest follow up period being 14 months and the maximum 
number of patients in the study was 85. (Bax et al., 2005) The end points in many studies 
were not sufficient to make a useful assessment of the studies applicability.  
Tissue Doppler imaging has good temporal resolution, yet limitations arise due to poor 
signal to noise ratio. It has not found widespread use due to unfamiliarity. Spatial 
resolution is low due to dependency on 2D colour Doppler imaging of the heart, and if 
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the alignment of the probe is off axis, both longitudinal and radial velocities are included. 
The measurement of longitudinal motion has a smaller range and wider variability than 
circumferential motion when measured with tagged MRI. (Helm et al., 2005) Colour 
coding indicates the velocity of myocardium, not myocardial contraction, allowing 
myocardial velocity curves to be constructed. Scarred areas will therefore be pulled by 
non scarred contracting areas, resulting in velocity without contraction.  
A high prevalence of dyssynchrony has been detected using TDI in HF patients. In a 
prospective study of 200 subjects, 112 with heart failure (67 patients QRS < 120, 45 > 
120) and 88 healthy controls (C. M. Yu et al., 2003b) the standard deviation of the time 
to peak in the 12 segments model was calculated.  Dyssynchrony measured with TDI in 
patients with narrow and wide QRS HF and controls. Figure 1-5 shows the scatter plot, 
which demonstrates an overlap between all groups, suggesting that it would be difficult 
to select patients for CRT on the basis of this model alone. If a maximum difference in 
Ts of greater than 100 ms was used to define systolic dyssynchrony the prevalence was 
0% in controls, 51% of the narrow QRS patients and 73% of the wide QRS.
32 
 
 
 
 
 
 
Figure 1-5 Dyssynchrony measured with TDI in patients with narrow and wide 
QRS HF and controls 
The standard deviation of the time to peak myocardial sustained systolic velocity (Ts-SD) 
and early diastolic velocity (Te-SD) of all 12 left ventricular segments in controls,  narrow 
QRS complexes (≤ 120ms) and wide QRS complexes (> 120ms).7 
                                                
7 Reproduced from Yu, C.M., Lin, H., Zhang, Q., et al. (2003) High prevalence of left 
ventricular systolic and diastolic asynchrony in patients with congestive heart failure and 
normal QRS duration. Heart, 89: (1): 54-60 with the permission of BMJ Publishing 
Group Ltd. 
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Studies of TDI in heart failure patients with narrow QRS 
Although TDI can identify dyssynchrony, it is not necessarily clinically applicable in 
patients with normal QRS and heart failure. (Cho et al., 2005) ROC curves analysis 
demonstrated that the optimal cut off value for the SD of the time to peak systolic 
velocity was 37ms (sensitivity 68%, specificity 71%) and the SD of the maximal 
temporal difference was 91 milliseconds (sensitivity 70%, specificity 68%) for detecting 
clinical events. The presence of dyssynchrony in 316 patients with left ventricular 
impairment was determined using pulsed spectral Doppler. (Perez de Isla et al., 2005) 
The sensitivity and specificity of this method of determining dyssynchrony in patients 
with left bundle branch block was 69.4% and 75.3%, respectively.  
 
1.5.5 Reproducibility of measures of dyssynchrony 
Curiously, the reproducibility of TDI measurements is poor. 40 subjects were studied to 
determine the reproducibility of myocardial and blood pool Doppler measures of 
dyssynchrony. (Gabriel et al., 2007) Each patient underwent two echocardiograms within 
an hour of each other by two experienced echo cardiographers. Blood pool Doppler was 
more reproducible (inter-study r = 0.8 - 0.86) than TDI (inter-study r = 0.28 – 0.59) and 
m-mode septal to posterior wall motion delay (inter-study r = 0.31). The peak velocity 
measures were more reproducible than the onset to wall motion using TSI. The poor 
reproducibility appears to reflect the limits of echocardiographic imaging techniques. The 
use of peak velocities, although more reproducible, may be problematic due to the 
variation in the timing of peak motion which may be affected by tethering, pre and after-
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load and sympathetic drive. These findings were mirrored in the PROSPECT study. 
(Chung et al., 2008) 
 
1.5.6 Predicting response to CRT using TDI 
Early small studies suggested that TDI could reliably predict response to CRT. (Bax et 
al., 2003a) In a study of 25 patients, analysis of the baseline data showed no correlation 
between aetiology of cardiomyopathy, QRS duration at baseline, LV ejection fraction 
and left ventricular volume and response. The septal to lateral peak systolic velocity 
delay was the only variable that differed between responders and non-responders. 
 
1.5.7 Studies of CRT in patients with echocardiographic evidence of dyssynchrony 
regardless of QRS duration 
Preliminary studies suggest that TDI could predict response, and further studies 
suggested that it might have a role in selection independent of QRS duration. (Bleeker et 
al., 2006b) In a study of 66 patients, half who had QRS duration of less than 120m. These 
patients were  implanted with CRT if there was tissue Doppler evidence of 
dyssynchrony. No correlation between QRS duration and dyssynchrony was found. 
 
1.5.8 Prediction of reverse remodelling using TDI 
In small studies, TDI was shown to predict reverse remodelling. (Yu et al., 2005b) The 
systolic synchronicity index was the only parameter on multiple regression analysis in 
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this study to predict response to CRT in terms of improved end systolic volumes at 3 
months. 
Although the presence of dyssynchrony on TDI predicts response, excess dyssynchrony 
prevents reverse remodelling. (Bax et al., 2004a) ROC curve analysis found 65ms was 
the optimal cut off for predicting symptomatic response with a sensitivity and specificity 
of 80%, predicting a reduction of left ventricular end systolic volumes of 15% with a 
sensitivity and specificity of 92%. Interestingly, whilst reverse remodelling occurred in a 
linear fashion, once the heart was extremely dyssynchronous (≥100ms) reverse 
remodelling remained did not occur ((see Figure 1-6) relationship between dyssynchrony 
and change in LVESV.). This observation suggests there is a limit of dyssynchrony 
beyond which the LV cannot be resynchronised. 
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Figure 1-6 Relationship between dyssynchrony and change in LVESV 
 
 
A linear relation existed between the extent of left ventricular (LV) dyssynchrony and the 
change in LV end-systolic volume (ESV) after cardiac resynchronization therapy. 
However, LV dyssynchrony over 100 ms did not result in further reduction in LV end-
systolic volume.8 
 
                                                
8 Bax, J.J., Bleeker, G.B., Marwick, T.H., et al. (2004) Left ventricular dyssynchrony 
predicts response and prognosis after cardiac resynchronization therapy. J Am Coll 
Cardiol, 44: (9): 1834 - 1840.with permission from Elsevier. 
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1.6 Tissue Doppler strain imaging 
One of the limitations of TDI is the inability to distinguish between active and passive 
movement, such that akinetic myocardium will move passively due to tethering. As a 
result, TDI imaging will facilitate time to peak motion analysis, which could be 
misleading. Strain imaging attempts to fill this void by determining whether the 
myocardium is changing length or just being pulled due to tethering. The timing and 
amount of myocardial movement can be determined using strain imaging, and is 
measured in terms of percentage change from original length. 
 
Acquisition of strain can be acquired using TDI or speckle tracking. TDI based strain 
analysis is derived from comparison of adjacent tissue velocities, so called “velocity-
regression”. More recently, two dimensional speckle tracking strain analysis from gray-
scale imaging acquired on standard echocardiography has been developed (see next 
section). 
 
There are limitations to strain rate imaging. TDI based strain analysis is limited by small 
windows, as a high frame rate is required. Thus only 2 walls may be visualised at any one 
time, and spatial resolution is low as one point in each wall is compared. Lagrangian 
strain analysis relies on measuring the change in length between two points, and strain 
rate requires the first derivative of each measurement. Strain echocardiographic imaging 
was found to correlate with sonomicrometry when studied in a dog model. (Dohi et al., 
38 
 
 
2006) One study of 18 patients with left bundle branch block has suggested that 
abnormal strain relationships may be reversed by CRT. (Helm et al., 2005) 
Strain analysis is complex and it can be difficult to acquire reliable data. (Marwick, 
2006) Myocardial strain imaging should allow assessment of systolic and diastolic 
function. Strain rate appears to give similar results to dP/dt, where as strain is better 
related to left ventricular ejection fraction. To obtain optimal results, the tissue Doppler 
signal must be optimal. The opening and closure of the aortic valve, and mitral valve 
opening must be defined, as post-systolic signals may be misinterpreted as systolic 
contraction. (Marwick, 2006) Reverberation artefact and adequate pulse-repetition are 
important to avoid aliasing. The Doppler frequency must be adequate to avoid including 
blood pool velocity in the signals. The angle of the transducer must be correct to avoid 
error. As the heart torts, the sample volume may move outside the myocardium, giving 
rise to further errors (see Figure 1-7). 
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Figure 1-7 Example of possible error in strain imaging – the impact of angulation 
on strain rate imaging. 
 
Interrogation parallel with the wall (mid-septum, shown in blue) identifies long-axis 
shortening, and at right angles to the wall (apex, shown in red) identifies short-axis 
thickening. However, an intermediate angle (apical septum, shown in yellow) causes 
underestimation—a mixture of vectors at 45º produces a net absence of recordable strain. 
Scan planes are shown as continuous lines, longitudinal and radial contraction vectors as 
broken lines.9 
  
                                                
9 Reproduced from Marwick, T.H. (2006) Measurement of Strain and Strain Rate by 
Echocardiography: Ready for Prime Time? J Am Coll Cardiol, 47: (7): 1313-1327 with 
permission of Elsevier. 
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Animal models suggest that strain analysis can detect changes after CRT. (Dohi et al., 
2006) In this study the dP/dt was measured with an electrode conductance catheter and 
left ventricular micro-manometer. This study demonstrated that angle corrected strain 
measurements are possible and correlate well with changes in dP/dt. Radial strain appears 
has a greater range than longitudinal strain, so the accuracy of radial strain is likely to be 
greater. 
1.7 Speckle tracking 
Tracking the myocardial speckles seen on two-dimensional echocardiography allows 
strain determination. Two advantages of speckle imaging are that it is not beam angle 
dependent as it does not rely on Doppler, and stored echocardiograms can be processed 
by the software. Speckle tracking has been validated with sonomicrometry, and 
correlated with cardiac magnetic resonance tagging (r = 0.87, p < 0.001). (Amundsen et 
al., 2006) Speckle tracking can measure Lagrangian strain from pre-systolic myocardial 
length, unlike tissue velocity based velocity-regression strain. However, speckle tracking 
requires high frame rates which can increase noise. 
 
1.8 Studies of strain analysis in CRT patients 
Small cohort studies suggest that strain analysis may be able to determine which patients 
will improve EF after CRT. (Suffoletto et al., 2006) The site of latest activation of left 
ventricle was determined and compared with the LV lead position. Using a cut off of 
radial speckle strain dyssynchrony of >130 ms predicted a response with 89% sensitivity 
and 83% specificity.  
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1.8.1 Strain analysis to determine optimal lead position 
A further use of strain analysis is to target the area to site the LV lead. (Becker et al., 
2007) The site of latest strain activation was targeted. Half the patients had sub-optimal 
positions, defined as not within immediate neighbourhood of the segment with latest 
contraction. The intra-observer and inter-observer agreement for whether the lead was 
optimal or sub-optimal were 0.95 and 0.91. Patients with optimal positions had 
statistically significant increases in ejection fraction (9% vs. 5%) at 3 months compared 
with sub-optimally positioned leads. However, there was no difference in NYHA class 
and peak VO2 max, between those with optimal and sub-optimal positions.  
 
1.8.2 Strain imaging and outcome of CRT 
Conflicting results have been reported in the use of strain analysis to predict response. 
Using ≥ 15 % increase in acute EF, a cut off of 130ms predicted response with 95% 
sensitivity and 88% specificity. (Dohi et al., 2005a) However, speckle tracking 
dyssynchrony analysis did not appear to predict CRT response at six months. (Knebel et 
al., 2007) A small study found it had sensitivity of 0.64 and specificity of 0.8 to predict 
volumetric response. However, the study has limitations in that clinical response was not 
measured and the number of patients was small. 
 
1.8.3 Tissue Doppler strain rate compared with tissue velocity imaging 
Strain imaging would be expected to be more effective than TDI as the effects of passive 
motion due to tethering would be detected. To determine whether strain detected with 
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TDI could predict outcome it was compared with TDI alone in 54 patients undergoing 
CRT. (Yu et al., 2005c) They found that TDI was more predictive of reverse remodelling 
after CRT than strain rate imaging. The time to peak strain did not predict reverse 
remodelling. Previous work processing 120 segments had found an intra-observer and 
inter-observer variability for TDI of 3% and 5% and for strain rate imaging 16% and 
19%. The presence of post systolic shortening and strain rate imaging parameters did not 
predict response to CRT. On multi-variable analysis only the SD of the time to peak 
systolic velocity predicted significant reverse remodelling.  
 
Targeting the LV lead position appears to improve myocardial function. (Breithardt et al., 
2003). At baseline, shortening is low in terms of systolic strain values. CRT had no 
significant effect on the maximum rate of strain or the peak shortening. During the 
isovolumic contraction time and in the ejection period there were significant differences 
in the longitudinal shortening (see table below). At baseline systolic septal shortening 
occurred during isovolumic contraction time (IVCT), and lateral wall shortening 
occurred during the ejection period. During CRT, the septum shortened during the 
ejection period, and lateral wall shortening occurred earlier. Prior to CRT the lateral wall 
shortened more than the septal wall, this was reversed during CRT (see Figure 1-8, 
Figure 1-9). The time to peak systolic contraction occurred earlier than the maximal 
negative strain, hence motion occurs before shortening. Breithard et al conclude that 
targeting the left ventricular lead to areas of late activation improve cardiac output by 
relieving over stretched myocytes.
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Figure 1-8 Typical velocity, strain rate and strain curve from the mid septum in 
LBBB 
AVO = aortic valve opening, AVC = aortic valve closure. Peak shortening is during 
systole (open arrow) and peak shortening velocity is during late systole (closed arrow). 
IVCT = isovolumic contraction time. IVRT = isovolumic relaxation time. 10 
                                                
10 Reproduced from: Breithardt, O.A., Stellbrink, C., Herbots, L., et al. (2003) Cardiac 
resynchronization therapy can reverse abnormal myocardial strain distribution in patients 
with heart failure and left bundle branch block. J Am Coll Cardiol, 42: (3): 486-494 
with permission from Elsevier. 
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Figure 1-9 Velocity and strain curves before and after CRT 
Taken from the septal and lateral wall mid-segments in a 73-year-old patient.  
The derived strain curves from the mid-segments portray the regional asynchrony in 
deformation. Maximal septal contraction occurs before aortic valve opening (top left 
panel, arrow) and is accompanied by lateral wall lengthening. The septum lengthens after 
aortic valve opening and does not contribute to ejection. Peak lateral wall contraction is 
observed very late in systole and persists into the post-systolic period (bottom left panel, 
arrowhead). During CRT, systolic contraction occurs simultaneously in both walls, 
contributing equally to ejection (right panels). Note also the shorter isovolumic 
contraction (IVC) time with CRT. IVRT = isovolumic relaxation time.11 
                                                
11 Reproduced from: Breithardt, O.A., Stellbrink, C., Herbots, L., et al. (2003) Cardiac 
resynchronization therapy can reverse abnormal myocardial strain distribution in patients 
with heart failure and left bundle branch block. J Am Coll Cardiol, 42: (3): 486-494 
with permission from Elsevier. 
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1.8.4 Echocardiographic Tissue Synchronisation Index 
Semi-automated construction of myocardial velocity curves, termed tissue 
synchronisation imaging (TSI) (GE Vingmed), uses colour to code time-to-peak tissue 
Doppler velocities. Using this technique, acute response to CRT may be detected. 
(Gorcsan et al., 2004) A ≥ 65 ms delay in contrarction measured from the anterior septum 
to the posterior wall (typical for LBBB patients) using had 87% sensitivity and 100% 
specificity for predicting an acute response. Placing the left ventricular lead in the area 
with the greatest regional delay was associated with acute response. 
 
Comparison between automated TSI and TDI shows good correlation. (Van de Veire et 
al., 2007)  TSI ≥ 65ms was found to predict clinical response and reverse LV remodelling 
after 6 months of CRT with a sensitivity of 81% and specificity of 89%. The correlation 
between the automated and manual methods was r=0.95. Interestingly, those patients 
with the most extreme dyssynchrony responded worst. 
 
1.8.5 Real time three dimensional echocardiography (RT3DE) 
Three dimensional echocardiography provides reliable left ventricular volume analysis 
and generates parametric polar maps of the timing of LV contraction. Three thousand 
points can be examined instead of limited segments. The site of latest activation may be 
colour coded, allowing this site to be targeted for placement of the left ventricular lead. 
This has been compared to tissue velocity imaging for assessment of dyssynchrony. 
Proponents claim that this technique allows simultaneous evaluation of dyssynchrony in 
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all segments, including those that cannot be imaged by tissue velocity imaging, and also 
allows longitudinal, circumferential and radial timings to be measured. One great 
advantage is the rapid acquisition of the whole ventricular volume dataset in 4 cardiac 
cycles. Potential limitations include poor temporal resolution and the need for good 
image quality.  
A direct comparison between TDI and RT3DE suggests two different parameters are 
measured. (Burgess et al., 2007) Dyssynchrony measured by TDI reflects peak systolic 
ventricular pressure which is reached early in systole, where as RT3DE measures 
minimal systolic volume which is reached late in systole. There is little evidence for 
selecting patients on the basis of velocity should be preferred over volumetric change. In 
this study, 23% were excluded from analysis of RT3DE due to poor imaging, whilst in 
51% TDI could not be assessed in all twelve segments. Inter-observer and intra-observer 
reproducibility were 24% and 13% for TDI and 18% and 14% respectively for RT3DE. 
There was no statistical correlation between TDI and RT3DE in this study (r=0.11). 
There was no correlation between the imaging techniques in determining the site of 
maximum delay. This study found significant limitations with TDI. 
The Systolic Dyssynchrony Index (SDI) is a measure of dispersion in the time taken to 
reach the minimal regional volume for each segment during the cardiac cycle. In a small 
study, at follow up after CRT implantation those who felt symptomatically better were 
classed as responders and were found to have a significant decrease in SDI, where as non 
responders had an increase in SDI. (Kapetanakis et al., 2005) 
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1.8.6 Echocardiographic studies of dyssynchrony 
The table below lists published studies into CRT where echocardiographic measures of 
dyssynchrony were evaluated to determine response. Clinical outcome was evaluated in 4 
of the 21 studies (see Table 1-4 Clinical measures of dyssynchrony used in studies of 
CRT.). In total, nineteen different measures of dyssynchrony were used.  
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Table 1-4 Clinical measures of dyssynchrony used in studies of CRT. 
Study Patients 
Follow 
Up Measure Outcome measured Outcome 
  (months)    
(Pitzalis et 
al., 2002) 20 1 SPWMD ≥130  Reverse LV remodelling + 
(Pitzalis et 
al., 2005) 60 14 SPWMD ≥130  Event-free survival + 
(Marcus et 
al., 2005)  79 6 SPWMD ≥130  Reverse LV remodelling - 
(Breithardt 
et al., 2002) 34  
Acute Lateral 
WM  
Delayed Acute 
haemodynamics + 
(Kawaguchi 
et al., 2002) 10 9 
Δ sept-lat 
fractional area 
40% LV dyss    
(Penicka et 
al., 2004)  49 6 
Ts basal LV, 
basal RV Inter 
+ intra LV 
delay  
Left ventricular ejection 
fraction + 
(Ansalone et 
al., 2001) 21 1 
Systolic dyss 5 
basal seg LV 
dyssynchrony Symptoms and LVEF + 
(Garrigue et 
al., 2001) 12 12 
Ts onset, set v 
lateral  
Improvement in 
Dyssynchrony, 
Symptoms + 
(Yu et al., 
2002) 25 3 
Ts 12 
segments SD 
of Ts  
Improvement in 
dyssynchrony + 
(Bax et al., 
2003a) 25  
Acute Sept-lat 
delay in Ts 
Delay ≥ 60 ms  LVEF + 
(Makaryus 
et al., 2003) 30 3 
Ts-SD 12 LV 
segments 
TsSD>33 ms  Reverse LV remodelling + 
(Bax et al., 
2003b) 85 12 Sept-lat delay 
in Ts Ts ≥ 65 
Reverse LV remodelling 
and events + 
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ms  
(Notabartolo 
et al., 2004) 49 3 
Diff Ts 6 basal 
segments Diff 
Ts≥ 65 ms  Reverse LV remodelling + 
(Yu et al., 
2004b) 54 3 
Ts-SD 12 LV 
segments Ts-
SD >31 ms  Reverse LV remodelling + 
(Søgaard et 
al., 2002a) 20 12 
Longitudinal 
contraction  Delayed LVEF + 
(Søgaard et 
al., 2002b)  20  
Acute Tissue 
tracking 
Optimise V-V 
delay  LVEF + 
(Breithardt 
et al., 2003) 18  
Acute SRI 
septal+lateral 
Higher lateral 
SR  
Strain rate reversal, lat to 
sept + 
(Dohi et al., 
2005a) 38  
Acute Radial 
strain 
sept,/post ≥130 
ms  Stroke volume + 
(Gorcsan et 
al., 2004) 29  
Acute TSI 
Sept/post 
delay>34ms  Reverse LV remodelling + 
(Yu et al., 
2005b) 56 3 
TSI 12 LV 
segments Ts-
SD>34 ms  Reverse LV remodelling + 
(Zhang et 
al., 2005) 13 3 3D echo Tmsv  
Improvement Tmsv 
Correlation  + 
(Penicka et 
al., 2007) 48 32 
Ts basal LV, 
basal RV Inter 
+ intra LV 
delay 
Clinical response, Events 
(9 deaths, 15 
hospitalisations; these 
patients defined as non-
responders, all others as 
responders).  + 
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1.8.7 Prospective evaluation of echocardiographic measures of dyssynchrony 
The largest study of echocardiographic techniques to predict outcome from CRT did not 
support its use in selection of patients for CRT. A prospective evaluation of 
echocardiographic predictors of outcome of CRT (PROSPECT study) in 300 patients 
with NYHA class III and IV attempted to assess the ability of echocardiographic factors 
in predicting outcome. (Chung et al., 2008) Tissue Doppler, strain rate imaging and 
conventional echocardiography were assessed. (Yu et al., 2005a) Clinical and reverse 
remodelling outcomes were reported at six months follow up. The primary outcome was 
a clinical composite score. Patients were classified as unchanged, worsened (hospitalised 
with heart failure, worsening NYHA class, or improved, or improvement in left 
ventricular end systolic volume by at least 15%. 
The study found that no single echocardiographic measure predicted outcome from CRT. 
The inter-observer variability was high for many measurements, 72% for septal to 
posterior wall motion delay, 33.7% for the Yu index, and 31.9% for the maximum 
difference for the time to peak systolic contraction in 6 basal segments. The sensitivity 
and specificity of the 12 measures studies were modest, and the authors concluded that 
on this basis the echocardiographic measures should not be used in clinical decision 
making. 
The PROSPECT study has cast into doubt the use of TDI and echocardiographic 
measures in deciding whether patients undergo CRT. One reason for the result seen in the 
study is the possibility that dyssynchrony does not predict outcome. However, the 
designers of the study have recently published a criticism of the study conduct, casting 
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into doubt the methods used to acquire the tissue Doppler indices. (Yu et al., 2009) The 
authors comment that lack of rigor in the acquisition of the TDI is responsible for the 
high inter-observer variability seen in the study. However, as a result of this study, 
current guidelines from the American Society of Echocardiography state that 
dyssynchrony analysis should not be used to select patients for CRT. (Gorcsan et al., 
2008) 
1.8.8 Myocardial Contrast Perfusion Echocardiography 
Patients with ischaemic heart disease have a poorer clinical response to CRT when 
compared with patients with dilated cardiomyopathy. (Reuter et al., 2002, Zhang et al., 
2009) This may be due to the inability of scarred areas to contribute to myocardial 
function.  
Myocardial perfusion echocardiography could aid patient selection. (Hummel et al., 
2005) All patients underwent myocardial contrast imaging to assess perfusion and had 
previously documented coronary artery disease. The myocardial perfusion was graded for 
each segment, using a 15 segment model as follows 0 to 2, 2 = normal, 1 = reduced and 0 
= absent. Patients were re-assessed clinically and with echocardiographic follow up at 6 
months. A perfusion score index was calculated (total segment score/ number of 
interpretable segments). The perfusion score index (PSI) correlated with improvement in 
stroke volume (R = 0.46, p = 0.08), change in ejection fraction (R=0.49, p=0.06) and 
change in Tei index (R=-0.78, p=0.002).  The improvement in 6 minute walk test 
correlated well with the perfusion score index tertile (low = 5 ± 54, medium 211 ± 145, 
high 358 ± 123, p = 0.01). The peak septal to lateral delay measured with tissue Doppler 
improved in some patients with poor viability, despite a lack of response to CRT, which 
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may be due to synchronization of passive movements. There was no reverse remodelling 
in patients with a PSI < 1.  
Contrast echocardiography may have a role in measuring dyssynchrony. (Kawaguchi et 
al., 2002) Within the ventricle, the contrast is high, and within the myocardial wall it is 
lower. The regional fractional area change time plots showed early septal shortening 
followed by early lateral stretch then lateral shortening (see Figure 1-10 Contrast 
echocardiography in the detection of dyssynchrony). When biventricular pacing was 
switched on, the regional fractional area change showed all plots contracting during 
systole. In this study, ventricular pacing prevented paradoxical septal motion rather than 
improving the function of the lateral wall, although this may have resulted from mixed 
left ventricular and biventricular pacing. This study demonstrates the feasibility of this 
technique to measure dyssynchrony, but does not have any measure of outcome. 
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Figure 1-10 Contrast echocardiography in the detection of dyssynchrony 
 
A shows the apical 4 chamber view without contrast, B shows an unprocessed image 
after the injection of contrast, C shows the enhanced view of the endocardial border, and 
D shows a super-imposed manual trace of the endocardial border.12 
                                                
12 Reproduced from: Kawaguchi, M., Murabayashi, T., Fetics, B.J., et al. (2002) 
Quantitation of basal dyssynchrony and acute resynchronization from left or biventricular 
pacing by novel echo-contrast variability imaging. J Am Col Cardiol, 39: (12): 2052-
2058 with permission of Elsevier. 
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1.9 Nuclear Imaging – Myocardial Scintigraphy 
Equilibrium radio nucleotide angiography can detect dyssynchrony (Fauchier et al., 
2002). The SD of the difference between the mean phases of each ventricle was taken as 
the measure of inter-ventricular dyssynchrony. In a study of DCM patients, the SD of the 
mean phase of right and left ventricles, and QRS duration were predictive of long term 
cardiac events (p < 0.001), but the inter-ventricular dyssynchrony calculated with his 
method was not predictive. Univariate analysis of 13 factors, found that the SD of the left 
ventricle mean phase and pulmonary capillary wedge pressure were predictive of major 
cardiac events.  
 
1.9.1 Nuclear Cardiology – Positron Emission Tomography 
Evidence from cardiac magnetic resonance studies on scar burden and morphology 
identified the presence of scar as important in predicting response to CRT. Initial 
evidence from PET scanning suggests that the presence of significant scar adversely 
effects response to resynchronisation. (Sciagra et al., 2004) Patients with significant 
perfusion defects had significantly worse quality of life and walk distance compared to 
those without defects. Whilst symptomatic benefit was seen in both groups, patient with 
significant perfusion defects did not exhibit reverse remodelling, unlike those without 
perfusion defects.  
Viability measured with PET correlates with response to CRT. (Ypenburg et al., 2007b) 
The total number of scarred segments correlated with response. Receiver operating 
characteristic curve analysis suggested that viability in 11 segments yielded a sensitivity 
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of 74% and specificity of 87%.  Non response was predicted by a scar score of 14 with a 
sensitivity of 83% and specificity of 74% (AUC 0.86). 
Mapping the position of the left ventricular lead with areas of scar predicts response to 
CRT. (Adelstein and Saba, 2007) The total amount of scar, the presence of scar adjacent 
to the LV lead and the number of segments with no uptake of tracer correlated with 
failure of left ventricular re-modelling after CRT.  
 
1.10 Endocardial mapping in CRT 
Intuitively, the site of latest intrinsic activation would be the ideal pacing site to achieve 
the greatest re-synchronisation response. Epicardial mapping has shown that the site of 
latest activation is the postero-basal or postero-lateral segments in normal hearts, and this 
is exaggerated in the presence of LBBB. 
Endocardial mapping identifies areas of slow conduction. (Lambiase et al., 2004) Pacing 
the area of normal activation compared with slow conduction resulted in 22% rise in 
dP/dtmax and increased cardiac output by 15%. Without mapping, the coronary sinus lead 
may be placed in areas of slow conduction caused by fibrosis and scarring. Avoiding 
pacing areas of slow conduction had the greatest haemodynamic benefit due to reduction 
in septal dyskinesia and early papillary muscle contraction. This has been shown to 
reduce mitral regurgitation and increases left ventricular filling times. (Fried et al., 1999) 
The response of patients with heart failure and prolonged activation times to CRT is 
dependent on the reduction in activation times.  
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1.11 Cardiovascular magnetic resonance 
Cardiovascular magnetic resonance (CMR) has a higher spatial resolution, better left 
ventricular border definition and lack of geometric assumptions in comparison with 
echocardiography, resulting in greater accuracy of left ventricular volume measurements. 
(Grothues et al., 2002) However, using present technology, this is at a cost of reduced 
temporal resolution.  
 
1.11.1  Myocardial tagging 
Tagging is a process where non physical markers are placed on the ventricle using 
magnetising pulses with a gradient. Tags are regions of tissue whose longitudinal 
magnetization has been altered before imaging so that they appear dark in subsequent 
magnetic resonance images. The pattern of deformation of the tags can be analysed 
during systole. The magnetisation pattern is called spatial modulation of magnetisation 
(SPAMM). This was later improved, termed complimentary spatial modulation of 
magnetisation (CSPAMM). Tagging allows motion to be determined in 3 dimensions, 
circumferentially, radially and longitudinally which enables determination of strain. Tags 
have approximately a one second lifetime, and are usually generated on the R wave. The 
initial use of tagging was to measure blood velocity. 
The development of SPAMM uses non selective excitation to produce parallel bands, 
which fade due to T1 relaxation. CSPAMM acquires two tagged images which are 180 
degrees out of phase with one another and then subtracts them, at the cost of increasing 
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acquisition time. The advantage of CSPAMM is the tags last longer, and thus both 
systole and diastole may be tagged. Each pulse sequence balances speed against signal to 
noise ratio.  
Analysis of tagging is now semi-automated. Tags are usually subjected to two 
dimensional Fourier transformations, which results in several spectral peaks. Fourier 
analysis gives both amplitude and phase of the frequencies, allowing the signal to be 
expressed at a vector (see Figure 1-11 Analysis of a CMR tagged image). Isolating an 
off-origin spectral peak from each image, and inverting the Fourier transformation of this 
peak results in a harmonic image (see Figure 1-12, Figure 1-13, Figure 1-14, Figure 1-15, 
Figure 1-16, Figure 1-17). Harmonic images are advantageous in that they involve a 
sinusoidal pattern with a sine and cosine image. A harmonic image has both real and 
imaginary images, and two components: magnitude and phase. The frequency of the 
harmonic image reflects strain. Compression (systole) results in the peaks moving closer 
together, and relaxation results in the crests moving apart.  
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Figure 1-11 Analysis of a CMR tagged image 
 
 
The signal has a sinusoidal pattern, which is converted into a phased image, where the 
slope changes with compression and expansion of the signal. 
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time = 0 time = 320 ms 
  
Figure 1-12 Vertical tags at two time points during the cardiac cycle 
 
  
Figure 1-13 Central slab of the Fourier transform magnitudes taken from Figure 1-12 
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Figure 1-14 Harmonic magnitude images taken from figure 1-13 
 
  
Figure 1-15 Mask derived from the harmonic magnitude images from figure 1-14 
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Figure 1-16 Harmonic phase images (masked). 
 
  
The figures demonstrate the transformation from a vertical tagged image to harmonic phase images. 
Isolating an off-origin spectral peak from each image, and inverting the Fourier transformation of 
this peak results in a harmonic image 
  
 
 
62 
 
 
 
Figure 1-17 Annular mesh style tagged image 
 
Endocardial (red) and epicardial borders (turquoise), midwall (green) of the left ventricle, 
segmented into octants.13 
 
                                                
13 From www.iacl.ece.jhu.edu/projects/harp (accessed 1st September 2007) 
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Circumferential and radial strains are measured by determining the change in distance as 
the heart moves through the cardiac cycle. Eulerian strain can be determined from the 
harmonic phase magnetic resonance using two images at 2 different parts of the cardiac 
cycle. This can be calculated at all points in the cardiac cycle and this will result in a 
strain map. In addition circumferential, radial strains, minimal and maximal strains and 
the contraction angle can be measured. The spacing between the crests of the harmonic 
MRI is related to the slope of the harmonic phase, thus the strain can be calculated from 
the slope of the harmonic phase. Lagrangian strain is a measure of deformation and 
required 2 points to be identified (see Figure 1-18). 
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Figure 1-18 A sequence of Eulerian strain maps from a Canine heart 
Red indicates circumferential shortening, yellow indicates stretch. A pacing lead is positioned 
at 5 o’clock, and stretching is seen at 10 o’clock.14 
 
                                                
14 Reproduced from www.iacl.ece.jhu.edu/projects/harp. (Accessed 1st September 2007) 
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The time to onset of shortening (T onset, in ms from the ECG R wave) is defined as the 
beginning of the circumferential strain curve, and may be determined semi-automatically. 
The time to peak onset of shortening may also be determined, and as some patients will 
have multiple waves, the time to first peak and maximum peak may be determined. 
(Zwanenburg et al., 2005) In normal hearts, left ventricular strain is highest at the base 
and decreases progressively towards the apex.(Moore et al., 2000) Strain and torsion 
were maximal in the endocardium and decrease from mid-wall to epicardium.  
Tagged CMR can be used to measure dyssynchrony. Interestingly, tagged CMR suggests 
that TDI may have significant limitations in the analysis of dyssynchrony due to 
limitation inherent in analysis of longitudinal motion. (Helm et al., 2005) In a canine 
model, mechanical dyssynchrony was measured using three measures. These were the  
temporal uniformity of strain, regional variance of strain and regional variance vector 
(RVVPS) which combining strain magnitude and location. At each of 28 segments a 
time-plot of strain was made, and each plot subjected to Fourier analysis. A straight line 
indicates no dyssynchrony, whilst first order indicates perfect dyssynchrony (S1) (see 
Figure 1-19).  
The effect of pacing on strain analysis was investigated. Longitudinal based motion only 
improved with BiV and not LV pacing. Circumferential analysis of strain showed 
improved synchrony during the whole cardiac cycle. Whereas, longitudinal based strain 
analysis during systole showed no improvement with LV pacing, and of borderline 
significance during diastole (P = 0.04). The RVVPS dyssynchrony score of 
circumferential motion improved with LV and BiV pacing. All 3 methods of 
dyssynchrony assessment based on longitudinal function found little resynchronisation 
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effect until diastole, whereas circumferential analysis demonstrated improvement in 
synchrony during systole and diastole with LV and BiV pacing.  
The authors found that longitudinal strain had less than half the dynamic range of 
circumferential strain and had twice the intra-subject variability, making assessment 
difficult. Based on longitudinal assessment of strain, LV pacing did not appear to 
resynchronise the heart, whereas circumferential measures showed evidence of LV 
pacing induced resynchronisation. These findings suggest that TDI may have limited 
ability to discriminate between synchrony and dyssynchrony because of the limitations of 
longitudinal motion.  
 
67 
 
 
 
 
 
Figure 1-19 Mechanical dyssynchrony measured using temporal uniformity of strain, 
regional variance of strain and regional variance vector (combining strain magnitude and 
location) 15 
 
                                                
15 Reproduced from Helm, R.H., Lecquercq, C., Faris, Q., et al. (2005) Cardiac 
dyssynchrony analysis using circumferential versus longitudinal strain: Implications for 
assessing cardiac resynchronization. Circulation, 111: (21): 2760-2767. Reproduced 
with permission from Wolters Kluwer Health 
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Tagged analysis suggests that mechanical synchrony is more important than electrical 
synchrony. (Leclercq et al., 2002) Mechanical dyssynchrony was delineated using 
“circumferential uniformity ratio estimate” (CURE). Using this analysis, synchronous 
contraction gave a CURE value of 1, and dyssynchronous contraction gave a value of 0. 
Analysis of the electrical activation showed that atrio-LBBB pacing resulted in activation 
spreading from right to left, atrio-left ventricular pacing produced the reverse, and atrio-
biventricular pacing caused electrical synchrony (see Figure 1-20). Left ventricular 
pacing resulted in the longest activation time. Electrical synchrony was impaired by left 
ventricular pacing as compared with biventricular pacing (see Figure 1-20, Figure 1-21.). 
Left ventricular and BiV pacing generated less early and late systolic stretch in the 
opposing wall compared with left bundle pacing. 
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Figure 1-20 Mechanical activation maps for atrio-LBBB, atrio-biventricular and 
atrio-left ventricular pacing. 
 
The colour bar indicates movement, with blue indicating shortening and yellow 
stretching. Biventricular and left ventricular pacing modes produced a significantly lower 
dyssynchrony index (p<0.001). The CURE index correlated with dP/dtmax but not with 
electrical delay (inter-electrode maximal electrical dispersion).16 
                                                
16 Reproduced from: Leclercq, C., Faris, O., Tunin, R., et al. (2002) Systolic 
Improvement and Mechanical Resynchronization Does Not Require Electrical Synchrony 
in the Dilated Failing Heart With Left Bundle-Branch Block. Circulation, 106: (14): 
1760-1763.Reproduced with permission from Wolters Kluwer Health. 
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Figure 1-21 Electrical activation map derived from nylon mesh electrode array 
 
 
The colour indicates the timing of activation, blue indicates early and red late activation. 
RA-LBBB shows right to left activation, with atrio-LV pacing showing the opposite 
pattern, and biventricular pacing showing more uniform activation. The relative activation 
time for each mode is shown for each mode.17
                                                
17 Reproduced from:  Leclercq, C., Faris, O., Tunin, R., et al. (2002) Systolic 
Improvement and Mechanical Resynchronization Does Not Require Electrical Synchrony 
in the Dilated Failing Heart With Left Bundle-Branch Block. Circulation, 106: (14): 
1760-1763. Reproduced with permission from Wolters Kluwer Health 
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Three dimensional strain analyses do not appear to offer advantages over 2D. (Tecelao et 
al., 2007) Three dimensional images were acquired by using an additional long axis scan, 
and then analysed by using HARP software (Diagnosoft, North Carolina). Strain, timing 
of circumferential shortening (time to onset, time to maximum first peak) were 
determined for each segment. The maximum peak shortening and the first peak of 
circumferential shortening were computed. The time to onset of circumferential strain 
was similar in normal subjects and LBBB on both 2D and 3D analysis. The coefficient of 
variance of circumferential shortening was used to determine dyssynchrony. The authors 
found no significant differences between 2D and 3D analysis, and thus 2D analysis will 
suffice.  
 
1.11.2 Tagging and Ventricular Interaction 
Right ventricular volume overload results in impairment of LV filling. (Vonk-
Noordegraaf et al., 2005) It was hypothesised that long right ventricular contraction time 
is related to bowing of the inter-ventricular septum to the left, and thus impaired cardiac 
output. Pulmonary artery flow was measured to determine stroke volume and calculate 
the cardiac output. Right and left ventricular volumes were determined on cine imaging. 
The LV filling rate was inversely related to a decreased peak filling rate of the LV and 
stroke volume. This study demonstrates that LV filling is impaired resulting in a decrease 
in stroke volume, showing that pulmonary hypertension impairs diastolic ventricular 
interaction.  
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Ischaemic patients do not exhibit uniform patterns of strain onset. (Zwanenburg et al., 
2005) The onset of shortening can be manipulated by pacing, whereas the time to 
maximal strain peak is the most common measurement of dyssynchrony. The first peak 
correlated best with time to onset of strain measured from the start of the R wave. In non-
ischaemic patients the time to onset of strain propagated from septum to lateral wall, but 
there was no consistent pattern in ischaemic patients. The authors comment that the lack 
of a consistent pattern may account for the less reliable response to CRT as compared 
with patients without ischaemia. 
Tagging has been used to determine the best site for LV lead implantation in an animal 
model, and this site may be the site of maximum dyssynchrony. (Helm et al., 2007) In 
this study, the optimum pacing area (> 70% peak response) covered 40% of left 
ventricular area in both controls and heart failure dogs. The optimal pacing site was 
situated on the lateral wall directed towards the apex, and was similar for failing and non-
failing hearts. The circumferential uniformity estimate (CURE) index was 0.57 ± 0.08 at 
baseline, and when 90% of the maximum dP/dt was achieved, it increased to 0.87 ± 0.01. 
The optimal CURE region was 32.2 ± 6.6% of the left ventricle, resulting in a CURE 
index of 0.81 ± 0.01. Stroke work correlated with increasing CURE index (r = 0.56, p < 
0.0001), and the lateral wall produced the greatest response in both measures. Apical 
pacing in all regions was more effective in terms of stroke work than basal regions (p < 
0.001). The optimal pacing site in all hearts is situated at the mid to lateral apex. The site 
of maximal dyssynchrony is the area which if paced will result in the greatest 
haemodynamic improvement.  
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The apex appears to be the best site for LV leads.  (Vanagt et al., 2005, Vanagt et al., 
2004) which may be due to the onset of torsion at the apex prior to spreading through the 
heart up to the base.  
One small acute haemodynamic study suggests that targeting the LV lead to the most 
dyssynchronous area results in the greatest acute improvement. (Nelson et al., 2000) The 
optimal pacing site depended on bundle branch block; patients with LBBB were best 
paced in the mid-lateral or antero-lateral coronary veins, and those with RBBB at the 
mid-right ventricular septum. Tagging analysis found a marked phase delay between 
early septal and late lateral shortening. On lateral wall contraction the antero-septum 
stretched, and akinetic transition zones were seen in the posterior wall. The greater the 
dyssynchrony, the greater the response seen in terms of maximum dP/dt measured. 
Circumferential strain appears more reliable than longitudinal strain (see Figure 1-22). 
The amount of circumferential strain was three times greater than the longitudinal strain. 
(Waldman and Covell, 1987, Waldman et al., 1988)  Radial strain cannot be assessed 
reliably due to insufficient myocardial tags. (Helm et al., 2005) A limitation of TDI 
measurements is the inclusion of not only longitudinal motion, but also torsion and 
translational movement. Contrasting Helm et al.’s study with Yu et al. experience, 
echocardiographic measures of longitudinal strain were poor at predicting response to 
CRT.  The methods of determining strain and the relationship with outcome is shown in 
Figure 1-23. 
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Figure 1-22 Time-dependent plots of cardiac dyssynchrony and resolution of 
dyssynchrony 
Based on analysis of Eulerian circumferential strain ( cc) and Eulerian longitudinal strain 
variance ( ll) (A, B) and spatially weighted strain disparities (C, D). The strain variance 
rises (more dyssynchrony) and peaks at late systole and early diastole. For each pacing 
mode, LV and BiV are compared with RA (dyssynchronous) pacing at early, mid, and late 
time points in both systole and diastole (gray highlight). The time-dependent spatially 
weighed vector index (RVVPS) is also displayed for Eulerian circumferential strain and 
Eulerian longitudinal strain (C, D). *P<0.009, P<0.05 vs dyssynchronous (RA pacing, 
LBBB) baseline.18  
 
 
                                                
18 Reproduced from: Helm, R.H., Lecquercq, C., Faris, Q., et al. (2005) Cardiac 
dyssynchrony analysis using circumferential versus longitudinal strain: Implications for 
assessing cardiac resynchronization. Circulation, 111: (21): 2760-2767 Reproduced with 
permission of Wolters Kluwer Health 
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1.12 Left ventricular torsion analysis 
The myocardium contracts in three ways during systole: longitudinally, circumferentially 
and as well as rotating. Tagged magnetic resonance imaging can demonstrate reduction 
of torsion in diseases of diastole such as aortic stenosis. Torsion analysis with CMR 
based tagging and TDI correlate well (see Figure 1-23, Figure 1-24). (Notomi et al., 
2005) Rotation of the LV can be calculated on the basis of the average motion of the 
midwall points.  
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Figure 1-23 Myocardial velocity sampling regions and velocity profiles for LV 
rotation measurements (apical level). 
Top panels: septal (Vsep) and lateral (Vlat) regions, difference of which yields rotational 
velocity (without radial component). Bottom panels: anterior (ant) and posterior (pos) 
regions, integral of which allows LV radius to be tracked (without any component of 
tangential motion). MVC and MVO indicate mitral valve closing and opening, whereas 
AVO and AVC indicate aortic valve opening and closing, which were determined by LV 
inflow and outflow Doppler profiles.19  
                                                
19 Reproduced from Notomi, Y., Setser, R.M., Shiota, T., et al. (2005) Assessment of 
Left Ventricular Torsional Deformation by Doppler Tissue Imaging: Validation Study 
With Tagged Magnetic Resonance Imaging. Circulation, 111: (9): 1141-1147. 
Reproduced with permission of Wolters Kluwer Health.  
 
77 
 
 
 
 
 
 
Figure 1-24 LV rotation profile by CMR and TDI in representative case. 
 
Blue, red, and black lines indicate apical rotation, basal rotation, and LV torsion, 
respectively.20  
 
 
 
 
                                                
20 Reproduced from Notomi, Y., Setser, R.M., Shiota, T., et al. (2005) Assessment of 
Left Ventricular Torsional Deformation by Doppler Tissue Imaging: Validation Study 
With Tagged Magnetic Resonance Imaging. Circulation, 111: (9): 1141-1147. 
Reproduced with permission of Wolters Kluwer Health. 
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Table 1-5 Methods of Determining Strain – Echo and MRI studies 
Study Patients Follow Up  Strain 
Measure 
Outcome 
  (months)   
(Suffoletto et 
al., 2006) 
50 8 ± 5 Difference in 
peak radial 
strain between 
anterior and 
posterior > 
130ms 
Increase in EF 
by 15% (89 
sensitivity, 83 
specificity) 
(Breithardt et 
al., 2003) 
18  Strain, strain 
rate 
 
(Becker et al., 
2007) 
47 3 Earliest and 
last peak 
systolic 
circumferential 
strain 
Optimal lead 
position 
(Dohi et al., 
2005b) 
38 Acute Radial: 
Difference in 
peak strain 
anterior vs. 
posterior 
Increase in EF 
by 15%. Cut 
off of 130ms – 
sensitivity 95% 
and 88% 
specificity 
(Yu et al., 
2004b) 
54 3 Time to peak 
strain, SD of 
strain rate, 
Absolute and 
Maximal 
differences in 
strain 
15% reduction 
in end systolic 
volume 
(Dohi et al., 
2006) 
8 dogs Acute Radial strain, 
peak segmental 
strain, work 
 
(Kayano et 
al., 2006)  
7 Acute Strain (septal 
vs. posterior), 
regional strain 
 
(Helm et al., 
2005) 
7 dogs Acute Tagged 
circumferential 
and 
Temporal 
uniformity of 
strain, temporal 
variance of 
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longitudinal strain, regional 
variance 
vector. 
Circumferential 
positive, 
longitudinal 
negative 
(Leclercq et 
al., 2002)  
7 dogs Acute Tagged 
circumferential 
Circumferential 
Uniformity 
Ratio Estimate 
(Tecelao et 
al., 2007) 
5 Diagnostic Tagged strain, 
circumferential 
shortening 
(time to onset, 
time to 
maximum first 
peak), 
Coefficient of 
variance 
 
(Zwanenburg 
et al., 2005) 
29 Diagnostic Tagging: 
Circumferential 
strain 
Onset of strain, 
time to peak 
strain 
(Prinzen et 
al., 1999) 
7 dogs Acute Tagging Circumferential 
strain, external 
work and total 
work 
(Helm et al., 
2005) 
5 dogs RV 
paced, 5 
dogs CCF 
Acute Tagging Circumferential 
Uniformity 
Ratio Estimate, 
Time to peak 
circumferential 
strain 
(Azevedo et 
al., 2004)  
14 dogs Diagnostic Tagging 
Lagrangian 
circumferential 
strain, strain 
rate, peak 
strain, torsion, 
peak 
untwisting rate 
 
(Paetsch et 31 Diagnostic – 
stress 
Tagging – 
circumferential 
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al., 2005) tagging for 
CAD 
shortening, 
maximal 
lengthening 
velocity, mean 
rotation, 
untwist time 
(Nelson et al., 
2000)  
22 Acute Tagging – 
midwall strain, 
Lagrangian 
strain, 
Circumferential 
strain, 
Coefficient of 
variance 
Mean strain 
and strain 
variance useful 
(Kramer et 
al., 1996) 
28 5 ± 2 days 
post anterior 
MI 
Tagging – 
percent 
circumferential 
shortening in 
endocardial, 
midwall and 
epicardial 
Reduced 
shortening in 
basal lateral 
and trend to 
decreased 
shortening in 
mid-inferior 
wall 
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1.13 Predictors of response 
Reverse remodelling has been postulated as a marker of response to CRT, and has 
become widely used in clinical studies. Reverse remodelling in heart failure trials of 
angiotensin converting enzyme inhibitors have shown that left ventricular end systolic 
volume is the strongest predictor of survival. (Konstam et al., 1992)  
The use of left ventricular volume reduction as a surrogate for mortality in patients 
treated with CRT has not been conclusively proven. Heart failure studies in the era prior 
to CRT have demonstrated a decrease in LVESV correlates with improvement in 
survival. Beta blockers have been shown in echocardiographic studies (Doughty et al., 
1997) and CMR imaging (Bellenger et al., 2004) studies to cause reverse remodelling in 
patients with heart failure. Reverse left ventricular remodelling is associated with 
increased survival. (H. D. White et al., 1987) However, an intervention which results in 
an improvement in ejection fraction does not necessarily translate into an improvement in 
mortality. (Packer et al., 1991) Furthermore, when heart failure is advanced, therapies 
may reduce neurohormonal activation but have little effect due to ongoing myocyte 
changes which become independent of neuro-hormones (Mann and Bristow, 2005). The 
use of reverse remodelling in the CRT population as a surrogate for mortality requires 
clarification.   
A further issue regarding the use of left ventricular volumes in studies is the accuracy of 
the measurements. Left ventricular ejection fraction and volume measurements can be 
difficult to perform with accuracy. In a comparison of echocardiography with CMR 
analysis all patients in the study underwent two CMR and two echocardiograms, which 
were completed on the same day and within 60 minutes. (Grothues et al., 2002) The 
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results were analysed by two observers for each technique. To detect a 3% absolute 
change in ejection fraction by echocardiography in patients with heart failure would 
require 115 patients, and 14 by CMR, and to detect a 10ml reduction in end systolic 
volume would require 82 and 12 patients respectively. The coefficient of variability was 
7.4% by CMR and 19.4% by echocardiography. This suggests that small studies which 
use left ventricular volumes determined using Simpson’s rule as an end point, could be 
inaccurate. 
Cardiac resynchronisation therapy results in reverse remodelling. (Yu et al., 2005b) The 
largest study of 141 patients found that baseline variables including QRS duration, 
NYHA class, 6 minute walk distance, quality of life score and left ventricular volumes 
were not significantly different between survivors and non-survivors. TDI dyssynchrony 
was significantly higher in survivors compared with those who died, 62.9 ± 47.3 ms vs. 
28.3 ± 23.5 ms. At follow up, there was no statistical difference between those who 
survived and those who died in terms of change in NYHA class, 6 minute walk distance 
and quality of life scores. In this study, patients with the greatest dyssynchrony score had 
the best survival, (≥ 60 ms mortality 6.6% vs. < 60ms 21.8%). ROC curve analysis found 
that a LVESV reduction of 9.5% was identified as the optimum cut off for predicting 
long term survival. 61.7% of the patients had a greater than 10% reduction in LVESV 
and were termed responders. 93% of the responders survived during follow up compared 
with 70.4% of non responders. Clinical response in terms of NYHA class, 6 minute walk 
distance and quality of life scores did not predict survival. It was concluded that this 
study demonstrates that reverse remodelling predicts survival benefit from CRT, 
consistent with previous studies of medical therapy. In view of the inaccuracies inherent 
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in measurement of EF, large scale studies are required to validate the cut off value of a 
10% reduction in LVESV. Reverse remodelling is straight forward to measure, and is 
now widely reported in clinical trials of CRT. 
 
1.13.1 Role of dyssynchrony in predicting response 
Although difficulties remain in defining what is a response to CRT and what represents a 
failure of therapy, (Cleland et al., 2009) both in clinical practice and studies a definition 
of outcome is required. Clinical evidence supports the effectiveness of CRT to be related 
to the presence of dyssynchrony, the amount of scarring and viability, optimisation of 
atrio-ventricular pacing delay and diastolic ventricular interaction. There is no gold 
standard for measuring dyssynchrony, and early work by Xiou et al demonstrates that all 
patients with dilated hearts have evidence of dyssynchrony measured using signal 
averaged ECG when compared with normal QRS on the standard surface 12 lead ECG.  
In this thesis, I intend to examine whether CMR based methods of determining 
dyssynchrony offer accurate determination of response. Cardiac magnetic resonance 
imaging offers the possibility of determining the aetiology of heart failure and prognosis 
after CRT in one examination.  
It is likely that all patients studied in currently published clinical trials have 
dyssynchrony. Yet, at present, 70% of patients with heart failure are excluded from CRT 
on the basis of QRS duration of less than 120ms. However, Xiou et al have demonstrated 
that in patients with cardiomegaly, the surface QRS duration underestimates the true 
QRS. (Xiao et al., 1996) On the basis of experimental series, pacing patients with narrow 
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QRS heart failure, (Turner et al., 2004) and preliminary cohort studies, patients with 
narrow QRS heart failure may respond to CRT. (Bleeker et al., 2006b, Yu et al., 2006) 
Recruitment of patients with severe dyssynchrony may reduce the detectable benefits of 
CRT. At extremes of dyssynchrony, there is a point beyond which reverse remodelling 
does not occur. (Bax et al., 2004b) The absence of viable myocardium is associated with 
a lack of reverse remodelling. (Bleeker et al., 2006c, White et al., 2006)  
1.13.2 Scar Burden on CMR 
The presence of myocardial scar detected on MRI has an adverse impact on prognosis in 
both ischaemic (Kwong et al., 2006) and dilated cardiomyopathy. (Assomull et al., 2006) 
Myocardial scar is delineated by scanning after injection of intravenous gadolinium. 
Gadolinium accumulates in oedematous area, resulting from loss of cell membranes and 
hence at sites of myocardial infarction. (Saeed et al., 1990) Increasing myocardial scar 
correlates with a poorer response in terms of NYHA class, 6 minute walk time and 
quality of life questionnaires. (White et al., 2006)  In multi-variable analysis, only 
percentage of total scar by delayed enhanced CMR was predictive of clinical response to 
CRT.  Using a percentage scar of 15% resulted in a sensitivity and specificity of 85% and 
90% for clinical using ROC analysis, whilst septal scar less than 40% provided 100% 
sensitivity and specificity for response. (See Figure 1-25) 
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Figure 1-25 Scar imaging and response to CRT 
Examples of scar distribution (bright signal) on delayed gadolinium enhancement 
magnetic resonance imaging from clinical non-responders (top row), responders without 
scar (middle row), and responders with scar (bottom row).21  
                                                
21 Reproduced from: White, J.A., Yee, R., Yuan, X., et al. (2006) Delayed enhancement 
magnetic resonance imaging predicts response to cardiac resynchronization therapy in 
patients with intraventricular dyssynchrony. J Am Coll Cardiol, 48: (10): 1953-
1960.with permission of Elsevier. 
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The location of scar is a key determinant of response. (Bleeker et al., 2006c) Patients with 
postero-lateral scar did not respond clinically or experience beneficial re-modelling in 
terms of improved left ventricular ejection fraction. TDI imaging found that the site of 
latest activation was the postero-lateral region in all patients. In this study, there was no 
optimisation of the left and right ventricular pacing parameters. In this study, a septal to 
lateral delay of greater than 65ms was taken as the criterion for dyssynchrony, with inter-
observer and intra-observer agreement of 90% and 96%, respectively. 
 
1.13.3 B-type natriuretic peptide and response 
Heart failure results in activation of neuro-hormonal pathways. A sensitive marker of this 
activation is the serum B type natriuretic peptide (BNP).  Mortality in heart failure is 
predicted by the level of BNP. In comparison with heart failure patients treated with best 
medical therapy alone, patients treated with CRT have reduced levels of BNP. (Fruhwald 
et al., 2007) 
Baseline levels of BNP predict hospitalisation after CRT implantation. (Pitzalis et al., 
2006) On multivariate analysis BNP at baseline (HR 2.09) and one month predicted those 
patients who would be hospitalised (HR 2.23). Higher baseline BNP levels were 
associated with adverse outcome.  
Baseline BNP also appears to predict CRT response. (Lellouche et al., 2007) Indeed, 
BNP was the only significant predictor of response on multivariate analysis. The 
optimum cut off for predicting response was 447 pg/ml, which had a specificity of 79% 
and sensitivity of 62% in predicting response to CRT. The pre-implantation BNP was 
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significantly higher in patients with intra-ventricular dyssynchrony (845 ± 779 pg/ml vs. 
248 ± 290 pg/ml). Thus, BNP was correlated with intra-ventricular dyssynchrony. Follow 
up BNP measurements appear to detect response to CRT. (Yu et al., 2005c) NT-proBNP 
reduction correlated with reduction in LVESV.  
The available evidence suggests that BNP can be a sensitive marker of benefit from CRT, 
suggesting that CRT has a beneficial effect on decreasing neuro-hormonal activation. 
 
1.14 Summary 
The effect of CRT appears to be mediated by correction of dyssynchrony. Other factors are 
important, including correction of diastolic mitral regurgitation and DVI. Numerous 
echocardiographic methods of detecting dyssynchrony are discussed, but determination of 
outcome using these techniques appears problematic. CMR, using myocardial tagging 
appears to be promising, but little human data is available to validate the animal findings. 
Patients with myocardial scar do not appear to fare as well in the short term, but long term 
data are not available.
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CHAPTER 2. CARDIOVASCULAR MAGNETIC RESONANCE 
TISSUE SYNCHRONISATION INDEX (CMR-TSI) 
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2.1 Introduction 
Dyssynchrony has been demonstrated in patients with systolic HF. However, the 
proportion of patients with dyssynchrony varies depending on the technique used to 
measure it. Early studies using M-mode echocardiography in patients with HF and LBBB 
demonstrated delay in the contraction of the posterior wall in relation to the septum. 
Thus, the link between electrical and mechanical delay was clearly established. The aim 
of cardiac resynchronisation therapy is to correct this electro-mechanical delay.  
Although the exact mechanism by which CRT achieves its effect required further 
clarification, correction of dyssynchrony has been extensively studied. Identification of 
dyssynchrony could allow precise targeting of device therapy to achieve the greatest 
benefit. Clinical trials have shown that patients with symptomatic heart failure and poor 
left ventricular function may benefit from CRT, providing there is evidence of prolonged 
QRS duration. (Bristow et al., 2004, Cleland et al., 2005b)  
It was shown using M-mode echocardiography that patients with dilated left ventricles 
and left bundle branch block pattern on the surface electrocardiogram had delayed 
activation of the posterior wall. (Xiao, 1994)  TDI is now widely used to measure delay 
in activation of the left ventricle, and several authors have measured delay in activation 
of the left ventricle in an attempt to predict response to CRT. More recently, cohort 
studies of patients with mechanical dyssynchrony measured using TDI but without 
prolonged QRS (greater than 120 ms) have been found to respond to CRT. (Achilli et al., 
2003, Bleeker et al., 2006b, Yu et al., 2006)  
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Identification of mechanical dyssynchrony in patients without evidence of conduction 
delay may result in benefit from CRT. However, the only randomised controlled trial of 
CRT in patients with cardiomyopathy undergoing ICD implantation, did not find a 
benefit from CRT in patients with a QRS < 120 ms at six months follow up. (Beshai et 
al., 2007) 
Cardiac magnetic resonance (CMR) imaging is the gold standard for measuring left 
ventricular volumes and ejection fraction as measurements are made without geometric 
assumptions. (Jenkins et al., 2008) In contrast, echocardiographic images of patients with 
heart failure are often poor due to left ventricular dilatation which makes accurate 
assessment difficult, coupled with the problems of poor acoustic windows. The most 
accurate two-dimensional echocardiographic measure of ejection fraction, Simpson’s 
methodology makes geometric assumptions.  
Sophisticated echocardiographic techniques, such as tissue velocity imaging are angle 
dependent and inter-observer reproducibility is variable. Yu at al. compared heart failure 
patients with controls and found considerable overlap between patients and controls. (Yu 
et al., 2003b) CMR offers high quality images with good temporal and spatial resolution. 
We sought to measure left ventricular radial wall motion synchrony in normal subjects, 
to allow comparison with patients with cardiac failure. Short axis stacks of the left 
ventricle have been used to quantify segmental wall motion and thickening.  
The assessment of cardiac dyssynchrony is becoming increasingly important in clinical 
practice. In patients with HF, echocardiographic studies using TDI have shown that 
intraventricular dyssynchrony is an independent predictor of clinical decompensation. 
(Bader et al., 2004) In the field of CRT, numerous studies have shown that cardiac 
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dysfunction results from mechanical dyssynchrony. (Burkhoff et al., 1986, Pak et al., 
1998, Park et al., 1985) Accordingly, echocardiographic markers of cardiac 
dyssynchrony are being used to predict the response to CRT. (Auricchio and Yu, 2004, 
Kass, 2003, Nelson et al., 2000, Pitzalis et al., 2005, Søgaard et al., 2001, Yu et al., 
2003a)  
Echocardiographic studies, however, have shown a considerable overlap in measures of 
left ventricular dyssynchrony between healthy controls and patients with HF, (Yu et al., 
2003b) suggesting that not all patients with HF have LV dyssynchrony. In the assessment 
of cardiac dyssynchrony, echocardiography provides excellent temporal resolution, but it 
is limited to imaging only a portion of the left ventricle. CMR may be more sensitive at 
detecting cardiac dyssynchrony as it can image the whole heart. We have used short axis 
stacks of the LV to quantify segmental wall motion. Time-to peak wall motion (Twm) has 
been employed in the derivation of dyssynchrony scores, in a manner similar to 
echocardiographic methods. (Yu et al., 2003a) We have assessed these CMR-derived 
dyssynchrony scores, expressed in terms of the standard deviation (SD) of Twm for all 
segments (CMR-TSI). 
2.2 Methods 
The methods used in this technique were first described by Chalil who described the 
technique, comparing heart failure patients and controls. In the same paper, the technique 
was validated against symptoms and clinical events in 77 patients with heart failure 
undergoing CRT. (Chalil et al., 2007d) 
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2.2.1 Cardiovascular magnetic resonance 
All subjects underwent a CMR study. Images were acquired on a 1.5 Tesla General 
Electric Signa scanner using a phased array cardiac coil during repeated 8-second breath 
holds. A short axis stack of LV images was acquired using a steady state free precession 
(SSFP) sequence (repetition time 3.0 to 3.8 ms; excitation time 1.0 ms; image matrix 224 
x 224; temporal resolution 27 to 34 ms; field of view 36 to 42 cm; flip angle 45o ) in 
sequential 8 mm slices (2 mm inter slice gap) from the atrioventricular ring to apex. Left 
ventricular volumes, ejection fraction and mass (myocardial density=1.05 g/cm3) were 
quantified using manual planimetry of all short-axis SSFP cine images with MASS 
analysis software (Medis, The Netherlands). Each slice in the short axis stack was 
divided into 6 equal segments in a clockwise fashion (see Figure 2-1), with the first 
segment commencing at the junction between the inferior right ventricular free wall and 
the interventricular septum. This yielded up to 60 segments per patient (see Figure 2-2) 
Each short axis slice in the short axis stack was divided into 100 cords in a clockwise 
manner, from the junction between the inferior right ventricular free wall and the inter-
ventricular septum (See figure 1). Radial wall motion was quantified for all cords at all 
phases in each R-R interval. The radial wall motion data (y) were fitted to an empirical 
sine wave function y = a + b * sin (t/RR + c). The mean segmental radial wall motion (a), 
the segmental radial wall motion amplitude (b) and the segmental phase shift of the 
maximum radial wall motion (c) were extracted from the fit. The CMR-TSI, a global 
measure of dyssynchrony, was expressed as the SD of all segmental phase shifts of the 
radial wall motion extracted from the fit.  
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Effectively, the CMR-TSI is based on the temporal dispersion of the time-to-peak inward 
endocardial motion. To assess the degree to which the fitted sinus curve agreed with the 
observed curve, the CMR data was fitted to increasingly complex harmonic models, 
starting with a zero order (naïve) model and then adding first, second and third order 
harmonic components in a stepwise manner. Higher than third order harmonic models 
were not explored, so as to avoid over fitting. For each modelling step, the full model 
was compared to the naïve model, to decide if the more complex model improved the 
model significantly and if this caused a substantial change in the first order phase shift. In 
all cases, the first order model was statistically superior to the naïve model (p<0.05). 
Second order harmonic models did increase the goodness of fit in most cases, while third 
order models did only improve the fit in some cases. As expected, the first order phase 
was not altered by adding higher order components to the fit, while the overall shape of 
the motion curve was better described with higher order harmonic fits. 
The wall motion in the six segments was plotted against time. (see Figure 2-3). Two 
examples are shown, comparing the heterogenous motion of the patient with HF and 
LBBB with the control participant. The data were exported to MatLab to create polar 
maps and four dimensional models (see Figure 2-4, Figure 2-5). The data were exported 
from Mass (Medis, The Netherlands) as an advanced report to R language to a bespoke 
program written by Berthold Stegemann, Principle Scientist at the Bakken Research 
Centre, Maastricht, The Netherlands. 
The patients studied were undergoing CMR and some underwent CRT implantation for 
HF. The studies were analysed at different time points during the research program, 
hence the number of patients in each study varied. 
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2.3 Figure legends 
Figure 2-1 shows the left ventricle sliced from base to apex, and then divided into 6 
segments.  
Figure 2-2 shows the intersection between the right ventricular free wall and the infero-
posterior aspect of the left ventricle is used to denote the first segment, which then spread 
in a clockwise fashion around the left ventricle. 
Figure 2-3 shows a plot of left ventricular wall motion against time in a control and a 
patient with heart failure and left bundle branch block. This illustrates the homogenous 
appearance of the wall motion in controls when compared with the heterogenous 
appearance seen in patients with heart failure and left bundle branch block, and illustrates 
the benefit of the spatial resolution afforded by CMR.  
A three dimensional plot of the left ventricle with the time of peak wall motion 
superimposed, allowing comparison between the control (Figure 2-4) and a patient with 
heart failure and left bundle branch block (Figure 2-5.). This image is produced in 
Matlab, and derived from the advanced reports produced in Mass. A four dimensional 
image illustrates the spread of wall motion over time. 
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Figure 2-1 Division of the left ventricular myocardium into slices 
 
Figure 2-2 Division of the left ventricular myocardium slices into segments 
This shows the junction between the interventricular septum and the right ventricular free 
wall delimits the beginning of segment 1 and the end of segment 6, counting clockwise. 
Wall motion in each segment is plotted over time in control patient, patient with heart 
failure and left bundle branch block.22 
                                                
22  
Figure 2-3 (top) and  b (bottom) Reproduced with permission from Chalil, S., Stegemann, 
B., Muhyaldeen, S., et al. (2007) Intraventricular Dyssynchrony Predicts Mortality and 
Morbidity After Cardiac Resynchronization Therapy: A Study Using Cardiovascular 
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Figure 2-3 Wall motion over time 
 
                                                                                                                                            
Magnetic Resonance Tissue Synchronization Imaging. J Am Coll Cardiol, 50: (3): 243-
252. 
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Figure 2-4 Three dimensional representation of the mechanical activation of the left 
ventricle in control 
 
 
Figure 2-5 Three dimensional representation of the mechanical activation of the left 
ventricle in patient with HF and LBBB 
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CHAPTER 3. LEFT VENTRICULAR FUNCTION AND 
RELATION TO RADIAL DYSSYNCHRONY AND QRS 
DURATION – A CARDIOVASCULAR MAGNETIC RESONANCE 
STUDY 
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3.1 Introduction 
Dyssynchrony has been demonstrated to be present in many patients with systolic HF. 
The relationship between HF and dyssynchrony is unclear, with some echocardiographic 
studies suggesting patients with HF and LBBB may not have any dyssynchrony. (Yu et 
al., 2003b)  Furthermore, these studies suggest that mechanical dyssynchrony is present 
in only certain populations of patients with heart failure, with little relationship to QRS 
duration. (Yu et al., 2003b) Thus some patients with heart failure do not have 
dyssynchrony. The uncertainty about how to measure dyssynchrony and the conflicting 
results of studies using different methodologies has lead to an epidemic of dyssynchrony 
has been declared. (Kass, 2008) 
The importance of the role of dyssynchrony extends beyond the interest in the imaging 
modality used to determine its presence, into the role of cardiac resynchronisation 
therapy (CRT) as a therapy for patients with heart failure. Currently, QRS duration alone 
is used to determine selection for CRT, with conduction delay used as a surrogate for 
mechanical dyssynchrony, with selection criteria pivoting on a QRS duration of 120 ms. 
However, concern has arisen that CRT may not benefit to all patients who meet the 
current criteria, and screening for mechanical dyssynchrony would avoid implantation in 
patients who do not gain a symptomatic benefit or reverse remodelling with CRT, the so 
called “non-responders”. Others argue that clinical trials show that all patients 
undergoing CRT benefit in terms of survival, with no subgroup shown to be at a 
disadvantage from CRT, and that lack of change in symptomatology may simply reflect 
underlying disease. (Cleland et al., 2008b)  
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The current paradigm of CRT is that mechanical dyssynchrony is required to gain benefit 
from CRT, and the greater the dyssynchrony, the greater the benefit from CRT. Avoiding 
pacing patients without sufficient mechanical dyssynchrony has been proposed in an 
attempt to improve the symptomatic response to CRT. (Auricchio and Yu, 2004, Van de 
Veire et al., 2007) However, there have not been any randomised clinical trial to examine 
this hypothesis, and the only prospective blinded multi-centre observational clinical study 
was unable to identify a single echocardiographic factor that predicted a change in the 
clinical composite score or left ventricular reverse remodelling. (Chung et al., 2008) The 
question as to whether this is a limitation of the tissue Doppler technology, (Marwick, 
2008) or one of trial design and methodology remains unresolved. (Yu et al., 2005a, Yu 
et al., 2009) Alternatively, the failure of the study could reflect a more fundamental issue, 
that detecting mechanical dyssynchrony is not helpful in selecting patients for CRT.  
Cardiac resynchronisation therapy has been studied in patients with evidence of electrical 
conduction delay determined from the twelve lead ECG. The advantage of identifying 
patients with mechanical dyssynchrony despite a narrow QRS (QRS < 120 ms.) would be 
to support clinical studies of CRT in patients with heart failure and narrow QRS. Small 
scale, non-controlled and single centre studies have suggested that the benefits of 
extending CRT to patients with narrow QRS and evidence of mechanical dyssynchrony 
on echocardiography is similar to those with a broad QRS in terms of symptomatic and 
echocardiographic change. (Bleeker et al., 2006b, Yu et al., 2006) However, the only 
randomised controlled study of CRT in patients with narrow QRS did not find a benefit 
from CRT at six months follow up. (Beshai et al., 2007) 
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We sought to explore the relationship between electrical synchrony, measured using the 
QRS duration, left ventricular volumes and ejection fraction and compare these to 
mechanical synchrony measured using CMR-TSI.  
3.2 Methods 
3.2.1 Subjects.  
The study group consisted of 225 patients with HF. Patients were referred for a CMR 
study in a single centre (Good Hope Hospital). The diagnosis of HF was made if 
symptoms of HF were associated with objective evidence of LV dysfunction on 
echocardiography, or if pulmonary oedema had been documented on chest radiography 
in the absence of valvular disease. The diagnosis of ICM was made if systolic 
dysfunction was associated with a history of myocardial infarction (Alpert et al., 2000) or 
if there was angiographically documented coronary heart disease (>50% stenosis in ≥ 1 
coronary arteries). Late gadolinium enhancement CMR was also used to distinguish 
between ICM from NICM. (Assomull et al., 2006) Patients with LV dysfunction in 
combination with the finding of transmural or subendocardial late gadolinium uptake 
were classified as having ICM whereas patients with LV dysfunction and no gadolinium 
uptake, patchy uptake or midwall hyperenhancement were classified as having NICM. 
Control subjects consisted of 50 asymptomatic individuals (age 47.8 ± 15.4 yrs) who had 
no history of cardiac disease and a normal ECG, including a QRS duration <120 ms (78.4 
± 21.5 ms). The study was approved by the local Ethics Committee. 77 patients had been 
included in an earlier study which described the technique. (Chalil et al., 2007d) 
3.2.2 Cardiovascular magnetic resonance 
This was undertaken as described in chapter 2. 
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3.2.3 Septal to lateral wall motion delay  
The septal-to-lateral wall motion delay (SLWMD) was defined as the time difference (in 
ms) between the time-to-peak inward wall motion of the septal and lateral segments, 
from base to apex. The observer was blinded to all other clinical details of the patients, 
including the outcome measures.  
3.2.4 Spatial Distribution of Dyssynchrony 
The CMR techniques described above permits visualization of radial wall motion 
throughout the entire LV. The radial wall motion data derived from each short axis CMR 
slices were colour-coded to construct radial wall motion polar colour maps. Values for 
radial wall motion were colour-coded from blue to red, with red denoting extreme delay 
in radial wall motion.  
3.2.5 Scar Imaging 
For scar imaging, gadolinium-diethylenetriamine pentaacetic acid (0.1 mmol/kg) was 
administered intravenously and images were acquired after 10 minutes using a segmented 
inversion-recovery technique in identical short-axis slices. Inversion times were adjusted 
to null normal myocardium (260 to 400 ms). Quantification of myocardial scarring was 
carried out by planimetry of hyper enhanced tissue on late-enhancement short-axis 
images. Infarct volume was calculated in cm3 by multiplying the plani metered area in 
each segment by the slice thickness. Scar volume was expressed as a % of left ventricular 
myocardial volume in the diastolic phase. Satisfactory images were obtained in 220/225 
patients with HF (125/130 patients with ICM). The observer was blinded to other CMR, 
echocardiographic and clinical data. 
104 
 
 
3.2.6 Statistical Analysis 
Continuous variables are expressed as mean ± standard deviation (SD). Normality was 
tested  using the Shapiro-Wilk test. Comparisons between continuous variables were 
made using the unpaired Student’s t test. Categorical data were presented as frequencies 
and were compared using the Chi-squared test and Fisher’s exact post-hoc test. Linear 
regression and Pearson’s correlation analyses were used to explore the relationship 
between continuous variables. Statistical analyses were performed using Statview (Cary, 
NC). A two-tailed p value of <0.05 was considered statistically significant. 
 
3.3 Results 
Ischaemic cardiomyopathy was associated with higher levels of mechanical 
dyssynchrony measured using CMR-TSI compared to patients with dilated 
cardiomyopathy, despite similar QRS duration and left ventricular ejection fraction. Only 
one patient had an ejection fraction of less than 35% and no dyssynchrony, defined as a 
CMR-TSI less than 30 (mean + two standard deviations). Echocardiographic left 
ventricular ejection fraction did not relate to CMR-TSI. There appeared to be an 
exponential relationship between CMR-EF and CMR-TSI, such that the worse the 
ejection fraction, the worse the dyssynchrony. 
Compared to patients with a QRS<120 ms, patients in the QRS 120-149 ms and the 
QRS≥150 ms groups were older, had a higher NYHA class and had higher LV volumes 
and a worse LVEF (Table 3-1). A greater proportion of patients in these groups had 
undergone CABG. Likewise, a greater proportion of patients in these groups were on 
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treatment with loop diuretics and spironolactone. In controls, there was no correlation 
between CMR-TSI and age (r=-0.16, NS). 
 
3.3.1 Dyssynchrony and QRS duration 
The distribution of CMR-TSI in healthy controls was narrow, at 21.8 ± 6.3 ms. 
Compared to healthy controls, CMR-TSI was 3.4 times higher in the QRS <120 ms 
group (74.8 ± 34.6 ms), 4.2 times higher in the QRS 120-149 ms group (92.4 ± 39.4 ms) 
and 4.8 times higher in the QRS≥150 ms group (104.6 ± 45.6 ms) (all p<0.0001) (see 
Figure 3-1). Adopting a cut-off of 34 ms for the definition of dyssynchrony (21.8 plus 2 x 
SD for healthy controls is 34.4 ms), it was present in 68/75 (91%) patients with a 
QRS<120 ms, 71/75 (95%) patients with a QRS 120-149 ms and in 74/75 (99%) patients 
with a QRS≥150 ms. On this basis, a total of 213/225 (95%) of patients with heart failure 
had dyssynchrony. If only patients in NYHA class III or IV were considered, 
dyssynchrony was present in 36/38 (95%) patients with a QRS<120 ms, 58/61 (95%) 
patients with a QRS 120-149 ms and 63/64 (97%) patients with a QRS≥150 ms.  
In contrast to CMR-TSI, the distribution of SLWMD in healthy controls was wider (50.8 
± 28.6 ms). Compared to healthy controls, SLWMD was 2.1 higher in the QRS <120 ms 
group (109.0 ± 82.6 ms p=0.0022), 2.9 times higher in the QRS 120-149 ms group (148.0 
± 104.8 ms, p<0.0001) and 3.3 times higher in the QRS≥150 ms group (168.5 ±113.0 ms, 
p=0.0004).  
As shown in Figure 3-1, however, there was a considerable overlap between the 
SLWMD in healthy controls and patients with heart failure. Adopting a cut-off of 99.4 
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ms for the definition of dyssynchrony (48.7 plus 2 x SD [2 x 25.4 ms] for healthy 
controls is 99.4 ms), dyssynchrony was present in 46% in the QRS <120 ms group, 62% 
in the QRS 120-149 ms group and 62% in the QRS≥150 ms group (168.5 ±113.0 ms). A 
total of 56% patients with heart failure had dyssynchrony on the basis of a SLWMD ≥ 
99.4 ms.  
As shown in Figure 3-2, CMR-TSI correlated positively with QRS duration in patients 
with HF (r = 0.35, p<0.0001). The correlation between SPWMD and QRS duration was 
also significant, although weaker (r = 0.27, p=0.0003). As expected, there was a 
correlation between CMR-TSI and SLWMD (r=0.37, p<0.0001). The patients classified 
as dyssynchronous by CMR-TSI were not necessarily the same as patients classified as 
dyssynchrony on SLWMD (discordance rate: 45%). 
 
3.3.2  Dyssynchrony and left ventricular function 
Dyssynchrony was demonstrated in 170/174 (97%) patients with LVEF<35%. As shown 
in Figure 3-3, CMR-TSI was related to LVEF across the whole study population, 
governed by the exponential function CMR-TSI = 178.3 . e (-0.033 . LVEF)  (p <0.0001). 
Similar exponential relationships were observed in relation to LVEDV and LVESV 
(p<0.0001). When all patients with HF were classified according to quartiles of scar size, 
the most extreme dyssynchrony was observed in patients with scars>75%. (Figure 3-4). 
For patients such as those included in the CARE-HF study, namely patients in NYHA 
class III or IV with an LVEF<35% and a QRS≥120 ms, dyssynchrony was present in 
132/133 (99%) patients. 
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3.3.3 Spatial distribution of dyssynchrony and QRS duration 
As shown in Figure 3-5, patients with heart failure had a relatively heterogenous 
distribution of radial wall motion, with polar colour maps showing numerous ‘patches’ of 
radial wall motion throughout the LV. In patients with heart failure, the number of 
patches of late radial wall motion correlated positively with QRS duration (r = 0.21, p = 
0.0060). 
 
3.4 Discussion 
The most salient finding from this study is that almost all heart failure patients with an 
ejection fraction of less than 35%, who currently meet criteria for cardiac 
resynchronisation therapy, exhibit dyssynchrony. This is in contrast to findings from 
echocardiographic techniques, which suggest that only certain patients exhibit sufficient 
dyssynchrony to benefit from CRT. (Bax et al., 2003a, Yu et al., 2003a) The relationship 
between increasing mechanical dyssynchrony and increasing ventricular conduction 
delay assessed using QRS duration appears intuitive, and is clearly seen with CMR-TSI, 
but not always with echocardiographic measures of dyssynchrony. (Yu et al., 2003b) 
Bleeker et al. noted dyssynchrony, defined as a septal to lateral wall delay in peak 
systolic velocity of 60 ms, in 20% of heart failure patients with a QRS less than 120 ms, 
60% in those with a QRS of 120 to 150 ms, and 70% in those with a QRS greater than 
150 ms. (Bleeker et al., 2004) 
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3.4.1 Left ventricular volumes 
The greatest dyssynchrony was seen in patients with the lowest left ventricular ejection 
fractions and highest volumes. An exponential relationship between left ventricular 
volumes, ejection fraction and CMR-TSI existed. The equation CMR-TSI = 178.3 e (-0.033. 
LVEF) explained the relationship between LVEF and CMR-TSI. Extreme dyssynchrony 
was therefore seen in those patients with the worst myocardial function. 
A criticism of CMR-TSI is the relationship between CMR-TSI and LVEF, suggesting 
that CMR-TSI is simply a reflection of function. However, the CMR-TSI technique 
involves the timing of peak wall motion, rather than simply being a reflection of left 
ventricular volume. Furthermore, we have previously shown that CMR-TSI is 
independent of left ventricular volumes using multivariate Cox proportional hazard 
analysis. (Chalil et al., 2007d)   However, in contrast echocardiographic studies using 
tissue velocity imaging found no relationship between left ventricular function, volumes 
and septal to lateral wall motion delay. (Bleeker et al., 2004)  
 
3.4.2 Myocardial Scar 
Left ventricular dyssynchrony was significantly higher in patients with myocardial scar. 
Furthermore, expressed as a percentage myocardium scarred, the CMR-TSI was 
significantly greater as the scar burden increased, suggesting that the disruption to 
myocyte function and electrical conduction after myocardial infarction results in 
mechanical delay. Again in contrast, Bleeker et al. found patients with ischaemic heart 
disease had less dyssynchrony than patients with dilated cardiomyopathy when assessed 
using septal to lateral wall motion delay on tissue velocity imaging. (Bleeker et al., 2004) 
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Clinical outcome studies of CRT have used an echocardiographic EF ≤35% as an entry 
criterion. (Bristow et al., 2004, Cleland et al., 2005b) In this study we have demonstrated 
that patients who meet the current clinical guidelines for CRT have dyssynchrony. 
Furthermore, we found that left ventricular volumes were also subject to an exponential 
function, such that extreme dyssynchrony relates to extreme left ventricular dilation. 
These findings suggest that the most extreme dyssynchrony is found in those with the 
worse cardiac function.  
Reviewing the current literature surrounding CRT, of which the majority is based on 
echocardiography, suggests that the greater the dyssynchrony, the greater the benefit 
from CRT. (Bax et al., 2003a, Yu et al., 2004a) However, on the basis of this study, the 
paradigm that “dyssynchrony is good” (at least for patients treated with CRT) is counter-
intuitive, when the most extreme dyssynchrony is associated with extreme left ventricular 
dysfunction and myocardial scarring. We and others have previously found that 
myocardial scar predicts a worse outcome after CRT. (Ypenburg et al., 2007b) Possibly 
those patients with the greatest dyssynchrony fare the worst in terms of morbidity and 
mortality. Consistent with these observations, Bax et al. demonstrated using tissue 
velocity imaging that beyond a posterior to lateral delay of 100 ms, there is no benefit 
from CRT in terms of reverse left ventricular remodelling. (Bax et al., 2004b) Similarly, 
findings in patients with heart failure untreated with CRT have found that extreme intra-
ventricular dyssynchrony measured with tissue velocity imaging had the greatest risk of 
heart failure decompensation. (Cho et al., 2005) An alternative paradigm for CRT is 
suggested, that all patients with moderate to severe systolic heart failure have intra-
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ventricular radial dyssynchrony, and that those with little response to CRT are those with 
the worst left ventricular function and the greatest volume of myocardial scar. 
 
3.4.3 Relationship between QRS duration and dyssynchrony 
The lack of symptomatic improvement to CRT in some patients with heart failure despite 
a QRS > 120ms has raised concern that the electrocardiogram is not sufficiently robust to 
measure dyssynchrony. (Perry et al., 2006) Perry et al. found that dyssynchrony was 
present in 65% of patients with systolic heart failure and a QRS < 120 ms, and 58% of 
patients with a QRS >120msec using a definition of time to peak systolic contraction, 
measured with TVI, greater than 105 milliseconds in opposing ventricular walls. Yu et al 
(Yu et al., 2003b) found that 3% of healthy controls had dyssynchrony, measured using 
the 12 segment TVI model, but as many as 36% of patients with a QRS ≥120 ms and 
57% of patients with a QRS<120 ms did not.  
The relative importance of mechanical and electrical dyssynchrony and electro-
mechanical coupling have not been resolved. It is possible that mechanical dyssynchrony 
may be more important than electrical dyssynchrony. Using tissue Doppler imaging, Yu 
et al. examined a 12 segment model of the left ventricle, and found that dyssynchrony 
was present in only 73% of patients with heart failure and a QRS > 120 ms. (C. M. Yu et 
al., 2003b) Our findings that 99% of patients with HF and an EF of less than 35% had 
dyssynchrony is in contrast to these and others findings using TVI. In relation to patients 
with HF and a QRS < 120 msec, TDI studies have suggested a prevalence of 
dyssynchrony of between 36 to 65% of patients, depending on the methodology. (Bleeker 
et al., 2004, Perry et al., 2006, Uchiyama et al., 2005, Yu et al., 2003b) When CMR-TSI 
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is used to measure intra-ventricular dyssynchrony, the prevalence in this study was much 
higher at 91% in patients with HF and a QRS < 120ms.  
The discrepancy between echocardiography and CMR based studies of dyssynchrony 
may be explained by a number of factors. The CMR-TSI technique takes into account 
wall motion affecting the whole ventricle, whereas echocardiographic techniques are 
limited to parts of the left ventricle. CMR-TSI is based upon radial wall displacement, 
rather than longitudinal velocities. Studies of TDI have found greater inter-observer 
variability (interobserver coefficient of variation of 33.7% for 12 segment model) (Chung 
et al., 2008), where-as it is much lower (9%) for CMR-TSI. (Chalil et al., 2007d) The 
PROSPECT study found large variations in the different echocardiographic techniques 
used to detect dyssynchrony. (Chung et al., 2008)  
The correlation between prolonged QRS and mechanical dyssynchrony is not consistent. 
QRS prolongation results in delayed left ventricular activation, and CMR tagging studies 
suggest that this is usually in the postero-lateral region. (Auricchio et al., 2004) Radio-
nucleotide phase analysis has reported a correlation between QRS duration and intra-
ventricular dyssynchrony, (Fauchier et al., 2002, Fauchier et al., 2003), although others 
have reported only a weak linear correlation. (Marcassa et al., 2007) In comparison, 
whilst one TDI study described a mild correlation (Haghjoo et al., 2007), many have not. 
(Bleeker et al., 2004, Perry et al., 2006, Yu et al., 2003b) Recently, Donal et al. reported 
a correlation between QRS duration and radial dyssynchrony using both two dimensional 
speckle tracking and tissue velocity imaging in heart failure patients with dilated 
cardiomyopathy, but not in patients with ischaemic cardiomyopathy. (Donal et al., 2008) 
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In this study QRS duration correlated (r= 0.35, p<0.0001) with CMR-TSI in patients with 
heart failure.  
 
3.4.4 Implications for CRT in narrow QRS 
The striking finding that the majority of patients with heart failure and narrow QRS 
(<120 milliseconds) exhibit dyssynchrony when measured with CMR-TSI suggest that 
CRT may have a role in treatment of patients with heart failure and a QRS < 120 
milliseconds.  
However, studies of CRT in patients with narrow QRS heart failure have reported mixed 
outcomes. The RETHINQ study comparing CRT-D to ICD therapy in patients with 
NYHA class III or IV heart failure and QRS < 130 milliseconds reported no 
improvement in peak metabolic activity, six minute walk test or quality of life at six 
months follow up, although there was a trend to improvement in NYHA class, which did 
not meet statistical significance. (Beshai et al., 2007) Yu et al. noted an improvement in 
NYHA class, six minute walk distance, quality of life and significant reverse remodelling 
in patients with hear failure and a QRS < 120 milliseconds. Switching off the therapy for 
four weeks resulted in reversal of the echocardiographic changes.  (Yu et al., 2006) 
Single centre cohort studies have reported similar benefits, but have lacked a control 
group. (Bleeker et al., 2006b) In this study, we found the majority (91%) of patients and 
QRS < 120 milliseconds had radial dyssynchrony, which provides a basis for further 
studies of CRT in this population.  
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An acute haemodynamic study suggests that CRT in narrow QRS heart failure improves 
cardiac function. (Williams et al., 2009) However, the mechanism is not yet fully 
elucidated and may result from reduction of external constraint. It is likely that correction 
of dyssynchrony is not the only mechanism by which CRT exerts an effect.  
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3.5 FIGURE LEGENDS  
Figure 3-1 Scattergrams of cardiovascular magnetic resonance tissue synchronisation 
index (CMR-TSI) in 50 healthy controls with a QRS <120 ms and in 225 patients with 
heart failure, grouped according to QRS duration;  
 
Figure 3-2 Regression and correlation analyses of a) cardiovascular magnetic resonance 
tissue synchronisation index (CMR-TSI) and b) septal-to-lateral wall motion delay 
(SLWMD) in 225 patients with heart failure. 
 
Figure 3-3 Regression analyses of CMR-TSI against parameters of left ventricular 
function 
 
Figure 3-4 CMR-TSI in relation to scar size 
Patients have been categorized according to strata of scar size. 
 
Figure 3-5 Bull’s eye maps of radial wall motion (colour bar indicates time in 
milliseconds) 
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Table 3-1 Clinical, electrocardiographic and magnetic resonance characteristics for 
patients included in the study, grouped according to QRS duration. 
  QRS duration p 
   A B C B vs A C vs A C vs B 
 <120 ms 120-149 ms ≥150 ms 
N 75 75 75   
Age, yrs  59.8 ± 11.6 66.5 ± 11.8 65.0 ± 11.9 0.0006 0.0078 NS 
Gender, male (%) 57 (76) 55 (73) 56 (75) NS NS NS 
NYHA class, n (%) 
  I 27 (36) 5 (7) 7 (9)    
 II 10 (13) 9 (12) 4 (5)  
 III 28 (37) 46 (61) 48 (64)  
 IV 10 (13) 15 (20) 16 (21) 
 As continuous variable  
 * 2.28 ± 1.09 2.95 ± 0.77 2.97 ± 0.81 <0.0001 <0.0001 NS  
Aetiology, n (%)  
 ICM 41 (55) 43 (57) 46 (61) NS  NS NS 
 NICM 34 (45) 32 (43) 29 (39) NS NS NS 
Co-morbidity, n (%) 
 Diabetes mellitus 7 (9) 15 (20) 8 (11)  0.0648 NS NS 
 Hypertension 21 (28) 20 (27) 17 (23)  NS NS NS 
 CABG  5 (7) 18 (24) 13 (17)  0.0032 0.0444 NS 
Medication, n (%) 
 Loop diuretics 43 (57) 59 (79) 62 (83)  0.0051 0.0007 NS 
 ACE-I or ARB 64 (85) 66 (88) 62 (83)  NS NS NS 
 Spironolactone 11 (15) 31 (41) 31 (41)  <0.0001 <0.0001 NS 
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ECG variables 
 SR, n (%) 64 (85) 61 (81) 56 (75) NS NS NS 
 AF, n (%) 11 (15) 14 (19) 19 (25) NS NS NS 
 QRS duration, ms 94.2 ± 12.4 129.1 ± 10.6 169.6 ± 17.7 <0.0001 <0.0001 <0.0001  
CMR variables 
 LVEDV, cm3 184.5 ± 64.9 230.1 ± 88.9 266.6 ± 102.8 0.0016 <0.0001 0.0112 
 LVESV, cm3 134.9 ± 63.0 181.2 ± 87.8 218.1 ± 100.4 0.0011 <0.0001 0.0087 
 LVEF, % 30.7 ± 13.2 24.6 ± 11.8 21.3 ± 9.2  0.0013 <0.0001 NS 
 % scar volume 21.5 ± 23.6 17.4 ± 21.3 18.3 ± 20.1 NS    NS NS 
  
p values refer to differences between the QRS<120 ms and the QRS≥120 ms groups. 
Continuous variables are expressed as mean ± SD. *, For functional class, statistical 
analyses were applied to NYHA class, expressed as a continuous variable. NYHA=New 
York Heart Association class. ICM = ischaemic cardiomyopathy; NICM = non-ischaemic 
cardiomyopathy; CABG = coronary artery bypass grafting; ACE-I=angiotensin 
converting enzyme inhibitors; ARB=angiotensin II receptor blockers; LVEF = left 
ventricular ejection fraction; LVEDV = left ventricular end-diastolic volume; LVESV = 
left ventricular end-systolic volume
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Figure 3-1 CMR-TSI and QRS duration 
 
 
 
CMR-TSI is on the y axis. 
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Figure 3-2 Correlation between CMR-TSI and QRS duration 
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Figure 3-3 Regression analyses of CMR-TSI against parameters of left ventricular 
function23 
                                                
23 CMR-TSI = cardiovascular magnetic resonance tissue synchronisation index; LVEF = 
left ventricular ejection fraction; LVEDV = left ventricular end-diastolic volume; 
LVSEV = left ventricular end-systolic volume in patients with heart failure (closed 
circles) and in healthy control subjects (open circles).  
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Figure 3-4 CMR-TSI in relation to scar size 
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Figure 3-5 Bull’s eye maps of radial wall motion24 
 
 
 
 
 
                                                
24 Radial wall motion is colour-coded from blue to red, denoting early and late inward 
radial wall motion. The centre of the bull’s eye relates to the left ventricular apex, 
whereas the outer perimeter relates to the base. Note the pattern of distribution in a 
healthy control, in patients with NICM and ICM. 
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CHAPTER 4. CMR-TSI PREDICTION OF OUTCOMES AND EVENTS 
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4.1 Introduction 
Cardiac resynchronisation pacing improves survival and quality of life in patients with 
moderate to severe heart failure, ventricular conduction delay and impaired left ventricular 
function. (Bristow et al., 2004, Cleland et al., 2005b) One of the mechanisms by which CRT 
acts is to reduce left intra-ventricular dyssynchrony. However, some patients do not gain the 
expected symptomatic benefit of CRT or reverse remodelling despite ventricular conduction 
delay.  
Echocardiographic studies have reported that a high proportion of these patients, those who 
do not experience negative remodelling, termed “non-responders”, do not have sufficient 
dyssynchrony, measured using advanced echocardiographic techniques such as TDI (Bleeker 
et al., 2006a, Yu et al., 2003a) and speckle tracking. (Ypenburg et al., 2008) Furthermore, 
some patients with normal left ventricular function have dyssynchrony when measured with 
TDI using the Yu twelve segment model, whilst a proportion of patients with left bundle 
branch block and impaired left ventricular function are not dyssynchronous. (Yu et al., 
2003b) In contrast, we have found that dyssynchrony is present in almost all cases of heart 
failure when assessed with CMR. We therefore sought to determine the value of 
dyssynchrony in determined by CMR in predicting the response to CRT. 
The aim of this study was to validate CMR-TSI against long term clinical-outcome in 
patients undergoing CRT. The clinical end-points used in this study were those used in the 
CARE-HF study. This study is a long term follow up study of CRT patients undergoing 
CRT. 
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4.2 Methods 
4.2.1 Subjects 
Participants were included if they met the criteria for implantation of cardiac 
resynchronisation pacing due to moderate to severe heart failure whilst treated with optimal 
tolerated medical therapy (QRS ≥ 120 ms, ejection fraction ≤ 35%, NYHA class III or IV). 
Patients in atrial fibrillation were included in the study. 153 participants underwent a pre-
implant six minute walk test, Minnesota living with heart failure questionnaire and their 
NYHA class was documented. Written informed consent was taken prior to enrolment in the 
study. Ethics permission had been obtained from North Birmingham Research Ethics 
Committee, and the study was approved by the Research and Innovation Governance 
department. This was a long term follow up study, and included 77 patients who had 
originally been included in Chalil et al.’s paper which was the first description of this 
method of analysis of dyssynchrony. (Chalil et al., 2007d) Additional patients, clinical and 
echocardiographic follow up and clinical events were collected, extending the follow up by 
two further years. 
 
4.2.2 Echocardiography 
Standard two dimensional echocardiograms were acquired with Vivid 5, and 7 equipment 
and digital loops were recorded for offline analysis by observers blinded to the clinical 
outcome. Left ventricular ejection fraction was calculated as left ventricular end-diastolic 
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volume (LVEDV) – left ventricular end systolic volume /LVEDV *100 and expressed as a 
percentage. 
 
4.2.3 Cardiovascular Magnetic Resonance 
Images were acquired as described previously, and the CMR-TSI calculated. 
 
4.2.4 Device Therapy 
All patients underwent transvenous biventricular pacemaker implantation using standard 
techniques under local anaesthesia. Patients were entered into the study only after a 
successful implantation and were followed-up in a dedicated CRT clinic. None of the 
patients in atrial fibrillation underwent atrioventricular node ablation. Patients in sinus 
rhythm (n =122) underwent transmitral Doppler-directed optimisation of atrioventricular 
delay ((Ritter et al., 1999)) at every scheduled visit. Backup atrial pacing was set at 60 beats 
per minute, and the pacing mode was set to DDDR with no intraventricular delay. For 
patients in chronic atrial fibrillation (n=31), right ventricular and LV leads were implanted, 
and a Medtronic InSync III generator (model 8042, Medtronic, Minneapolis, Minnesota) was 
used, plugging the atrial port and programming the generator to a ventricular triggered mode. 
Generators used included the Medtronic InSync III, model 8040 8042, St. Jude Frontier (St. 
Jude Medical, St. Paul, Minnesota), Vitatron CRT 8000 (Vitatron B.V., Arnhem, the 
Netherlands), Biotronik Stratos (Biotronik GmbH, Berlin, Germany), and Guidant Contak 
Renewal TR2 (Guidant Corp., St. Paul, Minnesota). 
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4.2.5 Definition of events 
After pacemaker implantation, patients were followed up in a dedicated cardiac 
resynchronisation clinic. At 6 weeks, 6 months and then 6 monthly thereafter patients 
underwent a 6 minute walk test, Minnesota Living with Heart Failure Questionnaire and 
echocardiogram. At each visit the NYHA class was documented. 
As in the CARE-HF study, the clinical end points which considered were the composite of 
death from any cause or an un-planned hospitalisation for a major coronary event, which 
included cardiac transplantation. Hospitalisations for worsening heart failure, myocardial 
infarction, unstable angina, arrhythmia, stroke, pulmonary embolism, or upgrading to an 
implantable cardioverter-defibrillator were included in this endpoint. The first event was 
included in the analysis. The second end point considered was the composite of death from 
any cause and unplanned hospitalisation with worsening heart failure. The third endpoint 
considered was mortality from any cause. The additional endpoint of cardiovascular 
mortality was also considered. Sudden cardiac death was defined as “a natural, unexpected 
death due to cardiac causes, heralded by an abrupt loss of consciousness within one hour of 
the onset of acute symptoms”. (Myerburg and Castellanos, 1997) Mortality data were 
collected through medical records, death certificates and post-mortem data and, where 
appropriate, from interviews with patients’ care providers.  
 
4.2.6 Statistics 
Receiver-operating characteristic (ROC) curves were used to derive optimal cut off points of 
CMR-TSI for predicting cardiovascular events in patients undergoing cardiac 
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resynchronisation pacing in a group of 77 patients undergoing CRT-P. (Chalil et al., 2007d) 
The value of CMR-TSI with the optimum sensitivity and specificity was 110ms for all end-
points.  
The ability of CMR-TSI to discriminate between patients in the various risk categories at 
this cut off value was assessed using Cox proportional hazards analyses and Kaplan-Meier 
survival curves. Differences in survival curves between the groups were assessed using the 
log-rank (Mantel-Cox) test. Statistical analyses were performed using Statview (Cary, North 
Carolina) and SPSS 13.0 (Chicago, Illinois). A 2-tailed p value of 0.05 was considered as 
significant. 
4.3 Results 
4.3.1 Baseline Characteristics 
The baseline clinical and CMR characteristics are shown in table 5.1. The patients were 
dichotomised according to the baseline CMR-TSI. There was no statistically significant 
difference in the age at implantation, underlying co-morbidities and baseline medical therapy 
use. More patients with ICM had CMR-TSI ≥ 110ms than those with NICM. The mean QRS 
duration was significantly higher in the patients with CMR-TSI ≥110ms. However, the 
proportion of patients in atrial fibrillation was similar in both groups.  
The CMR data show that patients with CMR-TSI ≥ 110ms had significantly greater left 
ventricular volumes, and poorer left ventricular function. The infarct volumes were also 
significantly greater in the group with CMR-TSI ≥ 110ms. However, there was no 
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significant difference between the two groups in terms of echocardiographic left ventricular 
volumes and ejection fraction. 
 
4.3.2 Symptomatic response to therapy 
Table 5.2 shows the baseline and last available clinical and echocardiographic follow up 
status. The mean follow up was 429 ± 293 days. CRT was similarly effective in reducing 
NYHA class and improving six minute walk distance. The patients with CMR-TSI < 110 ms 
had the greatest symptom scores on the Minnesota living with heart failure questionnaire, 
but both groups improve with CRT, and at the last available follow up there was no 
significant difference in the symptom score. Overall the group with CMR-TSI ≥ 110 ms did 
not experience left ventricular remodelling with CRT, unlike those with baseline CMR-TSI 
< 110 msec.  
 
4.3.3 Survival after CRT 
Figure 4-1 shows the Kaplan-Meier curves showing the survival after CRT dichotomised by 
CMR-TSI group, using the same outcomes as the CARE-HF study. (J. G. Cleland et al., 
2001). The long term survival, censored up to a maximum of 2250 days, shows that patients 
with a baseline CMR-TSI ≥ 110 ms have a significantly worse outcome in terms of overall 
mortality and hospitalisation for heart failure, cardiovascular mortality, and cardiovascular 
death and hospitalisation for heart failure. 
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4.3.4 Uni-variable and multi-variable predictors of outcome 
Table 5.3 shows the uni-variable and multi-variable Cox Hazard analysis for the clinical 
endpoints in relation to CMR variables. CMR-TSI emerged as a powerful predictor of total 
mortality, total mortality and cardiovascular events, sudden cardiac death, heart failure 
hospitalisation. Left ventricular volumes and ejection fraction were not predictors. Indeed, 
CMR-TSI was independent of ejection fraction, left ventricular volumes and QRS duration 
on multi-variable analysis. In terms of predicting cardiovascular death, those patients with a 
CMR-TSI ≥ 110ms were 5 fold more likely to die than those with a CMR-TSI < 110ms. 
 
4.4 Discussion 
The most striking finding is the confirmation of the original findings by Chalil et al. that 
CMR-TSI in a large group of patients as a powerful predictor of the long term outcome in 
patients treated with CRT. Furthermore, this finding supports the hypothesis that severe 
dyssynchrony is a marker of adverse outcome in patients treated with CRT, consistent with 
previous work. (Chalil et al., 2007d) 
This finding that severe dyssynchrony is associated with poor outcome is in contrast to 
echocardiographic studies which suggest firstly that not all cardiac failure patients are 
dyssynchronous, and secondly that those with the greatest amount of dyssynchrony benefit 
the most from CRT. However, given that there appears to be an inverse exponential 
relationship between ejection fraction, left ventricular volumes and CMR-TSI, the adverse 
outcomes associated with increasing dyssynchrony are unsurprising, reflecting poor left 
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ventricular function and a greater burden of ischaemic cardiomyopathy. Hence, the CMR-
TSI is a marker not only wall motion, but is also a measure of left ventricular function 
reflecting the heterogenous and dyscoordinate left ventricular wall motion seen in advanced 
left ventricular dysfunction. 
The recent multi-centre PROSPECT study has cast some doubt on the general applicability 
of these techniques as a wide inter and intra-observer reporting of the dyssynchrony 
findings, such that at the present time, the echocardiographic markers of dyssynchrony could 
not be used to select patients for CRT in routine clinical practice. (Chung et al., 2008) One 
explanation for this finding is the lack of expertise in some centres, such that acquisition of 
the images is not ideal. (Yu et al., 2009) However, Bax et al. noted that beyond a septal to 
posterior delay of 100 ms measured using tissue Doppler imaging, there was no significant 
reduction in LVESV, suggesting there is a limit beyond which CRT will not result in reverse 
remodelling. (Bax et al., 2004b) We found no significant change in EF in the patients with a 
CMR-TSI of greater than 110 ms. In addition, the outcome of patients with CMR-TSI 
greater than 110 ms was worse in terms of hospitalisations for heart failure and mortality. It 
appears that rather than dyssynchrony being a marker of good outcome after CRT, it is a 
marker of poor left ventricular function. Whilst all groups improved in terms of walk 
distance, quality of life and NYHA class, the improvement in NYHA class did not reach 
statistical significance in the patients with CMR-TSI ≥ 110ms. 
Cardiac resynchronisation therapy improves symptoms and clinical outcome. Although we 
have found that patients with greater dyssynchrony have a poorer outcome, we did 
demonstrate a significant improvement in six minute walk distance, quality of life and 
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NYHA class even in the group with CMR-TSI ≥ 110 ms. This is keeping with other studies 
which have found that clinical improvement does not always reflect survival from CRT, (C. 
M. Yu et al., 2005b) and the lack of correlation between clinical and echocardiographic 
response. (Bleeker et al., 2006a) CRT has other effects in addition to correction of 
dyssynchrony, including reducing mitral regurgitation (Achilli et al., 2003, Bax and 
Poldermans, 2006, Nunez et al., 2002), improving diastolic ventricular interaction (Bleasdale 
et al., 2004) and correction of prolonged AV delay.  In addition, the effectiveness of CRT 
may be governed by other factors such as left ventricular scar (Bleeker et al., 2006c) and 
heart rhythm. (Gasparini, 2008, Khadjooi et al., 2008) Our observation that CMR-TSI is 
highest in patients with ischaemic heart disease as compared to patients with non-ischaemic 
cardiomyopathy, and that scar burden is associated with increasing CMR-TSI may explain 
these findings. Thus, patients with ischaemic heart disease are more dyssynchronous than 
those with dilated cardiomyopathy. 
 
4.4.1 QRS duration and CMR-TSI 
The current guidelines for CRT select patients on the basis of evidence of electrical 
conduction delay, currently pivoting on QRS duration of 120ms. However, studies using 
TDI have not found a relationship between QRS duration and intra-ventricular 
dyssynchrony, (Yu et al., 2003b) whilst there does appear to be a weak correlation on the 
basis of pulsed Doppler measuring inter-ventricular delay. (Ghio et al., 2004) Clinical 
response to CRT is variable, with some patients deteriorating after implantation. (Chung et 
al., 2008) This is most likely due to the natural history of heart failure, which is supported by 
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evidence from the MUSTIC study, which found that more patients deteriorated without CRT 
than with CRT. (Cazeau et al., 2001) An alternative is failure of adequate resynchronisation 
or CRT causing worsening of dyssynchrony. As a result, the search for an improved 
predictor of response to CRT continues, with the hope that demonstrating mechanical 
dyssynchrony may be a better predictor than QRS duration. (Auricchio and Yu, 2004) 
Interestingly, CMR-TSI increases proportionally QRS duration, although the measurement 
of CMR-TSI is statistically independent of QRS duration. However, we found that QRS was 
unable to predict outcome in this study, either as a dichotomous (120 to 149ms, or ≥ 150ms) 
or continuous variable. In contrast, Gasparini et al found patients with a narrow QRS (129 – 
149ms) appeared to benefit more than those with QRS (≥ 150 ms) in terms of clinical 
progress after CRT. (Gasparini et al., 2003) 
The intra and inter-observer variability for CMR-TSI is low, (Chalil et al., 2007d) and hence 
has greater potential application than other methods of measuring dyssynchrony, such as 
echocardiography. (Chung et al., 2008) 
Cardiovascular magnetic resonance imaging of heart failure patients is becoming the 
expected standard of care providing information of structure, function, aetiology and 
prognosis in a single scan,(Germans and van Rossum, 2008) making CMR-TSI readily 
applicable. Other advanced CMR analysis techniques are available, including myocardial 
tagging and other indices of dyssynchrony, such as the CURE formula. (Bilchick et al., 
2008) However, clinical validation of these techniques is awaited before widespread 
adoption. The CMR-TSI measure requires validation by other groups, preferably against 
clinical events rather than another imaging parameter.  
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4.5 TABLE LEGENDS 
Table 4-1 Baseline clinical and cardiovascular magnetic resonance imaging characteristics 
for patients undergoing cardiac resynchronisation therapy 
 
Table 4-2 Clinical and echocardiographic outcome at baseline and last available follow up 
 
Table 4-3 Uni variable and multi-variable Cox proportional hazards analyses of clinical 
endpoints in relation to cardiac magnetic resonance variables according to imaging modality 
 
4.6 FIGURE LEGENDS  
Figure 4-1 Kaplan-Meier estimates of the time to the death from any cause or hospitalisation 
for major cardiovascular events, survival from cardiovascular death or hospitalisation for heart 
failure, survival from cardiovascular death or survival from death from any cause. Patients 
were stratified according to a pre-implant CMR-TSI (<110 msec or CMR-TSI ≥110 msec). 
HF=heart failure.  
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Table 4-1 Baseline clinical and cardiovascular magnetic resonance imaging 
characteristics for patients undergoing cardiac resynchronisation therapy 
 ALL CMR-TSI<110 CMR-TSI≥110 p 
N 153 92 61  
Male (%) 76.5 72.8 82.0 ns 
Age, years 66.8 ± 10.4 66.3 ± 10.8 67.5 ± 9.8 ns 
     
Aetiology (%)     
ICM 62.1 36.6 25.5 ns 
NICM 38.0 29.6 8.4 0.006 
     
Co-morbidity (%)     
Hypertension  28.1 29.3 26.2 ns 
CABG  22.2 18.5 27.9 ns 
Valvular heart disease  4.8 4.9 4.3 ns 
Upgrade  1.3 1.1 1.6 ns 
Diabetes Mellitus  17.0 14.1 21.3 ns 
     
Medication (%)     
Diuretic 87.6 90.2 83.6 ns 
ACE/ARB 92.8 93.5 91.8 ns 
Beta-blocker 56.2 53.3 60.7 ns 
Amiodarone  16.3 19.7 14.1 ns 
Spironolactone  43.1 44.6 41.0 ns 
     
ECG variables     
Mean QRS (ms) 144.5 ± 140.7 ± 28 150.1 ± 26.5 0.0408 
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27.9 
AF (%) 20.9 19.6 23.0 ns 
     
     
CMR variables     
Myocardial mass, g 106.56 ± 
36.53 
104.64 ± 33.59 109.6 ± 40.9 ns 
Infarct volume (%) 19.1 ± 19.1 13.68 ± 15.2 27.7 ± 21.5 <0.0001 
CMR End-systolic 
volume (mls) 
201 ± 94.5 176.3 ± 91.8 238.2 ± 86.6 <0.0001 
CMR End-diastolic 
volume (mls) 
248.1 ± 
98.2 
224.5 ± 95 283.8 ± 93.1 0.0002 
CMR Ejection 
fraction (%) 
22.05 ± 9.9 25.32 ± 10.57 17.13 ± 6.2 <0.0001 
CMR-TSI (ms) 102.4 ± 
45.5 
73.08 ± 21.5 146.7 ± 41.1 <0.0001 
     
Echo variables     
Echo end-systolic 
volume (mls) 
192.6 ± 
84.8 
187.5 ± 91.1 200.2 ± 74.7 ns 
Echo end-diastolic 
volume (mls) 
249.5 ± 
97.7 
242.1 ± 105.5 260.4 ± 84.5 ns 
Echo ejection fraction 
(%) 
23.6 ± 9.1 23.4 ± 9.4 23.8 ± 8.7 ns 
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Table 4-2 Clinical and echocardiographic outcome at baseline and last available follow 
up 
 
 ALL CMR-TSI<110 CMR-TSI≥110 p 
Last follow up (days) 429 ± 293 440 ±  285 413.5 ±  308  
     
Clinical status     
NYHA class 3.19 ± 0.52 3.2 ± 0.55 3.164 ±  0.49 ns 
FUP NYHA class 2.07 ± 0.83¥ 2.05 ± 0.89* 2.08 ± 0.71 ns 
     
6MWD (metres) 244 ±  117 239 ± 124 252 ±  107 ns 
FUP 6MWD (metres) 314.5 ± 
117.9§ 
322.46 ± 127§ 302.6 ± 103§ ns 
     
Quality of Life 
(Minnesota) 
56.4 ±  20.7 61.3 ± 20.4 48.9 ± 18.9 0.001 
FUP Quality of Life 
(Minnesota) 
32.46 ± 23.5§ 32.56 ± 24.5¥ 31.6 ± 22.2¥ ns 
     
Echocardiographic 
data 
    
Echo LVESV (mls) 192.6 ± 84.8 187.5 ± 91.1 200.2 ± 74.7 ns 
FUP Echo LVESV (mls) 186.97 ± 
90.8§ 
175.1 ± 95.5§ 204.5 ± 81.0 ns 
     
Echo LVEDV (mls) 249.5 ± 97.7 242.1 ± 105.5 260.4 ± 84.5 ns 
FUP Echo LVEDV (mls) 246.5 ± 101§ 234.1 ± 106.3§ 264.8 ± 90.8 ns 
     
Baseline Echo EF (%) 23.6 ± 9.1 23.4 ± 9.4 23.8 ± 8.7 ns 
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FUP Echo EF (%) 26.09 ± 
11.93¥ 
27.6 ± 12.8§ 23.8 ± 10.18 ns 
  
Significance between baseline and final measurements are shown in the table. * = p < 0.05, 
¥ = p ≤ 0.01, § = p ≤ 0.001
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Table 4-3 Uni variable and multi-variable Cox proportional hazards analyses of 
clinical endpoints in relation to cardiac magnetic resonance variables according to 
imaging modality 
  Exp p 
Total mortality - single variable   
CMR-TSI (ms) 2.633 (1.38 - 5.023) 0.0033 
CMR-LVESV (mls) 1.004 (1.000 - 1.008) 0.0357 
CMR-LVEDV (mls) 1.003 (0.999 - 1.006) ns 
EF-CMR (%) 0.97 (0.933 - 1.008) ns 
Mean QRS (ms) 1.009 (0.998-1.020) ns 
   
Total Mortality - multi-variable   
EF-CMR (%) 0.985 (0.944 - 1.028) 0.4854 
CMR-TSI (ms) 2.433 (1.238 - 4.785) 0.0099 
 
CMR-LVEDV (mls) 1.002 (0.998 - 1.005) 0.4039 
CMR-TSI  (ms) 2.457 (1.264 - 4.776) 0.008 
  
  
  
 
EF-CMR (%) 0.94 (0.909-0.973) 0.004 
CMR-LVESV (%) 1.004 (1.001-1.006) 0.0017 
CMR-LVEDV (%) 1.003 (1.001-1.006) 0.0088 
CMR-TSI (ms) 3.945 (2.241 - 6.945) <0.0001 
Mean QRS (ms) 1.006 (0.996-1.016) 0.2253 
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CMR-TSI (ms) 3.417 (1.884 - 6.2) <0.0001 
CMR-LVESV (mls) 1.002 (0.999 - 1.005) 0.1279 
   
CMR-TSI (ms) 3.59 (1.985 - 6.492) <0.0001 
CMR-LVEDV (mls) 1.001 (0.999 - 1.004) 0.2842 
   
CMR-TSI (msec) 2.954 (1.612 - 5.413) 0.0005 
EF-CMR (%) 0.961 (0.926 - 0.998) 0.367 
  
 
CMR-LVESV (mls) 1.004 (1.001 - 1.006) 0.0045 
CMR-LVEDV (mls) 1.003 (1.00 - 1.006) 0.0241 
EF-CMR (%) 0.941 (0.908-0.975) 0.0007 
mean QRS (ms) 1.009 (0.998 - 1.020) 0.1063 
   
Sudden Cardiac Death - Cox multi-variable   
CMR-TSI (ms) 2.345 (1.2 - 4.57) 0.123 
CMR-LVESV (mls) 1.003 (0.999 - 1.007) 0.1991 
  
  
 
EF-CMR (%) 0.96 (0.923 - 0.998) 0.0391 
CMR-TSI (ms) 2.718 (1.464 - 5.048) 0.0015 
   
CMR-LVESV (mls) 1.002 (0.999 - 1.005) 0.1744 
CMR-TSI (ms) 3.175 (1.724 - 5.848) 0.0002 
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CMR-LVEDV (mls) 1.001 (0.998-1.004) 0.3984 
CMR-TSI (ms) 3.357 (1.829 - 6.161) <0.0001 
   
Cardiovascular mortality - uni variable   
CMR-LVESV (mls) 1.004 (1.001 - 1.007) 0.0167 
CMR-LVEDV (mls) 1.003 (1.000 - 1.006) 0.0703 
EF-CMR (%) 0.941 (0.901 - 0.981) 0.0047 
CMR-TSI (ms) 5.028 (2.425 - 10.423) <0.0001 
mean QRS (ms) 1.008 (0.997 - 1.020) 0.1537 
   
Cardiovascular mortality - multi-variable   
CMR-LVESV (mls) 1.002 (0.998 - 1.005) 0.3667 
CMR-TSI (ms) 4.549 (2.127 - 9.728) <0.0001 
   
CMR-LVEDV (mls) 1.001 (0.997 - 1.004) 0.7068 
CMR-TSI (ms) 4.832 (2.264 - 10.31) <0.0001 
   
EF-CMR (%) 0.967 (0.922 - 1.014) 0.1688 
CMR-TSI (ms) 3.988 (1.832 - 8.681) 0.0005 
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Figure 4-1 Kaplan-Meier estimates of the time to the death 
From any cause or hospitalisation for major cardiovascular events, survival from 
cardiovascular death or hospitalisation for heart failure, survival from cardiovascular death 
or survival from death from any cause.  
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CHAPTER 5. MYOCARDIAL SCAR AND OUTCOME AFTER CRT 
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5.1 Introduction 
The main cause of death after CRT is progressive heart failure. (Cleland et al., 2005b) Until 
recently, the impact of aetiology of cardiomyopathy on outcome has been unclear. Patients 
with ICM have distinct areas of myocardial scarring due to infarction. Patients with ICM 
may be expected to have a worse prognosis after CRT. After myocardial infarction the 
prognosis is determined by left ventricular function and adverse left ventricular remodelling. 
Therefore, the greater the myocardial loss, the worse the expected prognosis.  
The efficacy of CRT in patients with extensive scarring might be expected to be less than 
those with little scar. In the field of revascularisation, registry data suggests that coronary 
bypass grafting surgery is of benefit to patients with poor left ventricular function and 
jeopardised viable myocardium, but revascularisation of patients without viable myocardium 
results in worse outcome that medical treatment alone. (Alderman et al., 1983) As a result, 
AHA/ACC 2004 guidelines state that in the absence of viable myocardium these patients 
should not be revascularised. (Eagle et al., 2004) Recently, Zhang et al. have found that in a 
relatively small cohort of patients from a single centre, in contrast with the multi-centre 
CARE-HF study, those with ICM have a worse outcome than those with NICM. (Q. Zhang 
et al., 2009) This has been confirmed in re-analysis of the CARE-HF data, which also found 
that the absolute benefit from CRT may be greatest in those with ischaemic cardiomyopathy. 
(Wikstrom et al., 2009) 
Postero-lateral scar appears to have particular importance in determining outcome. Bleeker 
et al. (Bleeker et al., 2006c) reported that patients with postero-lateral (PL) scar had a worse 
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outcome six months after CRT in terms of left ventricular remodeling compared with those 
without postero-lateral scar. It is postulated that PL scar results in failure of effective 
electrical stimulation of the left ventricle, as at implantation the lead is targeted towards the 
postero-lateral region. Additionally, there appears to be a threshold of scar, beyond which 
there is insufficient viable myocardium to obtain a response to CRT. (Adelstein and Saba, 
2007, Ypenburg et al., 2007a) 
The aim of this study is to evaluate the effect of myocardial scar on long term outcome after 
cardiac resynchronisation therapy. Specifically, in those patients with myocardial scar, the 
impact of volume and location of scar may be important in terms of survival. However, 
although the short term response to CRT in relation to scar has been evaluated, long term 
outcome has not been studied. 
This study is a longer term follow up study of the cohort of patients with ICM undergoing 
CMR and CRT. It includes the 62 patients included in previous work, (Chalil et al., 2007a, 
Chalil et al., 2007c) with further long term data on clinical status, clinical events and 
echocardiographic follow up as well as additional patients. As such, it form the largest long 
term study between CMR scar and CRT treated HF patients. 
 
5.2 Methodology 
Patients undergoing CRT underwent cardiovascular magnetic resonance imaging prior to 
implantation as described in chapter 2. In mid-2007, patients with estimated glomerular 
filtration rate of less than 30 ml per minute did not undergo administration of intravenous 
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gadolinium due to the potential risk of nephrogenic systemic fibrosis. (Thomsen et al., 2008) 
However, end stage renal failure was not common and thus this did not have a significant 
effect on the recruitment of subjects. 
5.2.1 Volume of scar 
The scans were transferred in digital imaging and communication in medicine (DICOM) 
format to an Apple computer running Osirix version 2.5 (Apple freeware available from 
www.osirix-viewer.com, downloaded 28 January 2007). The late enhanced areas, which 
denotes scar, on the slices were manually planimetered. The total area of scar in all the 
segments was calculated and multiplied by the thickness of the slices to give the volume of 
scar. The mass of myocardium in diastole was multiplied by 1.05 to give the volume of 
myocardium. The percentage of myocardial scar was calculated by dividing the volume of 
scar by the volume of myocardium. 
 
5.2.2 Scar location and transmurality 
The areas of scar were then segmented using the American Heart Association sixteen 
segment tomographic model of the heart (Lang et al., 2005). The slices were matched as 
closely as possible to the model. The amount of scar per segment was calculated by divining 
the diameter of scar by the diameter of the myocardial wall per segment, and this was 
expressed as a ratio. A ratio of greater than 0.51 was designated as transmural scar in line 
with previous work by Kim et al (Kim et al., 1999), and less than 0.51 indicative of non-
trans-mural myocardial infarction which is usually viable myocardium. 
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In patients who had scar, the presence was dichotomised into postero-lateral or other areas. 
In addition, a subset of the patients with NICM was noted to have midwall late enhancement, 
indicative of mid-wall myocardial fibrosis, which can be found in some patients with dilated 
cardiomyopathy. (Assomull et al., 2007, McCrohon et al., 2003, Moon et al., 2003, Moon et 
al., 2004) 
 
5.2.3 Device follow up 
Patients were followed up in a specialised device clinic post implant at approximately 6 
weeks, 6 months and then six monthly thereafter. At each visit, in patients in sinus rhythm 
the atrio-ventricular device timings were optimised using the iterative method to achieve the 
longest left ventricular filling time measured from the early wave to atrial contraction wave 
without allowing intrinsic conduction, and avoiding diastolic mitral regurgitation. The 
pulsed Doppler sample cursor was placed just below the mitral valve in the apical four 
chamber view. (Ritter et al., 1999) The offset between left and right ventricular stimulation 
was changed to achieve simultaneous time from the R wave to the aortic and pulmonary 
ejection, termed the aortic and pulmonary pre-ejection time measured using pulsed Doppler 
in the aortic and pulmonary outflow tracts, respectively. 
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5.2.4 Echocardiographic analysis 
Patients underwent a baseline echocardiogram (Vivid 5 and 7 systems, General Electric, 
Slough, UK) prior to pacemaker implantation, and then during pacemaker follow up. The 
echocardiogram was stored digitally and analysed using EchoPac.  
The left ventricular dimensions were recorded in M-mode, left ventricular volumes in the 
apical four chamber view at end-diastole (onset of the R wave) and systole (minimum 
volume) were used to determine the ejection fraction using modified Simpson’s 
methodology. (Lang et al., 2005)  
 
5.2.5 Clinical follow up 
At baseline and each visit the patients underwent a six minute hall walk test, completed a 
Minnesota living with heart failure questionnaire and the New York Heart Association class 
was recorded by an observer blinded to initial implant information (NI). In addition, 
medications were reviewed at each clinic follow up and adjusted appropriately as part of 
standard clinical care. 
As in the CARE-HF study, the clinical end points which considered were the composite of 
death from any cause or an un-planned hospitalisation for a major coronary event, which 
included cardiac transplantation. Hospitalisations for worsening heart failure, myocardial 
infarction, unstable angina, arrhythmia, stroke, pulmonary embolism, or upgrading to an 
implantable cardioverter-defibrillator were included in this endpoint. The first event was 
included in the analysis. The second end point considered was the composite of death from 
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any cause and unplanned hospitalisation with worsening heart failure. The third endpoint 
considered was mortality from any cause. The additional endpoint of cardiovascular 
mortality was also considered. Sudden cardiac death was defined as “a natural, unexpected 
death due to cardiac causes, heralded by an abrupt loss of consciousness within one hour of 
the onset of acute symptoms”. (Myerburg and Castellanos, 1997) Mortality data were 
collected through medical records, death certificates and post-mortem data and, where 
appropriate, from interviews with patients’ care providers.  
 
5.2.6 Determination of site of scar 
A posterolateral scar was defined as scar in the basal and mid posterior, and the basal and 
mid postero-lateral segments. Transmurality was defined as scar greater than 50% of the 
wall. (Kim et al., 1999) 
 
5.2.7 Left ventricular lead position  
Albertsen et al. described a method of recording the position of the left ventricular lead using 
bi-plane fluoroscopy. In the left anterior oblique view, the coronary sinus encircles the mitral 
valve rather like the hands upon a clock. The right anterior oblique view was used to record 
the position of the lead tip relative to the coronary sinus to mitral valve plane. (Albertsen et 
al., 2005)
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In this study we determined the lead position using the stored fluoroscopy images. The 
venograms were viewed on Osirix 2.5 (Apple Inc). We sought to determine whether the tip 
of the left ventricular lead was pacing scar by examining the delayed enhanced CMR 
images. Where available we used the coronary sinus venogram to determine the position of 
the veins. At the end of the procedure, images were acquired recording the position of the 
left ventricular lead. The distance from the coronary sinus, running in the atrio-ventricular 
groove, to the tip of the left ventricular lead was measured in the right anterior-oblique view. 
A reference fluoroscopic acquisition of a set distance was used to calibrate the image, 
allowing conversion from pixels to centimetres. The position of the lead in the left anterior 
oblique view was then recorded using the o’clock method, as described by Mortensen (see 
Figure 5-1).  
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Figure 5-1 Determination of left ventricular lead position using fluoroscopy 
  
 
 
 
The left anterior oblique view (LAO) is used for determining the left ventricular lead tip 
position from 12 to 6 o’clock. The right anterior oblique (RAO) view is used for determining 
the distance from the coronary sinus to the lead tip.25  
 
                                                
25 Taken from: Albertsen, A.E., Nielsen, J.C., Pedersen, A.K., et al. (2005) Left ventricular 
lead performance in cardiac resynchronization therapy: impact of lead localization and 
complications. Pacing Clin Electrophysiol, 28: (6): 483-488. Permission for reproduction 
obtained from John Wiley & Sons. 
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5.2.8 Determination of effect of pacing scar via the left ventricular lead 
Steady state free precision images of the 4 chamber view were used to plan the left delayed 
enhanced left ventricular short axis stacks, acquired from base to apex after the 
administration of intravenous gadolinium. The lines drawn to plan the acquisition which are 
perpendicular to the 4 chamber view were restored. The lines were examined to ensure that 
the most basal slice was acquired at the level of the aortic valve, which was assumed to be 
the level of the coronary sinus. If the slices were acquired below the valve, the distance from 
a line drawn perpendicular to the ventricle at the level of the aortic valve to the first planning 
line was measured. This distance was then added to the distance measured from the 
fluoroscopic images of the tip of the lead to the top of the coronary sinus. 
The delayed enhanced image slice thickness and the gap between slices was summed. The 
distance from the top of the coronary sinus to the lead tip was used to determine which left 
ventricular delayed enhanced short axis stack would show the heart at the level of the tip of 
the lead. Using the o’clock method, we determined whether the myocardium at the level of 
the lead contained full thickness (>51% in diameter) or partial thickness infarction.  
 
5.2.9 End points 
The primary endpoint considered was the composite endpoint of cardiovascular death or 
unplanned hospitalization for worsening HF. The first event was included in the analysis. 
The secondary endpoint was cardiovascular death. Mortality data was collected through 
medical records, and where appropriate, from interviews with patient’s carers. Information 
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regarding clinical outcome was collected by an investigator who was blinded to the CMR 
study. 
 
5.2.10 Statistics 
Continuous variables are expressed as mean ± standard deviation (SD). Normality was tested 
using the Shapiro–Wilk test (the W-statistic). Comparisons between normally distributed 
continuous variables were made using ANOVA with Fisher’s protected least significance 
difference test for multiple comparisons. Serially measured variables were analyzed using 
repeated measures ANOVA. Categorical variables were analyzed using χ2 tests. The effect 
ofmyocardial scarring on the various endpoints was explored using Cox proportional hazards 
analyses and Kaplan–Meier survival curves. Differences in survival curves between the 
groups were assessed using the log-rank (Mantel– Cox) test. Statistical analyses were 
performed using Statview (Cary, NC) and SPSS 13.0 (Chicago, Illinois). A two-tailed P 
value of <0.05 was considered statistically significant. 
 
5.3 Results 
The mean follow up to the clinical end-points was 862 days (range 2 to 2210). There were 
33 deaths, all from cardiovascular mortality during the follow up period. At baseline, the age 
of the patients with posterolateral (PL) and non-PL scar were not significantly different. The 
medical treatment, medical history and NYHA class were similar. The proportion of males 
was significantly higher in those with PL scar. The QRS duration was also similar in both 
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cohorts. There was a trend to greater left ventricular volumes in those with PL scar. The 
ejection fraction was significantly lower in those with PL scar (19.2% vs 25.3%). The 
percentage scar volume was non-significantly greater in those with PL scar. 
73/ 95 (76.8%) of patients responded to CRT, defined as a reduction of ≥1 NYHA class, and 
25% improvement in six minute walk distance. The last available clinical and 
echocardiographic follow up was used for analysis in those who had died. 
 
5.3.1 Effects of PL scar 
During the follow up period, 31/51 (60.7%) of those patients with PL scar had died, where as 
2/41 (14.7%) of those without postero-lateral scar had died. Kaplan-Meier survival estimates 
for the time to the two clinical endpoints for transmural and non-transmural PL scars are 
shown in Figure 5-2. 
Table 5-2 shows the differences in symptomatic response between those with PL scars and 
those with scar in other areas. There were no differences in terms of NYHA class at baseline 
and follow up in those with and without PL scar. Both groups improved significantly with 
CRT. Again both groups improved in terms of LVEF, six minute walk distance and quality 
of life score. The improvement from baseline LVEF was greatest in the patients without PL 
scar. The symptomatic responder rate was similar in both groups. Interestingly, in terms of 
echocardiographic derived LVEF, the baseline values were similar, in contrast to the CMR 
derived LVEF.  
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5.3.2 Effects of PL scar transmurality 
Patients with transmural PL scar did not improve significantly in terms of NYHA class and 
LVEF, whereas those without transmural PL scar improved significantly (see Table 5-3). 
However, quality of life measures and six minute walk distance improved significantly in 
both groups. The improvement in six minute walk distance and quality of life was greater in 
those without posterolateral transmural scar, but this did not reach significance. There was a 
trend to a greater symptomatic responder rate in patients with postero-lateral scar, but this 
did not reach statistical significance. 
Comparison between transmural and non-transmural posterolateral scar was made, although 
there were only 16 patients with non-transmural PL scar (see Table 5-4). In comparison, 
those with non-transmural PL scar had a greater improvement in NYHA class, six minute 
walk distance and LVEF. All patients with PL scar improved significantly in terms of quality 
of life, but those with non-transmural scar had a much greater improvement.  
 
5.3.3 Effects of pacing PL scar  
Kaplan Meier survival analysis shows a significantly worse outcome in terms of 
cardiovascular mortality and heart failure hospitalisations in patients where the left 
ventricular lead is pacing left ventricular scar (see Figure 5-3). The cardiovascular mortality 
was 5.6 fold greater (2.7 -11.4, p<0.0001). Response to CRT in terms of improvement by 
one NYHA class and 25% increase in six minute walking distance was worse in patients 
where the left ventricular lead was pacing scar (32% vs 79%, p<0.0001) compared with 
those where the lead was not pacing scar. However, it cannot be stated that placing the lead 
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outside the scar would have resulted in a difference in outcome, as this was purely an 
observational study, not a randomised controlled trial. 
 
5.4 Discussion 
The key finding from this observational study is that the presence of posterolateral scar 
predicts death and adverse events after CRT in comparison to patients without postero-
lateral scar. Furthermore, patients with trans-mural scar faired worse than those with non-
transmural scar both in terms of clinical response and outcome. The observation that placing 
the left ventricular pacing lead on myocardial scar resulted in worse outcome than pacing 
outside the scar in terms of mortality and hospitalisations is of clinical significance, 
suggesting that avoidance of scar could improve the outcome of patients undergoing CRT. 
 
Bleeker at al. noted that the response to CRT was lower in patients with PL scar in 
comparison to those without PL scar. This raises the hypothesis that resynchronisation is 
reduced in these patients. (Bleeker et al., 2006c) Our findings are consistent with Bleeker et 
al.’s results, showing a worse outcome in those with PL scar. The adverse events, 
cardiovascular death and heart failure hospitalisations were predicted by the presence of 
postero-lateral myocardial scar, and were independent of the volume of scarred myocardium. 
Furthermore, this was independent of LVEF, LVEDV, LVESV and QRS duration. Postero-
lateral myocardial scar is a powerful predictor of adverse outcome after CRT. 
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We have found that the extent of PL myocardial scar has less prognostic impact than 
whether the scar is transmural of subendocardial. Whilst symptomatic benefit can be 
achieved in patients with PL scar, the benefit is lower in comparison to those without 
transmural scarring. As a result the response rate is lower for transmural PL scar (66.6% vs. 
83%) when compared with subendocardial scar. This is in keeping with the findings of 
Bleeker et al, where a transmural scar was associated with a responder rate of 47%, 
compared with 83% for non-PL scar. (Bleeker et al., 2006c) Nevertheless, CRT results in 
symptomatic benefit in patients with transmural PL scar. The extent of scarring was less 
important than the trans-murality of scarring, suggesting that myocardial viability increases 
the benefit gained from CRT.  
 
5.4.1 Pacing PL scar 
Implantation of the LV lead over the site of scar is associated with a higher risk of 
cardiovascular death and hospitalisations. Furthermore, pacing over the scar results in a 
lower response rate to CRT, suggesting that resynchronisation is reduced. One mechanism 
by which the effectiveness of CRT is reduced is that pacing scar increases duration and 
fragmentation of QRS complexes. (Reddy et al., 2003, Schwartzman et al., 1999) 
Furthermore, scar tissue slows the conduction of the pacing stimulus. (Lambiase et al., 2004) 
Pacing outside the area of slowed conduction increases the effectiveness of electrical re-
synchronisation when measured acutely using non-contact mapping. (Lambiase et al., 2004) 
The observed mortality rate is admittedly high, as is the absence of reverse remodeling. This 
may be due to the inclusion of patients with, exclusively, ischaemic cardiomyopathy. The 
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CARE-HF study, in which 40% of patients in the paced group had ischaemic 
cardiomyopathy has shown a significantly higher mortality in patients with ICM, and lower 
uptake of medical therapy, as these patents were sicker. (Wikstrom et al., 2009)  Moreover, 
our study involves a greater proportion of patients in NYHA class IV (22%) than the CRT 
arms of the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) (9.9%) 
(Abraham et al., 2002) and the Multisite Stimulation in Cardiomyopathies (MUSTIC)  
(Cazeau et al., 2001) studies. Patients in this study also had lower 6-min walking distance 
(275 m) than in the MIRACLE (307.2 m) and the MUSTIC (399 m) studies. 
 
5.4.2 Limitations of the study 
The presence of myocardial scarring does not take into account the effects of myocardial 
thinning. If thinning has occurred, the planimetered area of myocardial scar is likely to be an 
underestimation of the original scar size. Our finding of 33% as a cut-off for clinical 
response following CRT is the result of a retrospective analysis. Clearly, this threshold 
would be different if patients were not selected on the basis of QRS duration. These findings 
therefore require confirmation in a validation series. 
This observational study generates the hypothesis that pacing scar results in a worse 
outcome, and patients with PL myocardial scarring have reduced benefit from CRT. 
Confirmation of this finding would require randomised studies, although the strength of 
effect is so great that there would be concern as to whether deliberately pacing scar would be 
ethical. Whilst we have demonstrated that patients with PL scar have worse outcome than 
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patients without PL scar, we have not shown that patients with PL scar do not benefit from 
CRT.  
This study was exclusively comprised of patients with ICM, but some patients with DCM 
demonstrate mid-wall enhancement, (Assomull et al., 2006, McCrohon et al., 2003) which 
may also have prognostic impact.  
Recent attempts to improve selection of patients for CRT have largely focussed on pre-
implant dyssynchrony echocardiography. This study did not measure dyssynchrony. 
However, the use of TDI in addition to CMR to assess dyssynchrony and scar, respectively, 
found little additive benefit from TDI when assessed in terms of clinical response and 
reverse remodelling assessed using echocardiography. (Bleeker et al., 2006c) 
 
The presence of PL scar in patients with ICM identifies a group with a higher risk of 
cardiovascular death. In addition, pacing left ventricular scar is associated with a worse 
outcome than pacing outside scar. It is reasonable to avoid pacing scar wherever possible, 
and pre-implant CMR will make this achievable. 
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5.5 Table legends: 
Table 5-1 Baseline clinical and cardiovascular magnetic resonance characteristics of the 
study group 
Table 5-2 Baseline and last available follow up clinical and echocardiographic 
characteristics of the study group according to presence or absence of posterolateral scar. 
Table 5-3 Baseline and last available follow up clinical and echocardiographic 
characteristics of the study group according to presence or absence of trans-mural 
posterolateral scar. 
Table 5-4 Baseline and last available follow up clinical and echocardiographic 
characteristics of the study group according to transmurality of posterolateral scar. 
Table 5-5 Cox proportional hazard analyses of clinical magnetic resonance variables in 
relation to clinical endpoints 
5.6 Figure legends 
Figure 5-2 Kaplan Meier outcome transmural PL scar vs non-transmural PL 
Figure 5-3 Kaplan-Meier outcome of pacing scar vs not pacing scar
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Table 5-1 Baseline clinical and cardiovascular magnetic resonance characteristics of the 
study group 
 
 
 All 
Non-PL 
scar PL scar P 
     
 
Number 95 43 52  
 
Age, yrs 68.0 ± 10.0  67.6 ± 9.4 68.3 ± 9.96 0.97 
 
Sex, male (%) 81 (85.2) 33 (76.7) 48 (92.0) 0.03 
 
NYHA Class, n (%) 3.2 ± 0.55 3.07 ± 0.55 3.23 ± 0.55 0.1876 
 
Co-morbidity, n (%)     
Diabetes mellitus 18 (18.9) 8 (18.6) 10 (19.2) 0.9382 
 
Hypertension 28 (29.4) 15 (34) 13 (25) 0.29 
 
CABG 33 (34.7) 10 (23.2) 23 (44.3) 0.032 
 
Medication, n (%)     
Loop diuretics 85 (89.4) 40 (93.0) 45 (86.5) 0.3 
 
ACEI or AIIB 89 (93.6) 40 (93.0) 49 (94.2) 0.39 
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ß-blockers 56 (58.9) 29 (67.4) 27 (51.9) 0.45 
 
Spironolactone 38 (40) 18 (41.8) 20 (38.4) 0.73 
 
ECG variables     
Sinus rhythm, n (%) 75 (78.9) 33 (76.7) 42 (80.7) 0.63 
 
Atrial fibrillation, n 
(%) 20 (21.1) 10 (23.3) 10 (19.3) 0.63 
 
QRS duration, ms 
143.9 ± 
28.5 
144.5 ± 
28.2 143.5 ± 29.1 0.86 
 
CMR variables     
LVEDV, cm3 
252.3 ± 
96.5 
242.6 ± 
109.7 260.4 ± 84.4 0.12 
 
LVESV, cm3 
203.8 ± 
91.4 
188.2 ± 
101.6 216.8 ± 80.8 0.37 
 
LVEF, % 22.0 ± 9.7 25.3 ± 10.8 19.2 ± 7.8 0.0019 
 
Total scar volume, % 31.0 ± 18.3 27.6 ± 17.6 33.5 ± 18.6 0.1285 
     
     
 
 
162 
 
 
 
Table 5-2 Baseline and last available clinical and echocardiographic parameters 
according to presence or absence of posterolateral scar. 
 
 
 Non-PL PL scar p 
    
 
n 52 43  
NYHA class    
baseline 3.07 ± 0.55 3.23 ± 0.55 0.1581 
 
FUP 2.0 ± 0.89 2.27 ± 0.87 0.1083 
 
p 0.3387 0.0029  
Quality of Life    
baseline 52.1 ± 18.5 53.1 ± 19.7 0.8251 
 
FUP 28.4 ± 22.0 35.3 ± 26.4 0.217 
p 
 0.0034 0.0058  
6 minute walk distance    
baseline 251.3 ± 129.0 233.6 ± 107.6 0.5189 
 
FUP 324.2 ± 137.6 305.7 ±99.6 0.5031 
 <0.0001 0.0001  
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P 
 
LVEF (%)    
Baseline 24.1 ± 7.3 24.0 ± 8.4 0.9266 
 
FUP 30.5 ± 11.3 27.4 ± 10.9 0.2362 
 
p 0.4029 0.0619  
 
Responder (%)   75   79  0.6927 
 
FUP = follow up. LVEF = left ventricular ejection fraction. The significance value of changes 
from baseline to follow up is presented beneath the change.
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Table 5-3 Baseline and last available clinical and echocardiographic parameters 
according to presence or absence of PL scar. 
 
 
 Non-PL scar Transmural PL scar p 
 59 36  
    
NYHA class    
Baseline 3.119 ± 0.53 3.22 ± 0.6 0.377 
   Follow-up 1.96 ± 0.89 2.42 ± 0.8 0.015 
  P p=0.0086 p=0.1975  
Quality of life    
Baseline 52.2 ± 18.7 53.4 ± 18.7 0.7868 
  Follow-up 28.3 ± 22.7 38.9 ± 26.6 0.0653 
  P p=0.0011 p=0.0001  
6 minute walk distance    
Baseline 268.3 ± 121.4 197.5 ± 95.5 0.0093 
   Follow-up 332.4 ± 126.4 281.6 ± 94.4 0.0726 
   P p<0.0001 p=0.0014  
Symptomatic responders (%) 83 66.6 0.068 
  LVEF, %    
Baseline 23.2 ± 8.0 25.3 ± 8.9 0.2681 
  Follow-up 29.5 ± 12.0 27.6 ± 9.0 0.8177 
  p p=0.7032 p=0.0352  
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Table 5-4 Baseline and last available clinical and echocardiographic parameters 
according to either non-transmural or transmural posterolateral scar 
 
 
 
PL-non 
transmural 
Transmural PL 
scar p 
    
n 16 36  
  NYHA class    
Baseline 3.25 ± 0.5 3.3 ± 0.5 ns 
Follow-up 1.9 ± 0.9 2.4 ± 0.8 ns 
p p=0.0138 p=ns  
Quality of life    
Baseline 52.8 ± 22.5 53.2 ± 18.5 ns 
Follow-up 24.1 ± 21 41.4 ± 27.2 0.0385 
p p=0.001 p=0.0002  
6 minute walk distance    
Baseline 280.5 ± 119 208.6 ± 94.0 0.035 
  Follow-up 343.8 ± 103 283.8 ± 92.4 ns 
  P p=0.0071 p=0.0173  
Symptomatic responders    
LVEF, %    
Baseline 22.3 ± 7.4 24.8 ± 9.9 ns 
  Follow-up 28.1 ± 11.9 26.9 ± 10.6 ns 
 
    p=ns p=0.0171  
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Table 5-5 Univariate Cox proportional hazard analyses of clinical magnetic resonance 
variables in relation to clinical endpoints 
   
 
 HR (95% CI) P 
    
 
Cardiovascular death 
PL scar 3.5 (1.9 - 6.4) <0.0001  
Transmural PL scar 5.2 (2.5 - 10.9) <0.0001  
Total scar volume (%) 1.01 (0.99 - 1.03) 0.1775  
LVEF, % 0.93 - 0.97) 0.0949  
LVEDV  
 
1.00 (1.00-1.01) 
 
0.0249  
LVESV 1.01 (1.00 - 1.01) 0.0138  
QRS duration (ms) 0.99 - 1.02) 0.3578  
 
Cardiovascular death or hospitalisation for HF HR (95% CI) P  
PL scar 2.42 (1.6 - 3.8) <0.0001  
Transmural PL scar 2.29 (1.49 - 3.55) 0.0002  
Total scar volume (%) 1.01 (0.99 - 1.02) 0.2766  
LVEF, % 1.0 (0.97 - 1.02) 0.6464  
LVEDV  1.00 (1.00 - 1.01) 0.7829  
LVESV 1.00 (1.00 - 1.01) 0.9504  
QRS duration    
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1.00 (0.99 - 1.00) 0.1705 
HR (95% CI) PL = posterolateral, LVESV = left ventricular end systolic volume, LVEDV = left 
ventricular end diastolic volume, LVEF = left ventricular ejection fraction 
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Figure 5-2 Kaplan-Meier survival graphs of outcome of transmural PL scar vs non-
transmural PL scar 
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Figure 5-3 Kaplan-Meier survival graph of effect of pacing myocardial scar on 
outcome 
 
170 
 
  
 
 
 
 
 
 
 
 
CHAPTER 6. CMR-TSI AND SCAR 
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6.1 Introduction 
Pre-implant imaging with cardiovascular magnetic resonance identifies two variables 
which predict outcome in patients undergoing CRT implantation. Firstly, dyssynchrony 
can be assessed with CMR-TSI and additionally, posterolateral scar can be visualised. 
The role of dyssynchrony in relation to outcome appears central to the current paradigm 
of CRT that dyssynchrony is a major contributor to systolic heart failure and its 
correction with CRT results in clinical benefit. Quantification of dyssynchrony has been 
explored using different techniques in an attempt to predict patients who derive 
symptomatic benefit. Echocardiography has a high temporal resolution, and sophisticated 
advances in technology have facilitated detection of myocardial velocity and motion. A 
number of single centre studies had found that tissue velocity imaging could predict the 
outcome, in terms of response, from CRT. (Bleeker et al., 2005, Van de Veire et al., 
2007, Yu et al., 2002)  
The only multicentre study to explore the predictive value of echocardiographic measures 
of dyssynchrony found that no single echocardiographic measure reliably predicted 
outcome. (Chung et al., 2008) Others have reported difficulties in the reliability of 
assessment of dyssynchrony with tissue velocity imaging (Conca et al., 2009, De Boeck 
et al., 2008, Miyazaki et al., 2008), which may relate to technological difficulties with the 
methodology. (Kirn et al., 2008)  In the light of these disappointing results, the current 
American Society of Echocardiography guidelines recommend that dyssynchrony 
measured with echocardiography should not be used to exclude or select patients for 
CRT, (Gorcsan et al., 2008) a position statement which has been supported by Cleland et 
al. (Cleland et al., 2008b) Never the less, it may be the case that methodological issues 
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within the PROSPECT study resulted in the outcome that no single echocardiographic 
measure predicts outcome after CRT. (Yu et al., 2009) In contrast, we have found that the 
cardiovascular magnetic resonance imaging based tissue synchronisation index (CMR-
TSI) predicts outcome after CRT. (Chalil et al., 2007d) 
Myocardial viability influences the outcome after CRT. Bleeker et al. found that patients 
with transmural myocardial scar in the postero-lateral region, demonstrated with 
gadolinium enhanced cardiovascular magnetic resonance, did not improve 
symptomatically or demonstrate reverse remodelling at six months post implant. (Bleeker 
et al., 2006c) It has been shown that both short term (Ypenburg et al., 2007a) and long 
term outcome (Chalil et al., 2007a, Chalil et al., 2007b) are affected by both volume of 
scar and location. Transmural posterolateral scar results in the worst prognostic outcome 
after CRT relative to other groups.  
The aim of this chapter is to explore the value of pre-implant cardiovascular magnetic 
resonance imaging in patients undergoing CRT, combining the assessment of 
dyssynchrony with CMR-TSI and myocardial scar. The advantage of these two 
techniques is their simplicity, allowing assessment to be carried out without the need for 
specialised technology or complicated algorithms. 
6.2 Methods 
141 patients were prospectively enrolled in this prospective observational study. CRT 
was implanted for standard clinical indications (NYHA 3 or 4, left ventricular ejection 
fraction ≤ 35%, QRS duration ≥ 120ms) as approved by the National Institute for Clinical 
Excellence Healthcare Technology Appraisal. (Healthcare Technology Appraisal 120: 
Cardiac resynchronisation therapy for the treatment of heart failure, 2007) The patients 
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were treated with CRT without implantable defibrillator back up because implantable 
defibrillators were not funded for primary prevention at that time. 
6.2.1 Study Design 
All patients underwent clinical assessment at baseline, 6 weeks and then at six monthly 
intervals thereafter. A CMR study was performed at baseline, prior to pacemaker 
implantation. Clinical assessment included NYHA class, a six minute walk distance test 
(Guyatt et al., 1985) and Minnesota living with heart failure questionnaire. (Rector et al., 
1987) All patients provided written informed consent and the study was approved by the 
North Birmingham Research Ethics Committee. 
6.2.2 Device Therapy 
Biventricular pacemaker implantation was carried out after written informed consent 
under conscious sedation and local anaesthesia. Follow up took place in a dedicated 
device clinic where the pacemaker was checked by cardiac physiologists, the device 
optimised with echocardiography and medications adjusted by cardiac research fellows 
or the specialised heart failure and device nurse. Patients in atrial fibrillation did not 
undergo AV node ablation. (Khadjooi et al., 2008) Patients in sinus rhythm (n = 118) 
were optimised using echocardiography to prolong AV filling time whilst avoiding 
diastolic mitral regurgiation. (Ritter et al., 1999) The AV delay was optimised at each 
follow up visit thereafter. The back up atrial rate was set to 60 beats per minute, and the 
pacing mode set to DDD with rate response switched on, with a baseline inter-ventricular 
delay of 0 to 4 ms (nominal settings varied according to device manufacturer). In patients 
in atrial fibrillation (n = 23), the atrial port was plugged and the device was programmed 
to a minimum base rate with ventricular triggered pacing such that sensed right 
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ventricular activity would result in left ventricular stimulation. All patients had functional 
leads and generators during the study period.  
The position of the left ventricular lead was chosen by the implanting physician, who was 
blinded to the CMR study. Lead placement was determined using the o’clock method, 
which uses bi-plane fluoroscopy. (Albertsen et al., 2005) 
6.2.3 Cardiovascular Magnetic Resonance 
Imaging was performed using a 1.5 Tesla magnetic resonance imaging scanner as 
described earlier. 
6.2.4 Tissue Synchronization Index.  
The CMR-TSI was derived as previously described.  
6.2.5 Scar Imaging 
The CMR study was carried out as described earlier. Scar volume was calculated in cm3 
by multiplying the plani metered area of late gadolinium enhancement in each slice by 
the slice thickness. Scar volume was expressed as a % of LV myocardial volume in the 
diastolic phase. Areas of scar were then segmented using a 17 segment model.(Lang et 
al., 2005) A posterolateral (PL) scar was defined as a scar in ≥1 of the following 
segments: basal posterior, mid posterior, basal-PL and mid-PL. 
6.2.6 Echocardiography 
ECG gated two dimensional echocardiograms were acquired using standard protocols. 
The images were stored digitally for off line analysis. The left ventricular volumes were 
measured using planimetry and the left ventricular ejection fraction calculated using the 
modified Simpson’s technique in the apical four chamber view (EchoPac, GE, Slough).  
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6.2.7 Follow up and Endpoints 
The clinical endpoints considered were the composite of heart failure hospitalisation and 
cardiovascular mortality, and the composite of total mortality or heart failure 
hospitalisation for a major cardiovascular event. The latter endpoint included myocardial 
infarction, pulmonary embolism, upgrading to implantable defibrillator, cardiac 
transplantation or admission with worsening heart failure. The other endpoints were 
cardiovascular mortality and total mortality. Sudden cardiac death was defined as “a 
natural, unexpected death due to cardiac causes, heralded by an abrupt loss of 
consciousness within one hour of the onset of acute symptoms”. (Myerburg and 
Castellanos, 1997) Mortality was collected through medical records and, where 
appropriate, from interviews with patient’s caregivers, and was not confirmed by post 
mortem. Sudden death during sleep was assigned to sudden cardiac death.  Clinical 
outcomes were collected by an investigator who was blinded to other clinical and 
imaging data.  
6.2.8 Statistical analysis 
Continuous variables are expressed as mean ± standard deviation (SD). Normality was 
tested using the Shapiro-Wilk test.  Variables which were not normally distributed were 
log-transformed before statistical analyses. Comparisons between normally distributed 
continuous variables were made using ANOVA with Scheffe’s F procedure for multiple 
comparisons. Categorical variables were analysed using chi-squared tests and Scheffe’s 
post-hoc test. Changes in variables from baseline to follow-up were analyzed using 
paired Students’ t-tests. Variables showing significant group differences at baseline were 
entered into Cox proportional hazards analyses. 
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As in a previous study, (Chalil et al., 2007d) the value of CMR-TSI with the optimum 
sensitivity and specificity was 110 msec for all endpoints. The ability of CMR-TSI to 
discriminate between patients in the various risk categories at this cut-off value was 
assessed using Cox proportional hazards analyses and Kaplan-Meier survival curves. 
Differences in survival curves between the groups were assessed using the log-rank 
(Mantel-Cox) test. Statistical analyses were performed using Statview (Cary, NC) and 
SPSS 15.0 (Chicago, Illinois). A two-tailed p value of <0.05 was considered statistically 
significant. In a previous study, (Chalil et al., 2007d) intra-observer and interobserver 
variabilities for CMR-TSI were 3.0% and 8.8%, respectively.  
Analysis of wall motion was performed using the R statistical language.  The non-linear 
least square fit function implemented by Bates and DebRoy into the 'nls' packet of R was 
used for the sine fit. (Bates and Watts, 1988) 
 
6.3 Results 
6.3.1 Baseline characteristics 
The patients were grouped according to the CMR-TSI and the presence of posterolateral 
scar, as shown in table 1. Patients without posterolateral scar included patients with non-
ischaemic cardiomyopathy as well as patients with ischaemic cardiomyopathy who had 
scar in other locations. Furthermore, the groups with posterolateral scar only included 
patients with ischaemic cardiomyopathy, as well as a greater proportion of patients who 
had undergone coronary bypass surgery. The patients were well matched for age, but 
there were significantly more males in the patients with a CMR-TSI ≥ 110 ms with 
posterolateral scar. There were no significant differences in the numbers of patients who 
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had hypertension or diabetes mellitus at baseline. All the patients with posterolateral scar 
and CMR-TSI ≥ 110ms were in sinus rhythm, which was significantly greater than seen 
in other groups. There were no significant differences in the baseline pre-implant 
medications between the groups. The pre-implant use of beta blockers was lower than 
other studies such as CARE-HF, but the proportion of patients in NYHA class IV was 
greater, reflecting a sicker population, with a greater proportion of patients with 
ischaemic heart disease. (J. G. Cleland et al., 2005a, Wikstrom et al., 2009) In the CARE-
HF study patients with ICM were prescribed less medical therapy in comparison with 
those with NICM. (Wikstrom et al., 2009) 
There were no significant differences in the baseline QRS duration between the groups, 
although there was a trend to a greater QRS duration in the CMR-TSI ≥ 110 ms with 
posterolateral scar group. The ventricular volumes were greater in the group with CMR-
TSI ≥ 110 ms, and significantly greater in the CMR-TSI ≥ 110 ms without posterolateral 
scar group for LVEDV alone, and for both groups with CMR-TSI≥110ms for LVESV. 
The latter was also the case for both groups which had significantly lower LVEF. The 
scar volume was significantly greater in both the groups which had postero-lateral scar 
relating to the higher proportion of patients with ischaemic heart disease. 
The baseline characteristics of the participants are shown in Table 6-1. The maximum 
follow up of the participants was 1936 days (5.3 years) for events, there were 3 non-
cardiovascular deaths and 30 cardiovascular deaths. 24 were due to pump failure and 6 
due to sudden cardiac death. There were 5/91 (5.5%) sudden cardiac deaths in patients 
with ischaemic cardiomyopathy and 1/50 (2%) in patients with non-ischaemic 
cardiomyopathy (p = NS). One patient underwent cardiac transplantation. The risk of 
reaching all endpoints was greatest in the group with the CMR-TSI ≥ 110 ms with 
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posterolateral scar, amounting to approximately 10 times as many events as in the CMR 
< 110ms and no PL scar group (all P <0.001). In the CMR≥110 msec and PL scar group, 
14/15 (93%) of the cardiovascular deaths were due to pump failure. In the CMR-TSI 
≤110ms and no PL scar group, 4/7 (57%) of the cardiovascular deaths were due to pump 
failure. See Table 6-2 
In terms of the risk of the composite endpoint of cardiovascular mortality and heart 
failure hospitalisation, this was higher in the CMR-TSI≤110 ms and PL scar than in the 
CMR-TSI≥110 msec and no PL scar group (P=0.026), although no other differences 
emerged in terms of the other end points. As the risk of reaching the endpoints was 
similar in both groups, the groups were amalgamated. Using Kaplan-Meier survival 
analysis, curves were drawn for 3 risk groups: 1) CMR-TSI≤ 110ms and no PL scar, 2) 
CMR-TSI≥ 110ms and no PL scar or CMR-TSI≤ 110ms and PL scar, and 3) CMR-TSI≥ 
110ms and PL scar. As shown in Figure 6-1, the group with CMR-TSI≥ 110ms and PL 
scar emerged as the highest risk group with respect to all endpoints (log-rank P<0.001). 
Kaplan-Meier survival analysis for ICM and NICM are presented in Figure 6-2. 
Uni-variable Cox proportional hazard analyses were used to explore the value of 
assessing CMR-TSI alone, scar location alone, or the combination of both. As shown in 
Table 6-3, both the CMR-TSI and PL scar location emerge as the strongest predictor of 
all endpoints when considered separately in uni-variable models. The highest difference 
between low and high risk groups, however was observed when both CMR-TSI and PL 
scar were combined. Patients with a CMR-TSI≥110 ms and PL scar were identified as a 
particularly high risk group for all endpoints (all p<0.01), compared to patients with 
CMR-TSI≤110msec and no PL scar. Although other CMR variables, such as LV 
volumes, LVEF and scar volume, reached statistical significance in univariate Cox 
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models, all had HR ≤ 1.0. Age and gender failed to emerge as predictors of the various 
endpoints in univariate analyses. In multi-variable Cox proportional analyses, the finding 
of CMR-TSI ≥ 110 msec and PL scar or the finding of either CMR-TSI ≥ 110 msec or a 
PL scar emerged as strong predictors of all the endpoints, independent of LVEF and scar 
size. 
6.3.2 Clinical and echocardiographic data 
As shown in Table 6-4 similar changes in NYHA class, 6 minute walking distance and 
quality of life scores were observed across the groups. Significant reductions in LVEDV 
(p = 0.049) and LVESV (p = 0.0007) were only observed in the CMR-TSI ≤ 110 msec 
and no PL scar group. Similarly, an increase in LVEF was only observed in this group (p 
<0.001). 
6.4 Discussion 
Cardiovascular magnetic resonance provides unique information with regard to 
diagnosis, aetiology, function and outcome in patients with cardiomyopathy (Assomull et 
al., 2006, McCrohon et al., 2003). The key finding from this study is that CMR can 
provide unique information regarding risk stratification in terms of morbidity and 
mortality of patients undergoing CRT pacing. This study demonstrates that the morbidity 
and mortality after CRT was lowest in patients with CMR-TSI < 110 ms and absence of 
posterolateral scar. In contrast, the highest risk group were identified as those with CMR-
TSI ≥ 110 msec and the presence of PL scar, and this group were twelve fold more likely 
to experience cardiovascular death or hospitalisation with heart failure. Strikingly, all 
groups benefit from CRT in terms of symptomatic improvement, although the patients 
with CMR-TSI≥ 110msec and PL scar did not improve in terms of left ventricular 
ejection fraction at follow up. 
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6.4.1 Dyssynchrony and outcome 
The finding that dyssynchrony is associated with worse outcome after CRT is not 
surprising given the relationship between CMR-TSI and other measures of myocardial 
performance and electrical dyssynchrony. We have demonstrated that CMR-TSI is 
greatest in patients with ischaemic heart disease when compared to non-ischaemic 
cardiomyopathy (see Chapter 3). Outcome from CRT is worst in patients with ischaemic 
cardiomyopathy. (Wikstrom et al., 2009, Q. Zhang et al., 2009) Furthermore, we have 
shown that dyssynchrony is inversely related to left ventricular ejection fraction, 
governed by an exponential relationship, so that the greatest CMR-TSI is seen in patients 
with the lowest LVEF. This is in line with findings from observational studies which 
show that NT-pro-BNP, a marker of left ventricular dysfunction and neurohumoral 
activation, predicts outcome after CRT, with those with the highest levels experiencing 
the worst outcome. (Cleland et al., 2008a, Fruhwald et al., 2007) Dyssynchrony and BNP 
has not been evaluated in many studies, but Lellouche et al. found that BNP was related 
to the presence of dyssynchrony on tissue Doppler imaging in patients undergoing CRT 
implantation. (Lellouche et al., 2007)  
Myocardial viability is essential to gain benefit from revascularisation in the field of 
ischaemic cardiomyopathy, (Dakik et al., 1997, Pagley et al., 1997, Schvartzman et al., 
2003) It would seem logical that viable myocardium is required to gain benefit from 
CRT, as pacing scar and attempting to stimulate myocardium which has little residual 
viability is likely to be futile. Recent work has suggested that stress echocardiography 
could aid patient selection for CRT, identifying those patients with sufficient contractile 
reserve to benefit. (Da et al., 2006)   
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6.4.2 CMR dyssynchrony and outcome – contrast with echocardiographic 
dyssynchrony 
The relationship identified between CMR-TSI and both left ventricular volume and QRS 
duration, lies in contrast to findings which emerge predominantly from 
echocardiographic studies. (Bax et al., 2004b, Van de Veire et al., 2007, Yu et al., 2003a) 
Although QRS duration has not been shown to predict outcome after CRT, this may be 
because it is too insensitive as a marker. (Bristow et al., 2004, Cleland et al., 2005b) The 
COMPANION study suggested patients with the broadest QRS duration gained the 
greatest absolute benefit from CRT in terms of reduced mortality and hospitalisations, 
but the study was not powered for subgroup analysis. A longer follow up may determine 
if there is a benefit to starting CRT in those with a narrower QRS, who may be at an 
earlier stage in the disease process. (Bristow et al., 2004) The worst outcome in our study 
was seen in patients with the most dyssynchrony and the presence of posterolateral scar, 
and these patients were at greatest risk of pump failure. This finding is consistent with 
the observation that these patients had the worst left ventricular function pre-
implantation.  
6.4.3 Effect of posterolateral scar 
The presence of PL scar may have prevented adequate resynchronisation. The finding of 
a better outcome in patients with CMR-TSI ≥ 110 msec but without PL scar is consistent 
with this hypothesis. This study suggests that those patients with the most damaged and 
dyssynchronous ventricles benefit the least from CRT. An interesting finding from 
studies using septal to lateral delay to predict outcome after CRT  found that beyond a 
septal to lateral delay of 100 msec, there was no benefit from CRT, suggesting that 
182 
 
  
beyond a certain threshold beyond which there is little benefit from CRT.(Bax et al., 
2004b) 
The advantage to this technique of risk stratification is the simplicity of the technique. 
This application of CMR demonstrates the ability to determine outcome in terms of 
morbidity and mortality after CRT pacing, which has so far eluded other imaging and 
neuro-hormonal techniques. (Chung et al., 2008, Cleland et al., 2008a) There are a 
number of other CMR techniques which are under development, such as tissue velocity 
imaging, myocardial tagging (Curry et al., 1998, Helm et al., 2005), strain encoding 
(Kuijer et al., 2006) and velocity-encoding (Westenberg et al., 2006).  However, these 
techniques have not yet been applied to determine whether they have the ability to 
predict outcome after CRT.  
The basis of measurement of CMR-TSI is the use of steady state free precession (SSFP) 
short axis stacks available on a routine LV perfusion study, which are straightforward to 
acquire and do not require specialised sequences or analysis. The very low inter-observer 
and intra-observer variabilities of CMR-TSI (< 9%) (Chalil et al., 2007d) and scar 
quantification (Bülow et al., 2005, Thiele et al., 2006) make these techniques readily 
applicable clinically. The disadvantage to measurement of CMR-TSI is that it is time 
consuming, taking up to 2 hours per scan, although in the future this could become 
automated. 
Pacing left ventricular scar is associated with worse outcome after CRT. This may simply 
relate to lack of myocardial viability at the pacing site, making the scar less excitable in 
response to the pacing stimulus. (Tedrow et al., 2004) The presence of scar is associated 
with delayed conduction of the stimulus through the myocardium (Lambiase et al., 2004), 
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which may in turn result in delayed contraction of the postero-lateral wall, which is 
crucial in CRT. (Breithardt et al., 2002) Furthermore, we have shown that posterolateral 
scar is associated with worse reverse remodelling after CRT implantation. (Chalil et al., 
2007c) 
The unique application of CMR-TSI coupled with the assessment of postero-lateral scar 
is a powerful risk-stratifier of patients with symptomatic moderate to severe heart failure 
undergoing CRT. Patients with marked dyssynchrony and the presence of posterolateral 
scar are 12 fold more at risk of cardiovascular death or heart failure hospitalisation. 
Furthermore, pacing left ventricular scar results in worse outcome after CRT. The 
findings demonstrate the value of a CMR scar prior to CRT implantation. 
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6.5 TABLE LEGENDS 
Table 6-1 Baseline clinical and cardiovascular magnetic resonance imaging characteristics 
for patients undergoing cardiac resynchronisation therapy, grouped according to degree of 
dyssynchrony and presence or absence of posterolateral scar 
Table 6-2 Clinical endpoints for patients undergoing cardiac resynchronisation therapy, 
grouped according to degree of dyssynchrony and presence or absence of posterolateral scar 
Table 6-3 Uni-variable Cox proportional hazards analyses of clinical endpoints in relation 
to cardiovascular magnetic resonance variables according to imaging modality 
Table 6-4 Clinical and echocardiographic variables during follow-up in patients undergoing 
cardiac resynchronisation therapy, grouped according to degree of dyssynchrony and 
presence of posterolateral scar at baseline 
 
6.6 FIGURE LEGENDS  
Figure 6-1 Kaplan-Meier estimates of the time to the various clinical endpoints. Patients 
were stratified according to a pre-implant CMR-TSI (<110 msec or CMR-TSI ≥110 msec) 
as well as presence or absence of a posterolateral (PL) scar. MCE=major cardiovascular 
events; HF=heart failure.  
 
Figure 6-2 Kaplan-Meier estimates of the time to the various clinical endpoints in patients 
with ischemic (ICM) or non-ischaemic (NICM) cardiomyopathy. MCE=major 
cardiovascular events; HF=heart failure.  
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Table 6-1 Baseline clinical and cardiovascular magnetic resonance imaging 
characteristics 
Grouped by dyssynchrony and presence or absence of posterolateral scar. 
 
 All CMR-TSI<110  CMR-TSI≥110 CMR TSI<110  CMR 
      TSI≥110 
  No PL scar No PL scar + PL scar  + PL scar    
 
N 141 62 28  24 27   
Age, yrs  66.8  65.4 68.1 68.4 67.0 
 ± 10.1 ± 10.4 ± 9.6 ± 9.6 ± 10.2 
Male sex % 76 68 75  88 85 *  
Aetiology % 
 ICM 65 39 57  100 100 *** 
 NICM 35 61 43  0 0 *** 
Co-morbidity % 
 Diabetes mellitus  15 11 25  17 11   
 Hypertension 28 29 29  29 22  
 CABG 23 16 7  33 * 48 ***  
Medication % 
 Loop diuretics 88 94 86  88 78 
 ACE-I or ARB 92 94 89  92 93 
 Beta-blockers 58 56 61  58 59 
 Spironolactone 47 53 36  33 56  
ECG variables 
 Sinus rhythm  
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 (n =118) % 84 82 71  83 100 *  
 QRS duration 145.0  143.9 146.9 135.0 156.8 
 , msec ±27.2 ± 28.1 ± 26.1 ± 20.8 ± 28.5   
CMR variables 
 LVEDV, cm3 243.0  217.8 288.1 220.2 276.9 
  ± 98.3 ± 94.5 ± 102.3 * ± 99.6 ± 79.6 
 LVESV, cm3 195.8  168.9 244.1 172.7 230.8 
  ± 95.7 ± 92.2 ± 98.0 ** ± 95.3 ± 74.5 * 
 LVEF, % 23.2  27.2 17.0 26.3 17.4 
  ± 11.0 ± 12.3 ± 6.0 *** ± 10.6 ± 6.6 *** 
 CMR-TSI, msec 101.4  69.8 134.2 76.2 161.4 
  ± 48.8 ± 23.8 ± 20.5 *** ± 16.1 ± 53.8 *** 
 Scar volume, % 20.0  11.1 19.7 26.9 35.1 
  ± 20.0 ± 16.5 ± 22.6 ± 14.5 ** ± 18.2 *** 
 
 
P values refer to differences between the groups and the group with a CMR-TSI < 110msec 
and no posterolateral (PL) scar. *, p<0.05, **, p<0.01, ***, p<0.001. 
187 
 
 
 
Table 6-2 Clinical endpoints for patients undergoing CRT in relation to PL scar 
 
 All CMR-TSI  
  <110 ≥110 <110msec ≥110msec 
   - PL - PL + PL + PL       
N 141 62 28 24  27   
Follow-up period, days 794   854 676 777  792  
 ± 483 ± 471 ± 570 ± 443  ± 448 
Endpoints % 
Total mortality or 30 8 25 * 46 *** 74 *** 
Hospitalisation for MCE (n=43) 
Cardiovascular mortality 26 6 14 42 *** 67 *** 
or hospitalisation for HF (n=36) 
Cardiovascular mortality (n=30)  21 5  18 * 29 ** 56 *** 
Total mortality (n=33) 23 6 21 * 33 ** 56 *** 
Mode of death % 
Pump failure (n=23) 16 3 11 † 17 * 52 ***  
Sudden cardiac death (n=7) 5 2 7 13 * 4 
Non-cardiac death (n=3) 2 2 4 4 0   
 
Variables are expressed as n (% of total patients in the group). Follow-up period is 
expressed as mean ± p values refer to differences between the groups and the group with a 
CMR-TSI < 110 msec and no posterolateral (PL) scar. MCE = major cardiovascular events; 
HF = heart failure. †, includes 1 heart transplant. 
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Table 6-3 Uni-variable Cox proportional hazards analyses of clinical endpoints 
Cardiovascular death or hospitalization for HF   
   HR (95% CI) p 
 Comparator 
Assessment of CMR-TSI or scar 
 CMR-TSI ≥ 110 msec 2.86 (1.46 - 5.59) 0.0022 
 CMR-TSI < 110 msec 
 PL scar 6.26 (3.00 -13.1) <0.0001
 No PL scar 
 
Assessment of CMR-TSI and scar 
 CMR-TSI ≥ 110 msec and PL scar 11.8 (3.99 - 35.0) <0.0001
 CMR-TSI <110 msec/No PL scar 
 CMR-TSI ≥ 110 msec or PL scar 4.77 (1.57 - 14.5) 0.0059 
 
Continuous variables 
 LVEF 0.94 (0.91 - 0.98) 0.003 
 LVEDV 1.00 (1.00 - 1.01) NS 
 LVESV 1.00 (1.00 - 1.01) NS 
 Scar volume 1.02 (1.01 - 1.04) 0.0029 
 
 
Death from any cause or hospitalisation for MCE 
Assessment of CMR-TSI or scar 
 CMR-TSI ≥ 110 msec 3.70 (1.96 - 6.99) <0.0001
 CMR-TSI < 110 msec 
 PL scar 5.07 (2.65 - 9.69) <0.0001
 No PL scar 
 CMR-TSI ≥ 110 msec/+PL scar 4.71 (2.52 - 8.78) <0.0001
 CMR-TSI ≥ 110 msec or PL scar or neither 
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Assessment of CMR-TSI and scar 
 CMR-TSI ≥ 110 msec and PL scar 12.6 (4.69 - 33.7) <0.0001
 CMR-TSI <110 msec/No PL scar 
 CMR-TSI ≥ 110 msec or PL scar 5.07 (1.88 - 13.7) 0.0013 
 
Continuous variables 
 LVEF 0.94 (0.90 - 0.97) 0.0006 
 LVEDV 1.00 (1.00 - 1.01) 0.0405 
 LVESV 1.00 (1.00 - 1.01) 0.0076 
 Scar volume 1.02 (1.00 - 1.03) 0.0066 
 
Cardiovascular Death 
Assessment of CMR-TSI or scar 
 
 CMR-TSI ≥ 110 msec 3.55 (1.66 - 7.60)    0.0011
 CMR-TSI < 110 msec 
 PL scar 4.38 (2.03 - 9.46)   0.0002
 No PL scar 
 CMR-TSI ≥ 110 msec/+PL scar 3.74 (1.81 - 7.71)    0.0004
 CMR-TSI ≥ 110 msec or PL scar or neither 
 
Assessment of CMR-TSI and scar 
 CMR-TSI ≥ 110 msec and PL scar 12.2 (3.54 - 42.3) <0.0001
 CMR-TSI <110 msec/No PL scar 
 CMR-TSI ≥ 110 msec or PL scar  5.29 (1.49 - 18.8) 0.0099 
 
Continuous variables 
 LVEF 0.94 (0.90 - 0.99) 0.0086 
 LVEDV 1.00 (1.00 - 1.01) NS 
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 LVESV 1.00 (1.00 - 1.01) 0.0147 
 Scar volume 1.02 (1.01 - 1.04) 0.0124 
 
 
Death from any cause 
Assessment of CMR-TSI or scar 
 
 CMR-TSI ≥ 110 msec 3.37 (1.62 -  7.01)   0.0011
 CMR-TSI < 110 msec 
 PL scar 3.39 (1.67 - 6.89)   0.0007
 No PL scar 
 CMR-TSI ≥ 110 msec/+PL scar 3.28 (1.62 - 6.65)   0.0010
 CMR-TSI ≥ 110 msec or PL scar or neither 
     
Assessment of CMR-TSI and scar 
 CMR-TSI ≥ 110 msec and PL scar 8.91 (2.95 - 26.9)   0.0001
 CMR-TSI <110 msec/No PL scar 
 CMR-TSI ≥ 110 msec or PL scar 4.64 (1.53 - 14.1) 0.0068 
Continuous variables 
 LVEF 0.94 (0.89 - 0.98) 0.0036 
 LVEDV 1.00 (1.00 - 1.01) NS 
 LVESV 1.00 (1.00 - 1.00) 0.0146 
 Scar volume 1.02 (1.01 - 1.03) 0.0098 
 
 
 
The comparator is the lowest risk group category in each model. HF = heart failure; HR 
(95% CI) = hazard ratio and 95% confidence intervals; CMR-TSI = cardiovascular 
magnetic resonance tissue synchronisation imaging score; PL = postero-lateral; MCE = 
major cardiovascular events; LVESV = left ventricular end-systolic volume; LVEDV = left 
ventricular end-diastolic volume; LVEF = left ventricular ejection fraction. 
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Table 6-4 Clinical and echocardiographic variables during follow-up in patients 
undergoing cardiac resynchronisation therapy, grouped according to degree of 
dyssynchrony and presence of posterolateral scar at baseline 
 
 All <110 msec  ≥110msec <110msec ≥110msec 
 -PL scar -PL scar + PL scar + PL scar   
 
N 141 62 28 24 27   
Clinical  variables 
NYHA class 
 Baseline 3.18 ± 0.54 3.19 ± 0.51 3.21 ± 0.42 3.21 ± 0.72 3.07 ± 0.54 
 Follow-up  1.98 ± 0.77 *** 1.93 ± 0.76 *** 2.09 ± 0.68 *** 2.0 ± 1.0 *** 1.96 ±0.66 *** 
6-min walk test, metres   
 Baseline 252.9 ± 111.2 259.4 ± 111.9 221.5 ± 115.8 235.8 ± 119.9 282.7 ±93.6 
 Follow-up  323.5 ± 116.4 *** 338.2 ± 129.9 ***287.6 ± 116.8*334.9 ± 113.1**319.0 ± 
93.8 ** 
Quality of life score 
 Baseline 56.7± 20.1 62.9 ± 20.4 54.9 ± 20.1 58.2 ± 18.3 44.7 ± 16.5 
 Follow-up  32.5 ± 23.7 *** 30.0 ± 22.1 *** 36.1 ± 20.4 * 37.5 ± 29.9 ** 29.5 ± 23.1*  
Echocardiography 
LVEDV, mL 
Baseline 231.4 ± 86.4 225.0 ± 95.9 257.3 ± 82.5 215.3 ± 70.0 232.5 ±  
      77.7 
Follow-up  209.6 ± 92.2 * 202.4 ± 115.7 * 225.2 ± 56.4 202.0 ± 64.5 218.5 ±  
      78.6 
LVESV, mL 
 Baseline 175.4 ± 75.7 172.0 ± 82.5 200.0 ± 73.5 159.4 ± 66.0 171.3 ±  
      68.0 
 Follow-up  148.0 ± 82.7 ** 139.5 ± 98.2 ***148.3 ± 56.4 146.4 ± 72.3 166.9 ±  
      72.2 
LVEF, % 
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 Baseline 25.2 ± 10.7 24.3 ± 10.7 23.1 ± 10.2 27.2 ± 11.5 27.4 ± 10.4 
 Follow-up  30.4 ± 11.5 *** 33.4 ± 10.2 *** 29.1 ± 11.1 30.4 ± 14.6 25.2 ± 10.2 
 
 
 
LVESV = left ventricular end-systolic volume; LVEDV = left ventricular end-diastolic 
volume; LVEF = left ventricular ejection fraction. P values refer to differences from 
baseline values within the group. *, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 6-1 Kaplan-Meier estimates of the time to the various clinical endpoints 
Patients were stratified according to a pre-implant CMR-TSI (<110 msec or CMR-TSI ≥110 
msec) as well as presence or absence of a posterolateral (PL) scar. 
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Figure 6-2 Kaplan Meier stratified according to ICM vs NICM 
Kaplan-Meier estimates of the time to the various clinical endpoints in patients with ischemic 
(ICM) or non-ischaemic (NICM) cardiomyopathy. MCE=major cardiovascular events; 
HF=heart failure.  
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CHAPTER 7. DEVELOPMENT AND VALIDATION OF A 
CLINICAL INDEX TO PREDICT SURVIVAL AFTER CARDIAC 
RESYNCHRONISATION THERAPY 
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7.1 Introduction 
Outcome in patients with moderate to severe heart failure is improved by CRT, but 
cannot be predicted in an individual patient. Various pre-implant factors have been 
shown in multicentre controlled clinical trials to affect the long term outcome, for 
instance, patients in class IV heart failure do not survive as long as patients in class III 
heart failure. (Lindenfeld et al., 2007) Despite this, there are a number of case series of 
patients in cardiogenic shock at the time of implantation, who survived for long periods 
after being implanted with CRT. (Herweg et al., 2007)  
It is widely recognised that the effect of CRT is variable. As many as 20-30% of patients 
fail to gain symptomatic improvement (Abraham et al., 2002, Molhoek et al., 2002) and 
the survival benefit varies between patients. (Chalil et al., 2007a, Chalil et al., 2007b) 
Identifying a pre-implant measure that robustly predicts mortality in patients undergoing 
CRT is, therefore, desirable. In many other fields of medicine, it has been considered 
desirable to determine which patients benefit from particular interventions, for instance 
reperfusion treatment in acute myocardial infarction. This allows efficacious treatment to 
be directed at those most likely to gain benefit, which is particularly important for 
relatively high cost interventions.  
Cardiovascular magnetic resonance (CMR) is becoming a routine investigation for 
patients with heart failure, being the gold standard for the in vivo assessment of cardiac 
structure, function, and dyssynchrony. (Lardo et al., 2005) In this thesis, CMR tissue 
synchronisation index (CMR-TSI), derived from a routine CMR scan, has been found to 
be a powerful predictor of mortality and morbidity after CRT. In addition, CMR also 
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allows visualisation and quantification of myocardial scarring. (Chalil et al., 2007c,  
White et al., 2006) Importantly, the size (burden), trans-murality and location of a 
myocardial scar in the LV free wall, the target location for the left ventricular lead in 
CRT, have been linked to a poor outcome after CRT. (Bleeker et al., 2006c, Chalil et al., 
2007c, Chalil et al., 2007d, White et al., 2006) 
Having shown that CMR-TSI and posterolateral scar are important determinants of 
outcome, we sought to develop a risk score to enable prediction of outcome after CRT. 
We have explored the value of pre-implant CMR measures of dyssynchrony and 
myocardial scarring, as well as more conventional heart failure risk factors, (Aaronson et 
al., 1997) in predicting cardiovascular mortality after CRT. This study focuses on the 
derivation and validation of a clinical risk index based on a combination of such non-
invasive measures. 
 
7.2 Methods 
7.2.1 Patients 
A total of 148 consecutive heart failure patients were prospectively enrolled from 
January 2001 to April 2008 at a single centre (Good Hope Hospital). Patients were 
selected if they were due to undergo CRT for standard indications (ischaemic or non-
ischaemic cardiomyopathy, New York Heart Association [NYHA] class III or IV, LV 
ejection fraction [LVEF)] <35%, QRS duration ≥120 ms). The majority of patients were 
recruited prior to the publication of the guidelines on implantable cardioverter-
defibrillator therapy in the United Kingdom. (Implantable cardioverter defibrillators for 
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arrhythmias. Review of Technology Appraisal 11. Technology Appraisal 95, 2006) All 
patients had undergone coronary angiography. The clinical diagnosis of systolic heart 
failure was based on clinical criteria and evidence of systolic dysfunction on 
echocardiography.  The diagnosis of ischaemic cardiomyopathy was made if systolic 
dysfunction was associated with a history of myocardial infarction, (Alpert et al., 2000) 
the findings of coronary angiography, or if the pattern of late-gadolinium 
hyperenhancement was characteristic of a myocardial infarction. (Assomull et al., 2006) 
The study was approved by the North Birmingham Ethics Committee. 
 
7.2.2 Study design 
A CMR study was performed at baseline. For validation of the DSC risk index, the 
clinical endpoint considered was cardiovascular death. For qualitative comparisons with 
the CARE-HF study, we also considered the composite endpoint of death from any cause 
or hospitalizations for major cardiovascular events, as defined in the CARE-HF study 
protocol. (Cleland et al., 2005b) Mortality data was collected through medical records 
and, where appropriate, from interviews with patient’s caregivers. Clinical outcome data 
were collected on a 2-monthly basis by an investigator who was blinded to other clinical 
and imaging data. Sudden cardiac death was defined as “a natural, unexpected death due 
to cardiac causes, heralded by an abrupt loss of consciousness within one hour of the 
onset of acute symptoms”. (Myerburg and Castellanos, 1997)  
7.2.3 Device therapy 
Biventricular pacemaker (CRT-P) implantation was undertaken as previously described.  
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7.2.4 Cardiovascular magnetic resonance 
The CMR-TSI and scar imaging was measured as previously described. 
 
7.2.5 Statistical analysis 
Continuous variables are expressed as mean ± standard deviation (SD). Normality was 
tested  using the Shapiro-Wilk test.  Variables which were not normally distributed were 
log-transformed before statistical analyses. Comparisons between normally distributed 
continuous variables were made using ANOVA with Scheffe’s F procedure for multiple 
comparisons. Categorical variables were analyzed using chi-squared tests and Scheffe’s 
post-hoc test. Changes in variables from baseline to follow-up were analyzed using 
paired Students’ t-tests. Variables showing significant group differences at baseline were 
entered into Cox proportional hazards analyses. 
Differences in Kaplan-Meier survival curves between the risk groups were assessed using 
the log-rank (Mantel-Cox) test. Areas under the receiver-operating characteristic curves 
(AUC) were used to derive optimal cut-off points for the DSC index. Statistical analyses 
were performed using Statview (Cary, NC) and SPSS 13.0 (Chicago, Illinois). A two-
tailed p value of <0.05 was considered statistically significant. Analysis of wall motion 
was performed using the R statistical language. 
7.2.6 Development of the risk index  
This was developed on the basis of the data presented in this chapter. In line with 
Harrell’s recommendations on multivariate prognostic modelling, (Harrell et al., 1984, 
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Harrell et al., 1996) candidate variables were selected on the basis of their proven 
clinical, pathophysiological and epidemiological relevance to the endpoint in question.  
Accordingly, studies of patients with heart failure treated (Chalil et al., 2007a, Chalil et 
al., 2007b, Chalil et al., 2007c, Chalil et al., 2007d) and not treated (Aaronson et al., 
1997, Anker et al., 2003, Lee et al., 2003) with CRT were used to guide data reduction. 
Continuous rather than dichotomous variables were used wherever possible. (Harrell et 
al., 1996) The aim throughout the data reduction process was to identify a small number 
of variables which, on the basis of their biological relevance to heart failure and CRT, 
explained survival. (Harrell et al., 1984) Interactions between variables were extensively 
explored using interaction terms in Cox proportional hazards models. Linearity 
assumptions were checked using Martingale residuals. Cross-product terms were added 
to check for additivity assumptions. The proportional hazards assumption was checked 
using Schoenfeld residuals. (Schoenfeld, 1982) 
Variables achieving a p<0.10 in univariate Cox proportional hazards analyses were 
entered in a stepwise multivariate model using Akaike’s information criterion as a 
stopping rule (χ 2 for a set of variables > 2 degrees of freedom), implemented using the 
Harrell ‘Design’ package version 2.1-1in R. (Harrell, 2007) 
7.2.7 Validation 
Validation was implemented using bootstrapping. (Harrell et al., 1984) (Efron, 1979, 
Harrell et al., 1996) This nonparametric method, which estimates sampling distributions 
of a predictor variable by resampling with replacement from the original sample, is, in 
effect, an impression of the validity of predictions in new but similar patients. For each 
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group of 200 bootstrap samples, the model was refitted and tested against the observed 
sample in order to derive an estimate of the predictive accuracy and bias. This was used 
to select 148 ‘new’ patients from the original cohort, one at a time with replacement, 200 
times over.  
For each of these 200 samples, the following parameters were derived: 1) the ß 
coefficients from Cox proportional hazards models; 2) Somer’s D rank correlation index 
and 3) an estimate of the slope shrinkage. (Harrell et al., 1984) The apparent Somer’s D 
(Dapp) was derived using stepwise Cox proportional analyses. The bootstrap-corrected 
performance of the predictor equation, or ‘optimism’, (Harrell et al., 1996) was 
quantified by assessing the difference between Somer’s D in the original sample (Dorig) 
and D in the bootstrap sample (Dboot). The average optimism, termed O, was derived by 
repeating the above steps 200 times over. The bootstrap-corrected performance of the 
original stepwise model, Dapp – O, is, effectively, an honest estimate of internal validity. 
(Harrell et al., 1996) Actual survival was plotted against apparent estimated survival and 
bootstrap-corrected estimated survival.  
7.2.8 Calculation of the risk index 
The risk prediction index was expressed as the absolute value of the sum of the products 
of these variables and their ß coefficients [ie.weights] from the final stepwise 
multivariate Cox proportional hazards model, identified by Harrels’s routine (Harrell et 
al., 1984) (Harrell et al., 1996): Σ ßixi = |ß1x1+ß2x2+...+ßnxn|, where x1, x2,...xn are the 
values for the variables and ß1, ß2,...ßn are the coefficients for each variable. For 
categorical variables, presence was computed as the ß coefficient and absence as zero.  
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7.3 Results 
The characteristics of the study group are shown in Table 7-1. 
 
7.3.1 Predictor variables 
There were 20 cardiovascular deaths by 1 year and 28 by 2 yrs. After a median follow-up 
of 913 (interquartile range 967) days for events, there were 37 cardiovascular deaths. Of 
these, 28 were due to pump failure, 8 were sudden and one patient underwent cardiac 
transplantation. Table 7-2 shows the candidate variables, ranked according to the 
likelihood ratio (LR) χ 2. With respect to imaging variables, posterolateral scar location, 
CMR-TSI, scar size and LVEF emerged as the most significant predictors (all p<0.0001).  
Amongst circulating markers, sodium and creatinine were significant predictors (both 
p<0.01), uric acid only reached borderline significance (p=0.0808) and haemoglobin 
failed to reach significance. Male gender was also a predictor (p=0.0417). Age, NYHA 
class, QRS duration, presence of atrial fibrillation, as well as diagnosis of diabetes or a 
previous CABG failed to reach statistical significance. Similarly, use of loop diuretics, 
angiotensin converting enzyme inhibitors (ACE)/angiotensin-receptor blockers, beta-
blockers or spironolactone failed emerge as predictors of cardiovascular mortality (data 
not shown).  
Although ischaemic aetiology did emerge as a significant predictor of cardiovascular 
mortality in univariate analysis, addition of scar burden to this model rendered aetiology 
non-significant (data not shown). The decision not to include ischaemic aetiology in the 
multivariate model was taken in view of its expected interaction with scar burden and 
scar location (non-ischaemic cardiomyopathy is associated with little or no scar). In 
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addition, the diagnoses of ischaemic and non-ischaemic cardiomyopathy were made on 
the basis of size, transmurality and location of scar in the CMR scan. 
 
7.3.2 Derivation 
Variables that reached a p<0.10 on univariate Cox proportional hazards analyses were 
entered into stepwise models. These variables included gender, sodium, creatinine, scar 
burden, scar transmurality, CMR-LVEF, CMR-TSI and posterolateral scar location. As 
shown in Table 7-3, the variables identified in the final stepwise model were: 
Dyssynchrony, Scar location (posterolateral) and Creatinine. Therefore, the DSC index 
was calculated as follows: (2.5039 if posterolateral scar present; 0 if absent) + 0.0107. 
CMR-TSI [ms]) + (0.0132 * plasma creatinine [µmol/L]).  
 
7.3.3 The DSC index 
Strata of the DSC index were designated as low, intermediate or high risk, with cut-offs 
of <3, between 3 and 5 and ≥5. These were chosen arbitrarily for ease of use in clinical 
practice. Kaplan-Meier analyses were used to assess survival according strata of the DSC 
index (Figure 7-1).  The Cox proportional hazards analyses adopting cardiovascular 
mortality as the dependent variable and strata of the DSC index as an independent 
variable  were LR χ2: 59.1, p<0.0001. The AUC for the DSC index in relation to 
cardiovascular mortality at various time points is shown in Figure 7-3.  
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7.3.4 Validation 
Amongst the statistics derived from Harrell’s routine (Harrell, 2007, Harrell et al., 1996) 
was a bias-corrected slope of the model of 0.93, indicating an excellent model 
calibration, taking into account over fitting (Figure 7-2).  Somer’s Dappwas -0.70 and the 
optimism (O) was -0.01. The bias-corrected performance of the stepwise model (Dapp – 
O) was acceptable, at -0.69, indicating excellent internal validity. The optimism-
corrected discrimination index was 0.91; the optimism-corrected unreliability index U 
was 0.01 and the overall quality index was 0.85. 
 
7.4 Discussion 
These findings have been derived on the basis of the previous chapters demonstrating 
that dyssynchrony and postero-lateral scar imply an adverse outcome after CRT. We 
sought to develop a predictive index of mortality in patients prior to pacemaker 
implantation. This index is based on CMR variables as we have shown these to predict 
outcome after CRT. Echocardiographic variables may in future robustly determine 
outcome, but the methodology still requires further evaluation. (Yu et al., 2009) 
In deriving an index for the prediction of cardiovascular mortality after CRT, 16 non-
invasive variables have been considered which have been shown to be of prognostic 
value in patients with heart failure treated (Chalil et al., 2007c, White et al., 2006) and 
not treated (Aaronson et al., 1997, Anker et al., 2003, Lee et al., 2003) with CRT.  
The aim was to identify a non-invasive predictive index, derived from a small number of 
variables. The DSC index, which combines pre-implant measures of Dyssynchrony and 
location of myocardial Scar as well as Creatinine, is a novel, powerful predictor of 
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cardiovascular mortality in patients treated with CRT. Compared to patients in the lowest 
risk stratum, cardiovascular mortality in the intermediate and high risk strata of the DSC 
index were 11.1 and 30.5 times higher by the end of the follow-up period, respectively. 
This index may be useful in tailoring follow-up strategies and device selection in CRT 
patients. 
The collection of variables from which the DSC was derived included those which have 
previously been linked to a poor outcome in patients with heart failure. (Aaronson et al., 
1997, Anker et al., 2003, Lee et al., 2003) Of particular mechanistic relevance to CRT is 
scar burden and scar location.  
7.4.1 Role of posterolateral scar 
This study confirms our findings showing that the presence of myocardial scar over the 
posterolateral LV wall is a powerful predictor of cardiovascular mortality. The precise 
pathophysiological mechanism is still unclear, but several factors may contribute to this 
observation. Firstly, myocardial scars are not readily excitable. (Tedrow et al., 2004) A 
posterolateral scar reduces the volume of excitable myocardium in the vicinity of the LV 
pacing stimulus and delays activation of potentially recruitable myocardium, which is 
crucial for CRT. (Breithardt et al., 2002, Lambiase et al., 2004) Secondly, a 
posterolateral scar also reduces the amount of myocardium available for contraction in 
CRT, thereby leading to suboptimal reverse LV remodelling following CRT. (Bleeker et 
al., 2006c) Thirdly, posterolateral scarring may also preclude proper papillary muscle 
function, which is essential for competence of the mitral valve. The posterolateral region 
is commonly targeted for placement of the left ventricular lead. 
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7.4.2 Role of dyssynchrony 
This study is consistent with the previous chapters which found that dyssynchrony, 
assessed using CMR-TSI, predicts of a relatively poor outcome after CRT. These 
findings are in contrast to numerous echocardiographic studies showing that increasing 
dyssynchrony relates to increasing benefit from CRT. In other words, our findings point 
towards a ‘dyssynchrony is bad’ paradigm, whereas echocardiographic studies support a 
‘dyssynchrony is good’ paradigm of CRT.  
Our finding that ‘dyssynchrony is bad’ is, however, consistent with echocardiographic 
studies in non-paced patients with heart failure. (Bader et al., 2004) Bax et al. found that 
beyond a limit of dyssynchrony (a septal-to posterior wall motion delay of 100 ms), CRT 
does not result in reverse LV remodelling. (Bax et al., 2004b) The finding that 
dyssynchrony is an adverse prognostic marker is consistent with the non-paced data, and 
makes biological sense. 
 
7.4.3 Role of renal function in outcome 
The emergence of plasma creatinine in the final model is not surprising. Renal 
dysfunction is an important determinant of adverse prognosis in heart failure. (Dries et 
al., 2000, Hillege et al., 2000, Smilde et al., 2004) and it is on this basis that plasma 
creatinine has been included in risk prediction models for patients with heart failure. (Lee 
et al., 2003, Levy et al., 2006) We have shown that the inverse relationship between 
plasma creatinine and survival still holds in patients with heart failure undergoing CRT. 
The strength of this influence is reflected by the fact that it remained significant in final 
stepwise Cox proportional hazard models. 
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As our study did not include a control group, one cannot be certain the CRT-P led to a 
prognostic benefit. This, however, seems likely in view of the similarity between the 
prognostic risk profile of the present cohort and that of the CRT-P arm of the CARE-HF 
study (Figure 7-4). 
 
7.4.4 Limitations of the Study 
All patients in this study underwent implantation of a CRT device without defibrillator 
backup. Therefore, the DSC index may not be generalisable to a population of patients 
treated with defibrillator back-up (CRT-D). Ideally, external validation of the DSC index 
in a cohort of patients undergoing CRT-D would be desirable. The DSC index could be 
used to risk-stratify patients to CRT-P or the more costly CRT-D, which is more 
appropriate for patients at high risk of cardiovascular events. Importantly, however, the 
principal cause of cardiovascular death in this study was pump failure, rather than 
sudden, presumed arrhythmic death.  
As a further limitation, the use of beta blockers and spironolactone were relatively low. 
Whilst drug therapy failed to emerge as a predictor of cardiovascular mortality, we 
cannot discount the possibility that the relationship between the DSC score and 
cardiovascular mortality might be influenced by better optimised medical therapy. 
However, the proportion of patients in NYHA class IV heart failure was greater than 
randomised in contemporary studies, suggesting that these patients were sicker and 
possibly less able to tolerate medical therapy. 
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The presence of posterolateral scar implies such an adverse prognosis that it carries a 
proportionate weight. In terms of the model, as this is a dichotomous variable rather than 
a continuous variable, it makes the presence of posterolateral scar the dominant factor in 
the model.  
NT-pro-BNP was not included in this model, as it was not systematically available pre-
implant. NT-pro-BNP has been shown to be an important prognostic marker in patients 
treated with CRT and future work should be directed to studied the effect of this 
biomarker on the risk index. 
 
7.5 Summary 
This study comprised patients with heart failure in NYHA class III and IV, such as those 
included in the CARE-HF study. We conclude that, in such patients, the DSC index is a 
powerful risk-stratifier for cardiovascular mortality. Patients in the highest risk stratum 
were more than 30 times more likely to die from cardiovascular causes than those in the 
low risk group. These findings underline the value of a standard CMR LV study in the 
risk-stratification of patients undergoing CRT. Such risk stratification may be helpful in 
tailoring follow-up and further therapy. 
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7.6 Table legends 
Table 7-1 Clinical characteristics of the study patients, grouped according to survival 
status at the end of the study period Clinical characteristics of the study patients, grouped 
according to survival status at the end of the study period. 
Table 7-2 Univariate Cox proportional hazard analyses of predictors of mortality 
Univariate Cox proportional hazard analyses of predictors of mortality. 
Table 7-3 Final model from bootstrapped stepwise multivariate Cox proportional hazard 
analyses of predictors of mortality Final model from bootstrapped stepwise multivariate 
Cox proportional hazard analyses of predictors of mortality. 
7.7 Figure legend 
Figure 7-1 Kaplan-Meier estimates of the time to cardiovascular death. Patients were 
stratified according to pre-implant DSC index.  
 
Figure 7-2 Calibration of predictions of mortality after cardiac resynchronisation 
therapy.  
 
Figure 7-3 Receiver-operator characteristic curves of the DSC index against 
cardiovascular mortality at 1 and 2 years, and at the end of the follow-up period.  
 
Figure 7-4 Comparison of events in the present cohort and in the CARE-HF study. 
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Table 7-1 Clinical characteristics of the study patients, grouped according to survival 
status at the end of the study period 
 
 All  
     
 
N 148   
 
Age, yrs  66.7 ((10.4)  
 
Men, No. (%) 114 (77)   
 
Ischaemic aetiology, No.  (%) 92 (62)   
 
NYHA class 3.2 ((0.43)  
 
Creatinine, µmol/L 119.8 ((38.3)  
 
Sodium, mmol/L 139.0 ((5.8)  
 
Haemoglobin, g/dL 14.1 ((7.9)  
 
Co-morbidity, No. (%) 
 
 Diabetes mellitus 24 (16)    
 
 Hypertension 40 (27)  
 
 CABG 31 (21)  
  
Medication, No. (%) 
 
 Loop diuretics 129 (87)    
 
 ACE-I or ARB 136 (92)  
 
 Beta-blockers 81 (55)  
 
 Spironolactone 66 (45)   
  
ECG variables 
 Atrial fibrillation, No. (%) 23 (16)  
 QRS duration (ms) 145.9 ((26.5)    
 
CMR variables 
 
 LVEDV, mL 247.8 ((99.5)  
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 LVESV, mL 200.2 ((96.6)  
 
 LVEF, % 22.5 ((10.6)  
 
 CMR-TSI, ms 100.7 ((47.8)  
  
 Scar †  
  
  Volume, % 19.5 ((20.1)  
   
  Transmural, No. (%) 62 (42)  
 
  Posterolateral, No. (%) 48 (32)  
 
  
 
Abbreviations:  
NYHA, New York Heart Association; CABG, coronary artery bypass graft; ACE-I, 
angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; LVEDV, 
left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, 
left ventricular ejection fraction; CMR-TSI, cardiovascular magnetic resonance tissue 
synchronization index. 
† Transmural scars were those with ≥51% transmurality. Continuous variables are 
expressed as mean (SD).
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Table 7-2 Univariate Cox proportional hazard analyses of predictors of mortality 
    
 β coefficient (95% CI) HR (95% CI) LR χ2 p  
 
PL scar location   2.82 (1.94 to 3.70) 16.8 (6.94 to 40.5) 58.6 <0.0001   
CMR-TSI, ms*  0.015 (0.01 to 0.02)  1.01 (1.01 to 1.02) 22.5 <0.0001 
Scar burden, %    0.03 (0.01 to 0.04) 1.03 (1.01 to 1.04) 13.3 0.0001 
CMR-LVEF, % -0.06 (-0.10 to -0.02) 0.94 (0.90 to 0.98) 11.1 0.0032 
Sodium, mmol/L -0.13 (0.04 to -0.04) 0.88 (0.81 to 0.96) 8.2 0.0031 
Creatinine, µmol/L  0.01 (0.00 to 0.02) 1.01 (1.00 to 1.02) 7.92  0.0049 
Transmurality 0.92 (0.26 to 1.58) 2.51 (1.29 to 4.84) 7.64  0.0057 
Male gender  0.95 (-0.08 to 1.99) 2.59 (0.92 to 7.32) 4.15 0.0417 
Uric acid, µmol/L   0.00 (-0.00 to 0.00) 1.00 (1.00 to 1.00) 2.33 0.1265 
NYHA class 0.54 (-0.17 to 1.21) 1.73 (0.84 to 3.37) 2.24 0.1343 
CABG -0.28 (0.18 to -0.62) 0.75 (0.53 to 1.08) 2.42 0.1196  
QRS duration, ms   0.01 (-0.00 to 0.02) 1.01 (1.00 to 1.02) 1.01 0.2202 
Age, yrs   0.01 (0.02 to -0.01) 1.01 (0.98 to 1.05) 0.78 0.3765    
Atrial fibrillation   0.15 (-0.23 to 0.49) 1.16 (0.80 to 1.63) 0.64 0.4220 
Diabetes mellitus -0.17 (-0.55 to 0.28) 0.84 (0.57 to 1.33) 0.61 0.4324 
Haemoglobin, g/dL -0.02 (-0.19 to 0.02) 0.98 (0.83 to 1.02) 0.51 0.4763 
Abbreviations: HR, hazard ratio; CI, confidence interval; CMR-TSI, cardiovascular magnetic 
resonance tissue synchronization index ; CMR-LVEF, cardiovascular magnetic resonance left 
ventricular ejection fraction;  NYHA, New York Heart Association; CABG, coronary artery 
bypass graft. 
Variables are listed in order of statistical significance and likelihood ratio (LR) ( χ 2).  
* Log transformed value used for statistical analysis. 
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Table 7-3 Final model from bootstrapped stepwise multivariate Cox proportional hazard 
analyses of predictors of mortality 
 
 β coefficient (95% CI) HR (95% CI) Z-score p  
 
 
Posterolateral scar location   2.50 (1.60 to 3.40)  12.2 (4.97 to 30.1) 5.46    <0.0001   
 
CMR-TSI , ms*  0.01 (0.00 to 0.02)  1.01 (1.00 to 1.02) 3.26  0.0011 
 
Creatinine, µmol/L  0.01 (0.00 to 0.02)  1.01 (1.00 to 1.02) 2.83  0.0046 
 
Model LR χ2: 73.4, p<0.0001 
 
 
Abbreviations: HR, hazard ratio; CI, confidence interval; LR, likelihood ratio. 
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Figure 7-1 Kaplan-Meier estimates of the time to cardiovascular death.26 
 
 
                                                
26 Patients were stratified according to pre-implant DSC index. The event rate, number of 
patients in the DSC risk stratum and the percentage event rate are shown in brackets. The 
hazard ratio (HR) and 95% confidence intervals are also shown 
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Figure 7-2 Calibration of predictions of mortality after cardiac resynchronisation 
therapy27 
 
                                                
27 Graph shows actual versus bootstrap-corrected predicted survival 
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Figure 7-3 Receiver-operator characteristic curves of the DSC index against 
cardiovascular mortality at 1 and 2 years, and at the end of the follow-up period28 
 
 
                                                
28 AUC, area under the curve; sens, sensitivity, spec, specificity. Values refer to a DSC cut-off 
of 4.7 
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Figure 7-4 Comparison of events in the present cohort and in the CARE-HF study29 
 
                                                
29 Qualitative comparison of Kaplan-Meier survival estimates for the combined endpoint of 
death from any cause or hospitalisations for major cardiovascular events (MCE) for patients 
included in this study as well as those in the CRT-P and the optimum medical treatment (OPT) 
arms the CARE-HF study. Follow-up time in the present cohort has been truncated to 1500 
days. 
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CHAPTER 8. CONCLUSIONS 
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The studies included in this thesis were undertaken in the context that the prediction of 
the long tern outcome in patients with HF treated with CRT remains problematic. It is 
widely recognised that patient selection for CRT treatment is difficult as patients selected 
with the current criteria do not always gain a symptomatic benefit. Whilst CMR remains 
the gold standard imaging technique in patients with systolic heart failure, systematic 
evaluation for dyssynchrony using CMR has not been widely available. 
A study of a large cohort of patients with systolic heart failure revealed that 
dyssynchrony, measured with CMR-TSI, was highly prevalent regardless of QRS 
duration. We found that CMR-TSI was able to discriminate between normal patients and 
patients with systolic heart failure accurately. As might be expected, the CMR-TSI value 
was higher in patients with a broader QRS, and highest in those with the largest left 
ventricular volumes. Potentially, CMR-TSI may provide a global measure of left 
ventricular function. Further research comparing CMR-TSI with LVEF would 
demonstrate the prognostic value of this measure in other cohort, such as those 
undergoing revascularisation. 
Myocardial scarring strongly influences dyssynchrony. The greater the myocardial scar 
the worse the dyssynchrony measured with CMR-TSI. The presence of greater 
dyssynchrony may contribute to the lower response rate seen in ICM patients, and the 
poorer prognosis compared with NICM patients. Thus, patients with extreme 
dyssynchrony may have extremely scarred ventricles, and hence are less likely to gain 
benefit from CRT due to failure to resynchronise and less viable myocardium. Patchiness 
of dyssynchrony was seen to increase in line with QRS duration, and the relationship 
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between the patchiness of the LV and the LV lead position may be crucial to 
understanding about the correct placement of the LV lead.  
Septal to lateral wall motion delay measurement appeared less robust when compared 
with CMR-TSI in the heart failure cohort. CMR-TSI is a global measure of the LV 
motion, and hence contains a greater number of measurements compared with the septal 
to lateral delay, reducing the signal to noise ratio. An alternative explanation for the 
greater discrimination between HF patients and controls with CMR-TSI, is that a global 
measurement is more accurate than examining the difference between two regions of the 
left ventricle. This finding has implications for further research into predictors of 
response from CRT which has largely focussed on examining the difference in time to 
peak contraction in the septal to lateral region. Global measures of dyssynchrony, such as 
CMR-TSI and three dimensional echocardiography may be greater predictors of 
outcome. 
The aim of pre-implant imaging is to predict the likely outcome from CRT, and we 
examined this in an observational study of large cohort of patients. We have shown that 
CMR-TSI is a powerful predictor of long term clinical outcome. However, in contrast to 
echocardiographic findings, we have found that the patients with the severest 
dyssynchrony fair the worst from CRT. This raises the hypothesis that patients with 
severe dyssynchrony do not gain significant life expectancy from CRT.  
The role of QRS duration in selection of patients for CRT remains problematic. 
Interestingly, QRS duration did not predict outcome in our cohort of patients undergoing 
CRT implantation. In addition, we found that patients with heart failure and narrow QRS 
(<120 ms) had significant dyssynchrony measured with CMR-TSI. This finding, coupled 
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with the failure of QRS duration to predict outcome, suggests that further long term study 
of CRT in this group is worthwhile, examining long term outcome and clinical evaluation 
with proven prognostic measures. 
The visualisation of myocardial scar is straightforward with CMR, and this allows 
accurate measurement of the volume and distribution of scar. In a large cohort of patients 
with PL scar we found that transmural scar prevented significant long term symptomatic 
improvement. Furthermore, pacing left ventricular scar was associated with a worse 
symptomatic response and mortality and it is reasonable to suggest that pacing scar is 
detrimental.  
Analysis of our cohort had identified two major predictors of adverse outcome in our 
cohort, and in Chapter 6 we found that the combination of both PL scar and CMR-TSI 
emerged as powerful predictors of events. Combining both measures allowed the CRT 
cohort to be divided into 2 major risk groups, with those patients who did not have either 
PL scar or a CMR-TSI > 110ms having the lowest risk. This supports the use of CMR as 
a pre-implant measure, and suggests the examination of dyssynchrony or scar alone will 
not be sufficient to accurately risk stratify patients. 
The addition of standard parameters to CMR measures could potentially further risk 
stratify patients undergoing CRT, and this was examined in the final study of our cohort. 
We examined the importance of factors known to influence outcome, and sought to 
determine whether these factors independently predicted outcome. Based on three 
factors, the CMR-TSI, the presence of PL scar and the creatinine we developed a risk 
score which was then validated with bootstrapping. Unlike other heart failure scores, we 
found that the predictive impact of CMR was sufficient such that we required only three 
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markers to predict outcome. This study confirms the major role that CMR has in 
predicting outcome in HF patients. 
A number of limitations arise from this work. Most importantly, this is purely 
observational data, and has not been confirmed in clinical trials. Our cohort is relatively 
unusual as the majority of patients underwent CRT pacing and we did not study patients 
undergoing CRT with defibrillator (CRT-D) backup. Potentially, the outcomes may 
different in patients treated with CRT-D. A major criticism of the CMR-TSI technique is 
the lack of validation in another centre, by different researchers. The technique itself is 
not suitable for clinical use in its current form due to the labour intensity involved in 
demarcating the left ventricular borders, although potentially this could be automated.  
A further major limitation of this observational study is that patients were entered when 
their clinical condition was recognised to merit further treatment by their treating 
physician. As a result, patients will have been implanted with CRT at variable lengths of 
time remote from their myocardial infarct. The development of heart failure could be 
more insidious in patients with PL scar compared with other locations, which could result 
in lead time bias in this type of observational study. Although the medical treatment of 
HF patients is implemented, inevitably the maximum tolerated HF medication will vary 
between patients depending on their condition. We have seen that pre-implant beta 
blockade appears to strongly influence outcome, and controlling for medical factors is 
difficult in this type of study. Further development of the risk model in a larger cohort 
could examine the role of medication in the prediction of outcome. 
The position of the left ventricular lead influences outcome in observational series, and in 
this cohort in relation to scar. We did not include the left ventricular lead position in our 
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risk score, and this may weaken the model. However, designing a study to look into this 
would need to take into account both anatomical position and the tributary which had 
been selected. This is likely to require greater numbers to ensure that a valid result was 
obtained. The position of the right ventricular lead may be important, and this has not 
been examined and is a further limitation of this work.  
The importance of mitral regurgitation as a predictor of outcome is now well appreciated. 
We did not examine the importance of pre-implant mitral regurgitation on the CMR 
scans, and this is an additional parameter which requires investigation to determine 
whether it should be in the risk score. Assessment of mitral regurgitation on 
echocardiography is recognised to be difficult, but the importance of residual MR on 
outcome could be studied in relation to the other identified factors.  
Further work should investigate the importance of the patchiness of dyssynchrony and 
outcome. The development of CMR safe CRT or the use of computed tomography of the 
left ventricle could allow pre and post implant patch maps to be developed. The role of 
multi-site left ventricular pacing is unclear, but potentially this could be deployed in 
patients who had multiple patches of dyssynchrony despite left ventricular lead 
implantation.  
We have shown that CMR-TSI predicts outcome in paced patients with symptomatic 
heart failure, but we do not have data about un-paced patients. Furthermore, we do not 
know if patients with dyssynchrony on CMR-TSI but EF>35% who are asymptomatic 
could benefit from prophylactic medication or even CRT. 
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We observed that pacing left ventricular scar was associated with a worse outcome from 
CRT. These observational findings could be examined with an experimental study, 
possibly in an animal model, accepting the potential weaknesses of animal work. 
This thesis has confirmed the prognostic importance of CMR-TSI in patients undergoing 
CRT, calculated a reference range for normality and demonstrated the use of three 
dimensional polar maps showing the patchiness of dyssynchrony. Furthermore, we have 
explored the relationship between CMR-TSI, QRS duration and measures of left 
ventricular function. The combination of scar and CMR-TSI has good prognostic 
discrimination between groups, and combined with creatinine provides a powerful risk 
score for determining cardiovascular mortality. 
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APPENDIX I. CMR-TSI CALCULATION - WRITTEN BY 
BERTHOLD STEGEMANN 
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 t.wma.max <- t.wta.max <- as.data.frame (matrix (nrow=0, ncol=5));  #PatID, Slice, 
Segment, Value names (t.wma.max) <- names(t.wta.max) <- c('nr', 'slice', 'seg', 'val', 
'file'); 
disp.t.wma.max <- disp.t.wta.max <- as.data.frame (matrix (nrow=0, ncol=3)); #Patid,  
Value names (disp.t.wma.max) <- names(disp.t.wta.max) <- c('nr', 'val', 'file'); 
for (filenr in 1:length(files)){       
 
# analyse file and extract data 
file <- files[filenr];  
 print(file); 
 t <- NULL;  
 t <- toupper(readLines(file)); 
# obtain number of phase points from file   
idx <- grep("^NUMBER OF PHASES:",t); 
 if (length(idx)==0){print('Line Error: Number of Phases')}; 
phasenr <- read.table(file,header=F,sep='\t',nrows=1,skip=idx-
1,colClasses=c("NULL","double")); 
 phasenr <- as.double(phasenr); 
 
Obtain number of slices from file   
idx <- grep("^NUMBER OF SLICES:",t); 
if (length(idx)==0){print('Line Error: Number of Slices')}; 
slnr <- read.table (file, header=F, sep='\t', nrows = 1, skip = idx-1, colClasses = c 
("NULL", "double")); 
slnr <- as.double(slnr); 
 
Obtain phase time and volume table from file  
idx <- grep ("^PHASE\t", t); 
if (length(idx)==0){print('Line Error: Volumes')}; 
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time < read.table (file, header = F, sep='\t', nrows = phasenr, skip = idx, col Classes = 
c(rep("double",4)), na. strings="NA"); 
time <- as.data.frame(time);  
names (time) <- c("Phase", "Time", "LVendo", "LVepi"); 
 
Obtain rr-interval   
idx <- grep ("^HEART RATE:",t) ; 
if (length(idx)==0){print('Line Error: Heart Rate')};       
rr <- read.table (file,header=F, sep='\t',nrows = 1 , skip = idx-1, col Classes = c ("NULL", 
"double")); 
rr <- as.integer (60000/rr);      
 
Add on final time measurement to the t0 dataframe 
#time [nrow (time)+1,] <- time[1,] # add final one time measurement 
#time$Time [nrow(time)]   <- t1; # RR + 10 msec 
# obtain the slice index pointing at the start of the slices 
idx <- NULL; 
idx <- grep ("^SLICE NUMBER [1-9]*", t); # finds start of slices 
if (length (idx) == 0){print ('Line Error: Slice Number')}; 
 slidx <- idx; 
 
Calculate number of slices (number taken from MASS file may be incorrect) 
slnr <- length(slidx)/3; 
# set number of segments (constant 6) 
sgnr  <- 6 # number of segments 
 
# create NA data matrix with number of expected rows and columns 
d <- as.data.frame (matrix (nrow = sgnr*3*slnr, ncol = phasenr)) 
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names (d) <- time$Time;  
linect <- 1; 
for (i in 1:length(slidx)){ # run i over all elements of the slideidx 
sgidx <- (slidx[i] - 1 + grep("^\ *S[1-6]\t",t[slidx[i]:(slidx[i]+10)])); # find start of 
segments in each slice 
if (diag==T){print(sgidx)}; # Just to show what is happening  
 
Obtain phases contained in this slice 
tphase <- t[sgidx[1]-1] ; 
tphase <- strsplit(tphase,'\t'); 
tphase <- as.double(tphase[[1]][-1]); 
if (diag==T) {print(tphase)}; 
 
Obtain (data) lines  
For (j in 1:6) { # cycle through all 6 segment lines 
line <- t[sgidx[j]]; 
line <- strsplit(line,'\t'); 
line <- as.double(line[[1]][-1]); 
if (diag==T){print(line)}; 
# copy (data) lines into dataframe d 
For (k in 1:length(tphase)) 
d [linect,tphase[k]] <- line[k]; 
linect <- linect + 1; 
wta <- d[(1*(slnr*sgnr)+1):(2*(slnr*sgnr)),]; # dataframe for wall thickening 
wma <- d[(2*(slnr*sgnr)+1):(3*(slnr*sgnr)),]; # dataframe for wall motion absolute 
 
Create extended format with slice and segment indices 
slice   <- rep(1:slnr, each = 6, times = 1); 
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segment   <- rep(seq(1:6), slnr); 
wma.x  <- cbind(sli, seg, wma); 
wta.x  <- cbind(sli, seg, wta); 
 
Calculate the time of maximal systolic excursion for each segment 
xx <- time$Time; 
xr <- xx/rr*2*pi; 
for (i in 1: (slice number *segment number)) 
t.wma.max <- rbind(t.wma.max, NA); 
y  <- as.double (wma[i,]); 
yy <- subset (y ,!is.na(y)); 
xx <- subset (xr,!is.na(y));  
s0 <- list(a = mean(yy), b=max(yy)-min(yy), c = xx[sort (yy, decreasing = T, index = 
T)$ix[1]]); 
f <- nls (yy  ~ a + b * cos(xx - c) ,start = s0,na.action = na.omit); 
a0 <- coef (f)[1]; # Offset 
b0 <- coef (f)[2]; # Amplitude 
pt0 <- summary (f)$parameters[3,4]; 
pb0 <- summary (f)$parameters[2,4]; 
 
if( pt0 < 1.0){ # p-value  
 if (b0 >= 0){c0 <- (coef(f)[3])%%(2*pi);} 
else  
{c0 <- (coef(f)[3]-pi)%%(2*pi);} n0 <- 1; 
else  
c0 <- NA; 
if(diag==T){print(c(a0,b0,c0,c0 /(2*pi)*rr))}; 
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t.wma.max [nrow(t.wma.max),5] <- file;   # filename 
t.wma.max [nrow(t.wma.max),4] <- c0/(2*pi)*rr;  # time to maximum 
t.wma.max [nrow(t.wma.max),3] <- ((i-1)%%6)+1 # segment 
t.wma.max [nrow(t.wma.max),2] <- ((i-1)%/%6)+1  # slice 
t.wma.max [nrow(t.wma.max),1] <- filenr   # filenr 
} #for(i in 1:lines) 
 
Output the data per file, if wanted 
If (export == T){ 
write.table ( time, paste(file,' .vol', '.tab',sep=""), sep="\t",row.names=F, col.names=T, 
append=F); 
write.table (wma.x, paste(file,' .wma', '.tab',sep=""), sep="\t",row.names=F, col.names=T, 
append=F); 
write.table (wta.x, paste(file, '.wta', '.tab', sep=""), sep="\t",row.names=F, col.names=T, 
append=F); 
for (filenr in 1:length (files)) 
 
Calculate the global dispersion (TSI) 
For (filenr in unique(t.wma.max$nr)){ # for each file 
y <- sd(subset(t.wma.max, nr == filenr, select=c(val)),na.rm=T); 
disp.t.wma.max <- rbind (disp.t.wma.max, NA); 
disp.t.wma.max [nrow (disp.t.wma.max), 3] <- files[filenr]; 
disp.t.wma.max [nrow (disp.t.wma.max), 2] <- y; 
disp.t.wma.max [nrow (disp.t.wma.max), 1] <- filenr; 
} # for (filenr in pats) 
 
Write dispersion results into file 
write.table (disp.t.wma.max,paste ('tsi', '.global', '.t.wma', '.tab', sep=""), sep="\t", row. 
Names = T, col.names=F, append=F); 
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